0001161697-24-000049.txt : 20240119 0001161697-24-000049.hdr.sgml : 20240119 20240119171347 ACCESSION NUMBER: 0001161697-24-000049 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 56 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20240119 DATE AS OF CHANGE: 20240119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GlobeStar Therapeutics Corp CENTRAL INDEX KEY: 0001502152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 273480481 STATE OF INCORPORATION: WY FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55072 FILM NUMBER: 24546418 BUSINESS ADDRESS: STREET 1: 719 JADWIN AVENUE CITY: RICHLAND STATE: WA ZIP: 99352 BUSINESS PHONE: 509-531-1671 MAIL ADDRESS: STREET 1: 719 JADWIN AVENUE CITY: RICHLAND STATE: WA ZIP: 99352 FORMER COMPANY: FORMER CONFORMED NAME: AngioSoma, Inc. DATE OF NAME CHANGE: 20160622 FORMER COMPANY: FORMER CONFORMED NAME: First Titan Corp. DATE OF NAME CHANGE: 20100927 10-K 1 form_10-k.htm FORM 10-K ANNUAL REPORT FOR 09-30-2023
false FY --09-30 2023 false 0001502152 Unlimited Unlimited P3Y P5Y P1Y P1Y P5Y P5Y P1Y7M6D P5Y P2Y11M8D 0001502152 2022-10-01 2023-09-30 0001502152 2023-03-31 0001502152 2024-01-16 0001502152 2023-09-30 0001502152 2022-09-30 0001502152 us-gaap:SeriesAPreferredStockMember 2023-09-30 0001502152 us-gaap:SeriesAPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesBPreferredStockMember 2023-09-30 0001502152 us-gaap:SeriesBPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesCPreferredStockMember 2023-09-30 0001502152 us-gaap:SeriesCPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesDPreferredStockMember 2023-09-30 0001502152 us-gaap:SeriesDPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesEPreferredStockMember 2023-09-30 0001502152 us-gaap:SeriesEPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesFPreferredStockMember 2023-09-30 0001502152 us-gaap:SeriesFPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesGPreferredStockMember 2023-09-30 0001502152 us-gaap:SeriesGPreferredStockMember 2022-09-30 0001502152 2021-10-01 2022-09-30 0001502152 us-gaap:CommonStockMember 2021-09-30 0001502152 us-gaap:SeriesDPreferredStockMember 2021-09-30 0001502152 us-gaap:SeriesEPreferredStockMember 2021-09-30 0001502152 us-gaap:SeriesFPreferredStockMember 2021-09-30 0001502152 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001502152 gstc:StockPayableMember 2021-09-30 0001502152 us-gaap:RetainedEarningsMember 2021-09-30 0001502152 2021-09-30 0001502152 us-gaap:CommonStockMember 2022-09-30 0001502152 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001502152 gstc:StockPayableMember 2022-09-30 0001502152 us-gaap:RetainedEarningsMember 2022-09-30 0001502152 us-gaap:CommonStockMember 2021-10-01 2022-09-30 0001502152 us-gaap:SeriesDPreferredStockMember 2021-10-01 2022-09-30 0001502152 us-gaap:SeriesEPreferredStockMember 2021-10-01 2022-09-30 0001502152 us-gaap:SeriesFPreferredStockMember 2021-10-01 2022-09-30 0001502152 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2022-09-30 0001502152 gstc:StockPayableMember 2021-10-01 2022-09-30 0001502152 us-gaap:RetainedEarningsMember 2021-10-01 2022-09-30 0001502152 us-gaap:CommonStockMember 2022-10-01 2023-09-30 0001502152 us-gaap:SeriesDPreferredStockMember 2022-10-01 2023-09-30 0001502152 us-gaap:SeriesEPreferredStockMember 2022-10-01 2023-09-30 0001502152 us-gaap:SeriesFPreferredStockMember 2022-10-01 2023-09-30 0001502152 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2023-09-30 0001502152 gstc:StockPayableMember 2022-10-01 2023-09-30 0001502152 us-gaap:RetainedEarningsMember 2022-10-01 2023-09-30 0001502152 us-gaap:CommonStockMember 2023-09-30 0001502152 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001502152 gstc:StockPayableMember 2023-09-30 0001502152 us-gaap:RetainedEarningsMember 2023-09-30 0001502152 srt:OfficerMember 2022-10-01 2023-09-30 0001502152 srt:OfficerMember 2021-10-01 2022-09-30 0001502152 srt:ChiefExecutiveOfficerMember 2023-09-30 0001502152 srt:ChiefExecutiveOfficerMember 2022-09-30 0001502152 gstc:MrKatzaroffMember srt:BoardOfDirectorsChairmanMember 2022-02-01 2022-02-28 0001502152 gstc:MrKatzaroffMember srt:BoardOfDirectorsChairmanMember 2023-09-30 0001502152 gstc:MrKatzaroffMember srt:BoardOfDirectorsChairmanMember 2022-10-01 2023-09-30 0001502152 gstc:MrKatzaroffMember 2022-10-01 2023-09-30 0001502152 gstc:MrKatzaroffMember 2023-04-04 0001502152 gstc:MrKatzaroffMember 2023-04-02 2023-04-04 0001502152 gstc:RobertChicoskiMember srt:ChiefFinancialOfficerMember 2023-08-04 0001502152 srt:BoardOfDirectorsChairmanMember 2023-09-24 2023-09-26 0001502152 gstc:MrKatzaroffMember srt:ChiefExecutiveOfficerMember 2023-09-18 2023-09-19 0001502152 gstc:ConvertibleNoteDateApril132017Member 2022-10-01 2023-09-30 0001502152 gstc:ConvertibleNoteDateApril132017Member 2023-09-30 0001502152 gstc:ConvertibleNoteDateApril132017Member 2022-09-30 0001502152 gstc:ConvertibleNoteDateMay102023Member 2022-10-01 2023-09-30 0001502152 gstc:ConvertibleNoteDateMay102023Member 2023-09-30 0001502152 gstc:ConvertibleNoteDateMay102023Member 2022-09-30 0001502152 gstc:ConvertibleNoteDateJuly32023Member 2022-10-01 2023-09-30 0001502152 gstc:ConvertibleNoteDateJuly32023Member 2023-09-30 0001502152 gstc:ConvertibleNoteDateJuly32023Member 2022-09-30 0001502152 us-gaap:ConvertibleDebtMember 2022-10-01 2023-09-30 0001502152 gstc:May2023SecuritiesPurchaseAgreementMember 2023-05-08 2023-05-10 0001502152 gstc:May2023SecuritiesPurchaseAgreementMember 2023-05-10 0001502152 2023-05-08 2023-05-10 0001502152 2023-06-30 0001502152 gstc:July2023SecuritiesPurchaseAgreementMember 2023-07-02 2023-07-03 0001502152 gstc:July2023SecuritiesPurchaseAgreementMember 2023-07-03 0001502152 2023-07-02 2023-07-03 0001502152 gstc:ConvertibleDebtOneMember 2023-09-30 0001502152 gstc:ConvertibleDebtOneMember 2022-10-01 2023-09-30 0001502152 gstc:AdvanceMember 2023-09-30 0001502152 gstc:AdvanceMember 2022-09-30 0001502152 us-gaap:SeriesAPreferredStockMember 2022-10-01 2023-09-30 0001502152 us-gaap:SeriesBPreferredStockMember 2022-10-01 2023-09-30 0001502152 us-gaap:SeriesCPreferredStockMember 2017-09-12 0001502152 us-gaap:SeriesDPreferredStockMember 2017-09-21 0001502152 us-gaap:SeriesDPreferredStockMember 2017-09-20 2017-09-21 0001502152 us-gaap:SeriesDPreferredStockMember 2023-07-31 0001502152 us-gaap:SeriesEPreferredStockMember 2015-08-03 0001502152 us-gaap:SeriesEPreferredStockMember 2015-08-02 2015-08-03 0001502152 us-gaap:SeriesEPreferredStockMember srt:DirectorMember 2022-09-30 0001502152 us-gaap:SeriesFPreferredStockMember 2017-09-21 0001502152 us-gaap:SeriesFPreferredStockMember 2017-09-20 2017-09-21 0001502152 us-gaap:ConvertibleNotesPayableMember 2022-10-01 2023-09-30 0001502152 2023-04-06 0001502152 2023-04-03 2023-04-06 0001502152 us-gaap:WarrantMember 2021-10-01 2022-09-30 0001502152 us-gaap:LicenseAgreementTermsMember 2023-04-25 0001502152 us-gaap:LicenseAgreementTermsMember 2023-04-23 2023-04-25 0001502152 2023-07-01 2023-07-31 0001502152 2021-12-31 0001502152 2022-09-01 2022-09-30 0001502152 2022-12-01 2022-12-31 0001502152 us-gaap:WarrantMember 2022-12-01 2022-12-31 0001502152 2023-02-01 2023-02-28 0001502152 us-gaap:CommonStockMember 2023-02-28 0001502152 us-gaap:PrivatePlacementMember srt:MaximumMember 2023-09-30 0001502152 us-gaap:PrivatePlacementMember srt:MinimumMember 2023-09-30 0001502152 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2022-10-01 2023-09-30 0001502152 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2023-09-30 0001502152 gstc:CommonStockWarrantsMember 2022-10-01 2023-09-30 0001502152 gstc:SpivakManagementIncMember 2023-09-30 0001502152 gstc:SpivakManagementIncMember srt:MinimumMember 2022-02-01 2022-02-28 0001502152 gstc:SpivakManagementIncMember srt:MaximumMember 2022-02-01 2022-02-28 0001502152 gstc:SpivakManagementIncMember 2022-02-01 2022-02-28 0001502152 us-gaap:WarrantMember 2022-10-01 2023-09-30 0001502152 us-gaap:WarrantMember 2023-09-30 0001502152 gstc:MrKatzaroffMember 2023-09-30 0001502152 gstc:MrKatzaroffMember srt:MinimumMember 2022-10-01 2023-09-30 0001502152 gstc:MrKatzaroffMember srt:MaximumMember 2022-10-01 2023-09-30 0001502152 srt:ChiefFinancialOfficerMember 2022-10-01 2023-09-30 0001502152 gstc:RobertChicoskiMember 2022-10-01 2023-09-30 0001502152 gstc:MrFarleyMember 2022-10-01 2023-09-30 0001502152 gstc:MrPenderghastMember 2022-10-01 2023-09-30 0001502152 us-gaap:SeriesGPreferredStockMember 2021-08-11 0001502152 us-gaap:SeriesGPreferredStockMember 2021-08-09 2021-08-11 0001502152 us-gaap:SeriesGPreferredStockMember 2022-10-01 2023-09-30 0001502152 us-gaap:SeriesGPreferredStockMember us-gaap:CommonStockMember 2022-10-01 2023-09-30 0001502152 us-gaap:SeriesGPreferredStockMember 2021-10-01 2022-09-30 0001502152 us-gaap:SeriesGPreferredStockMember 2021-09-30 0001502152 us-gaap:SeriesGPreferredStockMember us-gaap:CommonStockMember 2021-10-01 2022-09-30 0001502152 2022-02-01 2022-02-28 0001502152 us-gaap:SubscriptionArrangementMember 2022-07-01 2022-07-31 0001502152 us-gaap:SubscriptionArrangementMember gstc:MrSpivakMember 2022-08-01 2022-08-31 0001502152 us-gaap:SubscriptionArrangementMember gstc:MrSpivakMember 2022-08-31 0001502152 2023-09-19 0001502152 2023-09-17 2023-09-19 0001502152 us-gaap:AccruedLiabilitiesMember 2023-09-17 2023-09-19 0001502152 us-gaap:NotesPayableOtherPayablesMember 2023-09-17 2023-09-19 0001502152 gstc:ConsultantAgreementMember 2022-10-01 2023-09-30 0001502152 gstc:ConsultantAgreementMember 2021-10-01 2022-09-30 0001502152 gstc:ConsultantAgreementMember 2023-08-08 2023-08-10 0001502152 us-gaap:CommonStockMember gstc:ConsultantAgreementMember 2023-09-30 0001502152 gstc:LicenseAgreementMember us-gaap:PatentsMember gstc:FabrizioDeSilvestriMember 2020-08-22 2020-08-23 0001502152 gstc:LicenseAgreementMember us-gaap:PatentsMember 2020-08-22 2020-08-23 0001502152 2020-08-22 2020-08-23 0001502152 us-gaap:RoyaltyArrangementMember 2022-10-01 2023-09-30 0001502152 us-gaap:RoyaltyArrangementMember 2023-09-30 0001502152 us-gaap:SubsequentEventMember 2023-11-01 2023-11-02 0001502152 us-gaap:ConvertibleNotesPayableMember 2023-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES 

SECURITY AND EXCHANGE COMMISSION

 WASHINGTON, D.C. 20549

_______________

 

FORM 10-K

_______________

 

(MARK ONE)

 

☒  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended September 30, 2023

 

or

 

☐  TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _________ to _________

 

Commission File Number: 333-170315

 

GlobeStar Therapeutics Corporation

(Exact name of registrant as specified in its charter)

     
Wyoming   27-3480481
(State or other jurisdiction of Incorporation or organization)   (I.R.S. Employer Identification Number)
     
719 Jadwin Avenue, Richland, WA   99352
(Address of principal executive offices)   (Zip code)

 

Registrant’s telephone number, including area code: 206-451-1970

 

Securities registered pursuant to Section 12(g) of the Act:

     
Title of Each Class   Name of Each Exchange on which Registered
Common stock, $0.001 par value   OTC Markets

 

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☐   No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes ☐   No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒   No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  

Yes ☒   No ☐

 

Indicate by check mark if disclosures of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Yes ☒   No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

         
  Large accelerated filer ☐ Accelerated filer ☐
  Non-accelerated filer ☐ Smaller reporting company ☒
  (Do not check is smaller reporting company) Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐   No ☒

 

The Aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter, March 31, 2023 was $4,851,851.

 

There were 1,026,417,320 shares of the Registrant’s common stock outstanding as of January 16, 2024.

 

- 2 -

 

GLOBESTAR THERAPEUTICS CORPORATION.

 

TABLE OF CONTENTS

 

Part I 5
Item 1. Business 5
Item 1A. Risk Factors 6
Item 1B. Unresolved Staff Comments 12
Item 2. Properties 12
Item 3. Legal Proceedings 12
Item 4. Mine Safety Disclosures 12
   
Part II 12
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 12
Item 6. Selected Financial Data 15
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of operations 16
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 19
Item 8. Financial Statements and Supplementary Data 19
Report of Independent Registered Public Accounting Firm 20
Consolidated Balance Sheets 23
Consolidated Statements of Operations 24
Consolidated Statements of Stockholders’ Deficit 25
Consolidated Statements of Cash Flows 26
Notes to the Consolidated Financial Statements 27
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 38
Item 9A. Controls and Procedures 38
Item 9B. Other Information 39
   
Part III 40
Item 10. Directors, Executive Officers and Corporate Governance 40
Item 11. Executive Compensation 42
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 43
Item 13. Certain Relationships and Related Transactions, and Director Independence 43
Item 14. Principal Accounting Fees and Services 44
   
Part IV 45
Item 15. Exhibits, Financial Statement Schedules 45
   
Signatures 46

 

- 3 -

Table of Contents

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

 

Certain statements in this report contain or may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements, identified by words such as “plan”, “anticipate”, “believe”, “estimate”, “should”, “expect” and similar expressions include our expectations and objectives regarding our future financial position, operating results and business strategy. These statements are subject to known and unknown risks, uncertainties and other factors, which may cause actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements were based on various factors and were derived utilizing numerous assumptions and other factors that could cause our actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, our ability to secure suitable financing to continue with our existing business or change our business and conclude a merger, acquisition or combination with a business prospect, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk, U.S. and global competition, and other factors. Most of these factors are difficult to predict accurately and are generally beyond our control. You should consider the areas of risk described in connection with any forward-looking statements that may be made herein. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Readers should carefully review this report in its entirety, including but not limited to our financial statements and the notes thereto and the risks described in our Annual Report on Form 10-K for the fiscal year ended September 30, 2022. We advise you to carefully review the reports and documents we file from time to time with the Securities and Exchange Commission (the “SEC”), particularly our quarterly reports on Form 10-Q and our current reports on Form 8-K. Except for our ongoing obligations to disclose material information under the Federal securities laws, we undertake no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.

 

OTHER PERTINENT INFORMATION

 

When used in this report, the terms, “we,” the “Company,” “GSTC,” “our,” and “us” refers to GlobeStar Therapeutics Corporation., a Wyoming corporation.

 

- 4 -

Table of Contents

 

PART I

 

ITEM 1. BUSINESS

 

Overview

 

GlobeStar Therapeutics Corporation (the “Company”) was incorporated on April 29, 2016. The Company’s year-end is September 30. On October 4, 2019, the Company filed Articles of Continuance with the Secretary of State of Wyoming to continue its business in the state of Wyoming. As part of these Articles of Continuance, effective October 4, 2019, the Company has no limit on the authorized shares of common stock that can be issued. The Company filed its Certificate of Dissolution with the Secretary of State of Nevada on October 21, 2019 because it is no longer a Nevada corporation.

 

We changed our name to GlobeStar Therapeutics Corporation on April 27, 2021 to better reflect our expanded platform of products that include breakthrough addition of treatment for Multiple Sclerosis and other neurodegenerative diseases.

 

GlobeStar Therapeutics Corporation, based in Richland Washington, is a clinical stage Pharmaceutical Company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. GlobeStar Therapeutics owns the exclusive global license from the inventors, who are based in Italy. GlobeStar Therapeutics is initiating discussions with the FDA on clinical trial design in preparation for FDA submission and approval pathway.

 

On November 2, 2023, the Company entered into a definitive agreement with Advanced Innovative Partners (“AIP”) for AIP to provide advice to Company and SMI HealthCare LLC (“SMIHC”) on the global design, strategy and execution of clinical trials, regulatory filings, intellectual property rights filings, and manufacturing for Project Amethyst™. Project Amethyst™ is a compound intended to treat neurodegeneration from multiple sclerosis (“MS”). GSTC is the exclusive worldwide licensee for Project Amethyst™, including all patents and patent applications relating thereto.

 

The Company and AIP agreement has been approved by the parties' respective boards and is immediately effective. AIP will initially advise the Company and SMIHC on the design and launch of an initial clinical trial in India and the associated regulatory approvals for GSTC's MS products in North America and Europe. A memorandum of understanding previously had been entered into by the Company and AIP to design and implement clinical trials for Project Amethyst™, subject to the execution of definitive agreement. Pursuant to the parties' agreement, the Company retains ownership of all intellectual property rights, and final approval of Project Amethyst™, including the right to engage additional advisors and subject matter experts. For its consulting services, AIP will be paid a monthly consulting fee and bonuses, a portion of which will be deferred and will become payable only if the Company secures FDA marketing approval. If AIP introduces the Company or SMIHC to potential customers, or strategic partners, subject to compliance with applicable law, AIP may also become entitled to receive commissions on certain revenues or profits derived from those relationships.

 

The agreement with AIP builds on the recent agreement of the Company with SMI HealthCare LLC (“SMIHC”) to manage an initial clinical trial, regulatory filings, intellectual property rights filings, manufacturing, sales and distribution in India, Southeast Asia, Africa, and the Middle East. On September 26, 2023, the Company entered into an agreement with SMIHC to manage an initial clinical trial, regulatory filings, intellectual property rights filings, manufacturing, sales and distribution in India, Southeast Asia, Africa, and the Middle East, excluding Israel and Iraq, and for government and private aid organizations, for the Company's patented Multiple Sclerosis treatment. The agreement with SMIHC was approved by the parties’ respective boards of directors. Implementation of the first phase is subject to the Company arranging financing. The first phase includes formation of the Company and SMIHC subsidiaries in India, the clinical trial, regulatory and intellectual property rights filings in India, identifying manufacturers, and planning for the commercial launch in India and countries in the region that accept Drug Controller General of India (“DCGI”) approvals. Implementation of the second phase is expected to commence approximately nine months later, and is subject to receipt of DCGI marketing approval and the Company arranging financing. The second phase may continue for the duration of patent validity, and consists initially of sales, marketing and distribution in India and thereafter, countries in SMIHC’s territory that will permit sales and distribution based upon DCGI approval. After proof of market in those countries, the intention is to seek regulatory approvals elsewhere in SMIHC’s territory in order to expand the sales and distribution of the Company’s MS products. Pursuant to with SMIHC, the Company will receive a 5% royalty on any sales under the agreement by the company formed in India under this agreement, and 50% of any sublicense revenue from the India company formed under the agreement. The Company will pay the following (i) initial fees of between $15,000 - $22,500, and monthly fees of between $5,000 and $12,500 per month for Phase A (ii) monthly fees of $12,500, increase after six months to $17,500 per month, and to $25,000 per month after one year. The fee will increase by 5% per year thereafter for Phase B (iii) an initial management fee of $15,000 upon certain milestones and monthly management fee of $5,000 per month thereafter.

 

- 5 -

Table of Contents

 

SMIHC is an affiliate of SMI Group LLC, a privately-held Los Angeles-based company. The chairman of SMI Group is a shareholder of the Company and consultant, though he did not advise the Company on this transaction and has waived fees payable to an SMI company for introducing SMIHC to the Company.

 

Professional Team

 

We have adopted a Medical Advisory Board and appointed medical doctors and medical professionals that have extensive education and hands on experience with pharmaceutical and nutraceutical solutions for prevention and treatment of disease.

 

Management’s Plan to Attract Capital

 

In the near term, management will utilize debt or preferred stock financing to complete assembling the professional and management team to commence the process for clinical trials in compliance with FDA protocol. plans to continue to focus on raising the funds necessary to implement the Company’s business plan. Management will continue to seek out debt financing to obtain the capital required to meet the Company’s financial obligations. There is no assurance, however, that investors will continue to advance capital to the Company or that the new business operations will be profitable. The possibility of failure in obtaining additional funding and the potential inability to achieve profitability raise doubts about the Company’s ability to continue as a going concern.

 

In the midterm, management will enhance its capital position with a public offering of equity securities to finance clinical trials and the necessary actions to obtain approval of worldwide marketing of our MS treatment.

 

In the long term, marketing the Company’s pharmaceutical and nutraceutical products will provide the necessary cash flow to support future growth. However, there can be no assurances that the Company’s planned activities will be successful, or that the Company will ultimately attain profitability. The Company’s long-term viability depends on its ability to obtain adequate sources of capital to support near term and midterm business operations, and the ability of the Company to achieve adequate profitability and cash flows from operations to support its operations.

 

Corporate Governance

 

We have adopted codes and committees for governance of the corporation that include: (i) audit committee charter, (ii) written acknowledgement of code of ethics for directors and senior officers, (iii) compensation committee charter, (iv) confidential information policy, iv) corporate governance guidelines, (vi) executive committee charter, and (vii) nominating committee charter.

 

ITEM 1A. RISK FACTORS

 

You should carefully consider the following risk factors discussed below and the matters addressed under “Special Note Regarding Forward-Looking Statements,” together with all the other information presented in this prospectus, including our audited financial statements and related notes. The risks described below are the only presently known risks facing us or that may materially adversely affect our business. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially and adversely affect our business. If any of the following risks develop into actual events, our business, financial condition or results of operations could be materially adversely affected and you may lose all or part of your investment.

 

We cannot be certain that our potential pharmaceuticals will receive regulatory approval, and without regulatory approval we will not be able to market pharmaceuticals.

 

Our business currently depends largely on the successful development and commercialization of pharmaceutical products to treat multiple sclerosis. Our ability to generate revenue related to product sales, if ever, will depend on the successful development and regulatory approval of such pharmaceuticals.

 

We currently have no products approved for sale and we cannot guarantee that we will ever have marketable products. The development of a product candidate and issues relating to its approval and marketing are subject to extensive regulation by the FDA in the United States and regulatory authorities in other countries, with regulations differing from country to country. We are not permitted to market our product candidates in the United States until we receive approval of an NDA from the FDA. We have not submitted any marketing applications for any of our product candidates.

 

- 6 -

Table of Contents

 

NDAs must include extensive preclinical and clinical data and supporting information to establish the product candidate’s safety and effectiveness for each desired indication. NDAs must also include significant information regarding the chemistry, manufacturing and controls for the product. Obtaining approval of an NDA is a lengthy, expensive, and uncertain process, and we may not be successful in obtaining approval. The FDA review processes can take years to complete, and approval is never guaranteed. If we submit an NDA to the FDA, the FDA must decide whether to accept or reject the submission for filing. We cannot be certain that any submissions will be accepted for filing and review by the FDA. Regulators in other jurisdictions have their own procedures for approval of product candidates. Even if a product is approved, the FDA may limit the indications for which the product may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming clinical trials or reporting as conditions of approval. Regulatory authorities in countries outside of the United States and Europe also have requirements for approval of drug candidates with which we must comply with prior to marketing in those countries. Obtaining regulatory approval for marketing of a product candidate in one country does not ensure that we will be able to obtain regulatory approval in any other country. In addition, delays in approvals or rejections of marketing applications in the United States, Europe or other countries may be based upon many factors, including regulatory requests for additional analyses, reports, data, preclinical studies and clinical trials, regulatory questions regarding different interpretations of data and results, changes in regulatory policy during the period of product development and the emergence of new information regarding our product candidates or other products. Also, regulatory approval for any of our product candidates may be withdrawn.

 

If we are unable to obtain approval from the FDA, or other regulatory agencies, for product candidates, or if, subsequent to approval, we are unable to successfully commercialize our other product candidates, we will not be able to generate sufficient revenue to become profitable or to continue our operations, likely resulting in the total loss of principal for our investors.

 

Any statements in this filing indicating that product candidates has demonstrated preliminary evidence of efficacy are our own and are not based on the FDA’s or any other comparable governmental agency’s assessment of our product candidates and do not indicate that our product candidates will achieve favorable efficacy results in any stage trials or that the FDA or any comparable agency will ultimately determine that our product candidates are effective for purposes of granting marketing approval.

 

We face substantial competition, which may result in others developing or commercializing products before or more successfully than we do.

 

The development and commercialization of our potential drug candidates is highly competitive. We expect that we will face significant competition from other companies that develop and market potential drug candidates.

 

Many of our existing and potential future competitors have significantly greater financial resources and expertise in research and development, manufacturing, and potential drug candidates than we do.

 

Product liability lawsuits against us could divert our resources, cause us to incur substantial liabilities and limit marketing of our potential drug candidates.

 

We face an inherent risk of product liability claims. For example, we may be sued if any product we sell allegedly causes injury or is found to be otherwise unsuitable. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Regardless of the merits or eventual outcome, liability claims may result in:

 

● decreased demand for our products or products that we may develop;
   
● injury to our reputation and significant negative media attention;
   
● significant costs to defend resulting litigation;
   
● substantial monetary awards to users;
   
● loss of revenue;
   
● reduced resources of our management to pursue our business strategy; and
   
● the inability to commercialize our products and additional products that we may develop.

 

- 7 -

Table of Contents

 

Risks Related to Our Financial Position and Need for Additional Capital

 

Implications of Being an Emerging Growth Company

 

As a company with less than $1.0 billion of revenue during our last fiscal year, we qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we may remain an emerging growth company for up to five years. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure and other requirements that are applicable to other public companies that are not emerging growth companies. In particular, in this 10-K, we have provided only two years of audited consolidated financial statements and have not included all of the executive compensation related information that would be required if we were not an emerging growth company. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock.

 

We have a history of operating losses and expect to continue to realize losses in the near future. Currently our operations are producing inadequate revenue to fund all operating costs, and we rely on investments by third parties to fund our business. Even as our revenue grows, we may not become profitable or be able to sustain profitability.

 

From inception, we have incurred significant net losses and have not realized adequate revenue to support our operations. We expect to continue to incur net losses and negative cash flow from operations in the near future, and we will continue to experience losses for at least as long as it takes our company to generate revenue from the sale of products. The size of these losses will depend, in large part, on whether we develop products in a profitable manner. To date, we have had only limited operating revenues. There can be no assurance that we will achieve material revenues in the future. Should we achieve a level of revenues that make us profitable, there is no assurance that we can maintain or increase profitability levels in the future.

 

There is substantial doubt as to whether we will continue operations. If we discontinue operations, you could lose your investment.

 

The following factors raise substantial doubt regarding the ability of our business to continue as a going concern: (i) the losses we incurred since our inception; (ii) our lack of significant operating revenues since inception through the date of this prospectus; and (iii) our dependence on debt and equity funding to continue in operation. We therefore expect to incur significant losses in the foreseeable future. The financial statements do not include any adjustments that might result from the uncertainty about our ability to continue our business. If we are unable to obtain additional financing from outside sources and eventually produce enough revenues, we may be forced to curtail or cease our operations. If this happens, you could lose all or part of your investment.

 

Our lack of any profitable operating history makes it difficult for us to evaluate our future business prospects and make decisions based on those estimates of our future performance.

 

We do not have any substantial operating history, which makes it impossible to evaluate our business on the basis of historical operations. Our business carries both known and unknown risks. As a consequence, our past results may not be indicative of future results. Although this is true for any business, it is particularly true for us because of our lacking any profitable operating history.

 

Because our auditors have issued a going concern opinion, there is substantial uncertainty that we will be able to continue our operations.

 

Our auditors have issued a going concern opinion. This means that there is substantial doubt that we can continue to operate over the next 12 months. Our financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event we cannot continue in existence. As such, if we are unable to obtain new financing to execute our business plan we may be required to cease our operations.

 

Effective March 3, 2021, we changed management by electing James C. Katzaroff President and Chief Executive Officer.

 

There is no assurance Mr. Katzaroff will be successful in securing FDA clearance and marking the newly acquired license for treatment of Multiple Sclerosis.

 

- 8 -

Table of Contents

 

Our chief executive officer has the ability to significantly influence any matters to be decided by the stockholders, which may prevent or delay a change in control of our company.

 

James Katzaroff, our CEO, currently owns 1,000,000 shares of series E preferred stock. The owner of the series E preferred stock is entitled to the number of votes equal to double the number of votes of all other stockholders.  Therefore, Mr. Katzaroff has voting rights equal to two-thirds of all votes cast at any action of stockholders and can exert decisive influence over the outcome of any corporate matter submitted to our stockholders for approval, including the election of directors, removal of the entire board of directors and any transaction that might cause a change in control, such as a merger or acquisition. Any stockholders in favor of a matter that is opposed by this stockholder cannot overrule the vote of James Katzaroff.

 

James Katzaroff is one of three directors and CEO. The loss of Mr. Katzaroff could adversely affect our business.

 

Since Mr. Katzaroff is currently a director and CEO, if he were to die, become disabled, or leave our company, we would be forced to retain an individual to replace him. There is no assurance that we can find a suitable person to replace him if that becomes necessary. We have no “key man” life insurance at this time.

 

Risks related to our common stock

 

We lack an established trading market for our common stock, and you may be unable to sell your common stock at attractive prices or at all.

 

There is currently a limited trading market for our common stock on the OTC Market Group’s QB tier under the symbol “GSTC.” There can be no assurances given that an established public market will be obtained for our common stock or that any public market will last. As a result, we cannot assure you that you will be able to sell your common stock at attractive prices or at all.

 

The market price for our common stock may be highly volatile.

 

The market price for our common stock may be highly volatile. A variety of factors may have a significant impact on the market price of our common stock, including:

 

● the publication of earnings estimates or other research reports and speculation in the press or investment community;
   
● changes in the industry and competitors;
   
● our financial condition, results of operations and prospects;
   
● any future issuances of our common stock, which may include primary offerings for cash, and the grant or exercise of stock options from time to time;
   
● general market and economic conditions; and
   
● any outbreak or escalation of hostilities, which could cause a recession or downturn in our economy.

 

We may be subject to shareholder litigation, thereby diverting our resources that may have a material effect on our profitability and results of operations.

 

As discussed in the preceding risk factors, the market for our common shares is characterized by significant price volatility when compared to seasoned issuers, and we expect that our share price will continue to be more volatile than a seasoned issuer for the indefinite future. In the past, plaintiffs have often initiated securities class action litigation against a company following periods of volatility in the market price of its securities. We may become the target of similar litigation. Securities litigation will result in substantial costs and liabilities and will divert management’s attention and resources.

 

- 9 -

Table of Contents

 

Future sales of common stock by stockholders may have an adverse effect on the then prevailing market price of our common stock.

 

In the event a public market for our common stock is sustained in the future, sales of our common stock may be made by holders of our public float or by holders of restricted securities in compliance with the provisions of Rule 144 of the Securities Act of 1933. In general, under Rule 144, a non-affiliated person who has satisfied a six-month holding period in a company registered under the Securities Exchange Act of 1934, as amended, may, sell their restricted common stock without volume limitation, so long as the issuer is current with all reports under the Exchange Act in order for there to be adequate common public information. Affiliated persons may also sell their common shares held for at least six months, but affiliated persons will be required to meet certain other requirements, including manner of sale, notice requirements and volume limitations. Non-affiliated persons who hold their common shares for at least one year will be able to sell their common stock without the need for there to be current public information in the hands of the public. Future sales of shares of our public float or by restricted common stock made in compliance with Rule 144 may have an adverse effect on the then prevailing market price, if any, of our common stock.

 

We do not expect to pay cash dividends in the foreseeable future.

 

We do not anticipate paying cash dividends on our common stock in the foreseeable future. We may not have sufficient funds to legally pay dividends. Even if funds are legally available to pay dividends, we may nevertheless decide in our sole discretion not to pay dividends. The declaration, payment and amount of any future dividends will be made at the discretion of our board of directors, and will depend upon, among other things, the results of our operations, cash flows and financial condition, operating and capital requirements, and other factors our board of directors may consider relevant. There is no assurance that we will pay any dividends in the future, and, if dividends are paid, there is no assurance with respect to the amount of any such dividend.

 

As a public company, we are subject to complex legal and accounting requirements that will require us to incur significant expenses and will expose us to risk of non-compliance.

 

As a public company, we are subject to numerous legal and accounting requirements that do not apply to private companies. The cost of compliance with many of these requirements is material, not only in absolute terms but, more importantly, in relation to the overall scope of the operations of a small company. Our relative inexperience with these requirements may increase the cost of compliance and may also increase the risk that we will fail to comply. Failure to comply with these requirements can have numerous adverse consequences including, but not limited to, our inability to file required periodic reports on a timely basis, loss of market confidence and/or governmental or private actions against us. We cannot assure you that we will be able to comply with all of these requirements or that the cost of such compliance will not prove to be a substantial competitive disadvantage vis-à-vis our privately held and larger public competitors.

 

Compliance with changing regulation of corporate governance and public disclosure will result in additional expenses and pose challenges for our management.

 

Changing laws, regulations and standards relating to corporate governance and public disclosure, including the Dodd-Frank Wall Street Reform and Consumer Protection Act, and the rules and regulations promulgated thereunder, the Sarbanes-Oxley Act and SEC regulations, have created uncertainty for public companies and significantly increased the costs and risks associated with accessing the U.S. public markets. Our management team will need to devote significant time and financial resources to comply with both existing and evolving standards for public companies, which will lead to increased general and administrative expenses and a diversion of management time and attention from revenue generating activities to compliance activities.

 

We will need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms.

 

When we elect to raise additional funds or additional funds are required, we may raise such funds from time to time through public or private equity offerings, debt financings, corporate collaboration and licensing arrangements or other financing alternatives Additional equity or debt financing or corporate collaboration and licensing arrangements may not be available on acceptable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing acquisition, licensing, development and commercialization efforts and our ability to generate revenues and achieve or sustain profitability will be substantially harmed.

 

- 10 -

Table of Contents

 

If we raise additional funds by issuing equity securities, our stockholders will experience dilution. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any debt financing or additional equity that we raise may contain terms, such as liquidation and other preferences, which are not favorable to us or our stockholders. If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies, future revenue streams or product candidates or to grant licenses on terms that may not be favorable to us. Should the financing we require to sustain our working capital needs be unavailable or prohibitively expensive when we require it, our business, operating results, financial condition and prospects could be materially and adversely affected and we may be unable to continue our operations.

 

We are subject to penny stock regulations and restrictions, and you may have difficulty selling shares of our common stock.

 

Our common stock is subject to the provisions of Section 15(g) and Rule 15g-9 of the Securities Exchange Act of 1934 (the “Exchange Act”), commonly referred to as the “penny stock rule.” Section 15(g) sets forth certain requirements for transactions in penny stock, and Rule 15g-9(d) incorporates the definition of “penny stock” that is found in Rule 3a51-1 of the Exchange Act. The SEC generally defines a penny stock to be any equity security that has a market price less than $5.00 per share, subject to certain exceptions. We are subject to the SEC’s penny stock rules.

 

Since our common stock is deemed to be penny stock, trading in the shares of our common stock is subject to additional sales practice requirements on broker-dealers who sell penny stock to persons other than established customers and accredited investors. “Accredited investors” are persons with assets in excess of $1,000,000 (excluding the value of such person’s primary residence) or annual income exceeding $200,000 or $300,000 together with their spouse. For transactions covered by these rules, broker-dealers must make a special suitability determination for the purchase of such security and must have the purchaser’s written consent to the transaction prior to the purchase. Additionally, for any transaction involving a penny stock, unless exempt the rules require the delivery, prior to the first transaction of a risk disclosure document, prepared by the SEC, relating to the penny stock market. A broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative and current quotations for the securities. Finally, monthly statements must be sent disclosing recent price information for the penny stocks held in an account and information to the limited market in penny stocks. Consequently, these rules may restrict the ability of broker-dealer to trade and/or maintain a market in our common stock and may affect the ability of our stockholders to sell their shares of common stock.

 

There can be no assurance that our shares of common stock will qualify for exemption from the Penny Stock Rule. In any event, even if our common stock was exempt from the Penny Stock Rule, we would remain subject to Section 15(b)(6) of the Exchange Act, which gives the SEC the authority to restrict any person from participating in a distribution of penny stock if the SEC finds that such a restriction would be in the public interest.

 

Our common stock is subject to price volatility unrelated to our operations.

 

The market price of our common stock could fluctuate substantially due to a variety of factors, including market perception of our ability to achieve our planned growth, quarterly operating results of other companies in the same industry, trading volume in our common stock, changes in general conditions in the economy and the financial markets or other developments affecting our competitors or ourselves. In addition, the over-the-counter market is subject to extreme price and volume fluctuations in general. This volatility has had a significant effect on the market price of securities issued by many companies for reasons unrelated to their operating performance and could have the same effect on our common stock.

 

Trading in our common stock on the OTC Markets is limited and sporadic making it difficult for our shareholders to sell their shares or liquidate their investments.

 

Trading in our common stock is currently published on the OTC Markets. The trading price of our common stock has been subject to wide fluctuations. Trading prices of our common stock may fluctuate in response to a number of factors, many of which will be beyond our control. The stock market has generally experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of companies with no current business operation. There can be no assurance that trading prices and price earnings ratios previously experienced by our common stock will be matched or maintained. These broad market and industry factors may adversely affect the market price of our common stock, regardless of our operating performance. In the past, following periods of volatility in the market price of a company’s securities, securities class-action litigation has often been instituted. Such litigation, if instituted, could result in substantial costs for us and a diversion of management’s attention and resources.

 

- 11 -

Table of Contents

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

This item is not applicable to emerging growth companies.

 

ITEM 2. PROPERTIES

 

We maintain our corporate offices at 719 Jadwin Avenue, Richland, WA. Our telephone number is 206-451-1970.

 

ITEM 3. LEGAL PROCEEDINGS

 

We know of no other material, active or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceedings or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered beneficial shareholder are an adverse party or has a material interest adverse to us.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Market Information

 

Our common stock trades over the counter and trading is reported by OTC Markets under the QB tier under the symbol “GSTC”. The following table sets forth, for the period indicated, the prices of the common stock in the over-the-counter market, as reported and summarized by OTC Markets Group, Inc. These quotations represent inter-dealer quotations, without adjustment for retail markup, markdown, or commission and may not represent actual transactions. There is an absence of an established trading market for the Company’s common stock, as the market is limited, sporadic and highly volatile. 

 

Holders

 

As of the date of this filing, there were 42 holders of record of our common stock.

 

Dividends

 

To date, we have not paid dividends on shares of our common stock and we do not expect to declare or pay dividends on shares of our common stock in the foreseeable future. The payment of any dividends will depend upon our future earnings, if any, our financial condition, and other factors deemed relevant by our Board of Directors.

 

Common Stock

 

We are authorized to issue an unlimited number of shares common stock, with a par value of $0.001. The closing price of our common stock on January 16, 2024, as quoted by OTC Markets Group, Inc., was $0.0014. There were 1,026,417,320 shares of common stock issued and outstanding as of January 16, 2024. All shares of common stock have one vote per share on all matters including election of directors, without provision for cumulative voting. The common stock is not redeemable and has no conversion or preemptive rights. The common stock currently outstanding is validly issued, fully paid and non-assessable. In the event of liquidation of the Company, the holders of common stock will share equally in any balance of the Company’s assets available for distribution to them after satisfaction of creditors and preferred shareholders, if any. The holders of the Company’s common are entitled to equal dividends and distributions per share with respect to the common stock when, as and if, declared by the Board of Directors from funds legally available.

 

Our Articles of Incorporation, our Bylaws, and the applicable statutes of the state of Wyoming contain a more complete description of the rights and liabilities of holders of our securities.

 

During the year ended September 30, 2023, there was no modification of any instruments defining the rights of holders of the Company’s common stock and no limitation or qualification of the rights evidenced by the Company’s common stock as a result of the issuance of any other class of securities or the modification thereof.

 

- 12 -

Table of Contents

 

Non-cumulative voting

 

Holders of shares of our common stock do not have cumulative voting rights, which means that the holders of more than 50% of the outstanding shares, voting for the election of directors, can elect all of the directors to be elected, if they so choose, and, in that event, the holders of the remaining shares will not be able to elect any of our directors.

 

Securities Authorized for Issuance under Equity Compensation Plans

 

The following table shows the number of shares of common stock that could be issued upon exercise of outstanding options and warrants, the weighted average exercise price of the outstanding options and warrants, and the remaining shares available for future issuance as of September 30, 2023.

                   
Plan Category   Number of Securities to be issued upon exercise of outstanding options, warrants and rights     Weighted average exercise price of outstanding options, warrants and rights     Number of securities remaining available for future issuance  
Equity compensation plans approved by security holders.     —       —       10,000,000  
                         
Equity compensation plans not approved by security holders.     —       —       —  
                         
Total     —       —       10,000,000  

 

Preferred Stock

 

Our authority to issue preferred stock is unlimited shares of $0.001 par value preferred stock.

 

Series A Preferred Stock – Our board of directors has designated up to 6,000,000 shares of Series A Preferred Stock. The Series A Preferred Stock has a liquidation value of $2.00 per share. The initial number issued is 5,000,000 with additional shares to be issued as a dividend not to exceed a total of 6,000,000 shares. The rank of the Series A is prior to all common and preferred shares. In addition, the Series A Preferred Stock retains protective provisions to maintain their seniority with respect to liquidation or dissolution. The Series A Preferred Stock holds no voting rights and earns an 8% per annum dividend, payable in additional shares of Series A Preferred Stock. As part of a legal settlement with David Summers, during the year ended September 30, 2020, 5,800,000 shares of Series A Preferred Stock were returned to the Company and cancelled. At September 30, 2023 and 2022, no shares of the Series A Preferred Stock were issued and outstanding.

 

Series B Preferred Stock – Our board of directors has designated up to 1,000,000 shares of Series B Preferred Stock. The Series B Preferred Stock has a liquidation value of $1.00 per share. The holders of the Series B Preferred Stock are entitled to dividends of 8% per year payable quarterly in cash or in shares of common stock at the option of the Company. The holders of the Series B Preferred Stock have no voting rights. The Series B Preferred Stock is redeemable at the option of the Company at a price of $1.00 per share. At September 30, 2023 and 2022, no shares of Series B Preferred Stock were issued or outstanding.

 

Series C Preferred Stock – On September 12, 2017, our board of directors designated up to 1,200,000 shares of Series C Preferred Stock with a liquidation value of $0.50 per share. The holders of the Series C Preferred Stock have no voting rights. The Series C Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of one share of common stock for each share of Series C Preferred Stock. The Series C Preferred Stock is redeemable at the option of the Company at a price of $0.50 per share. The Series C Preferred Stock has been canceled as of September 30, 2017.

 

Series D Preferred Stock – On September 21, 2017, our board of directors designated up to 539,988 shares of Series D Preferred Stock with a liquidation value of $1.00 per share. The holders of the Series D Preferred Stock have no voting rights. The Series D Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock. The Series D Preferred Stock is not redeemable. During the year ended September 30, 2023, the Company converted 509,988 shares of Series D Preferred Stock into 50,998,800 shares of Common Stock. At September 30, 2023 and 2022, 0 and 509,988 shares of the Series D Preferred Stock were issued and outstanding.

 

- 13 -

Table of Contents

 

Series E Preferred Stock – Our board of directors has designated up to 1,000,000 shares of Series E Preferred stock. The Series E Preferred stock has voting rights on the basis of two votes for every outstanding share of common stock meaning that the holders of the Series E Preferred Stock have 2/3 of the voting rights in the Company. At September 30, 2023 and 2022, 1,000,000 shares of the Series E Preferred Stock were issued and outstanding.

 

Series F Preferred Stock – On September 21, 2017, our board of directors designated up to 501,975 shares of Series F Preferred Stock with a liquidation value of $1.00 per share. The holders of the Series F Preferred Stock have no voting rights. The Series F Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock. The Series F Preferred Stock is not redeemable. During the year ended September 30, 2019, 60,000 shares of the Series F Preferred Stock were returned for cancellation. At September 30, 2021, 386,975 shares of the Series F Preferred Stock were issued and outstanding. During the year ended September 30, 2022, 257,984 shares of Series F Preferred Stock was converted into 25,798,400 shares of common stock. At September 30, 2022, 128,991 shares of the Series F Preferred Stock were issued and outstanding. At September 30, 2023 and 2022, 128,991 shares of the Series F Preferred Stock were issued and outstanding.

 

Series G Preferred Stock - On August 11, 2021, our board of directors designated up to 1,000,000 shares of Series G Preferred Stock with a liquidation value of $1.00 per share. The holders of the Series G Preferred Stock have no voting rights except on matters related specifically to the Series G Preferred Stock. The Series G Preferred Stock carries a dividend of 8% of the stated value per share, which is cumulative and payable upon redemption, liquidation or conversion, and increases to 22% in case of default. The Series G Preferred Stock and accrued dividends are convertible beginning 180 days from issuance at the option of the holder into shares of common stock at a rate of a conversion price of 75% of the average three lowest trading prices during the 15 days prior to conversion. The Company will be required to redeem the Series G Preferred Stock upon the earlier of 15 months from issuance date or upon on event of default as defined in the agreement. The Company sold 93,500 shares for net cash proceeds of $81,250.

 

Based on the economic characteristics of the Series G Preferred Stock, the Company determined that the Series G should be accounted for as a liability under ASC 480-10, based on the discounted conversion price providing an effectively fixed monetary amount that the preferred stock is convertible into. The Company recorded a debt discount of $25,000 for the difference between the cash proceeds and the total amount to be redeemed by the holder of $106,250. The Company amortized $2,425 of this discount through September 30, 2021. The dividends on the Series G Preferred Stock are recorded as interest expense and totaled $1,164 through September 30, 2021.

 

During the year months ended September 30, 2023, the Company sold an aggregate of 89,100 shares of Series G Preferred Stock for net cash proceeds of $73,000. The Company recorded a debt discount of $16,100 for the difference between the cash proceeds and the total amount to be redeemed by the holder of $89,100. The Company amortized $28,681 of discount related to Series G Preferred Stock for the year months ended September 30, 2023. The dividends on the Series G Preferred Stock are accrued as interest. The Company recognized $10,146 of interest on the Series G Preferred Stock and had an accrued interest balance of $3,556 and $3,983 as of September 30, 2023 and September 30, 2022, respectively. During the year months ended September 30, 2023, the holder of the Series G converted 227,975 shares of Series G and $9,119 of dividends into 100,712,968 shares of common stock. The conversions were in accordance with the terms of the agreement and no gain or loss was recognized.

 

During the year ended September 30, 2022, the Company sold an aggregate of 369,875 shares of Series G Preferred Stock for net cash proceeds of $310,000. The Company recorded a debt discount of $59,875 for the difference between the cash proceeds and the total amount to be redeemed by the holder of $369,875. The Company amortized $54,664 of discount related to Series G Preferred Stock for the year months ended September 30, 2022. The dividends on the Series G Preferred Stock are accrued as interest. The Company recognized $15,852 of interest on the Series G Preferred Stock and had an accrued interest balance of $3,983 and $1,281 as of September 30, 2022 and September 30, 2021, respectively. During the year ended September 30, 2022, the holder of the Series G converted 324,500 shares of Series G into 109,052,543 shares of common stock, and the Company recognized a loss of $5,939.

 

As of September 30, 2023 and September 30, 2022, 0 and 138,875 shares of the Series G Preferred Stock were issued and outstanding, respectively.

 

- 14 -

Table of Contents

 

Recent Sales of Unregistered Securities

 

Set forth below is information regarding securities sold by during the quarter ended September 30, 2023 that were not registered under the Securities Act:

                     
Date of Sale   Title of Security   Number Sold   Consideration Received
and Description of
Underwriting or Other
Discounts to Market
Price or Convertible
Security, Afforded to
Purchasers		   Exemption from
Registration
Claimed		   If Option, Warrant
or Convertible
Security, terms of
exercise or
conversion
July 12, 2023   Common Stock   50,998,800   Conversion of 509,988 Shares of Series D Preferred Stock   Section 3(a)(9) of the Securities Act   —
                     
July 13, 2023   Common Stock  

2,105,263

 

   Cash subscription   Section 3(a)(9) of the Securities Act   —
                     
July 19, 2023   Common Stock  

1,515,152

 

   Cash subscription   Section 3(a)(9) of the Securities Act   —
                     
August 4, 2023   Common Stock   6,000,000   Cash subscription   Section 3(a)(9) of the Securities Act   —
                     
August 25, 2022   Common Stock   33,333,333   Cash subscription   Section 3(a)(9) of the Securities Act   —
                     
September 30, 2022   Common Stock   6,933,333   Conversion of Series G Preferred Stock   Section 3(a)(9) of the Securities Act   $0.0018
                     
September 30, 2023   Common Stock   11,555,556   Conversion of Series G Preferred Stock   Section 3(a)(9) of the Securities Act   $0.0018
                     
September 30, 2023   Common Stock   9,408,750   Conversion of Series G Preferred Stock   Section 3(a)(9) of the Securities Act   $0.0016
                     
September 30, 2023   Common Stock   2,000,000   Settlement of liabilities   Section 3(a)(9) of the Securities Act   —

 

ITEM 6. SELECTED FINANCIAL DATA

 

This item is not applicable to emerging growth companies.

 

- 15 -

Table of Contents

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

THIS FILING CONTAINS FORWARD-LOOKING STATEMENTS. THE WORDS “ANTICIPATED,” “BELIEVE,” “EXPECT,” “PLAN,” “INTEND,” “SEEK,” “ESTIMATE,” “PROJECT,” “WILL,” “COULD,” “MAY,” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. THESE STATEMENTS INCLUDE, AMONG OTHERS, INFORMATION REGARDING FUTURE OPERATIONS, FUTURE CAPITAL EXPENDITURES, AND FUTURE NET CASH FLOW. SUCH STATEMENTS REFLECT THE COMPANY’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND FINANCIAL PERFORMANCE AND INVOLVE RISKS AND UNCERTAINTIES, INCLUDING, WITHOUT LIMITATION, GENERAL ECONOMIC AND BUSINESS CONDITIONS, CHANGES IN FOREIGN, POLITICAL, SOCIAL, AND ECONOMIC CONDITIONS, REGULATORY INITIATIVES AND COMPLIANCE WITH GOVERNMENTAL REGULATIONS, THE ABILITY TO ACHIEVE FURTHER MARKET PENETRATION AND ADDITIONAL CUSTOMERS, AND VARIOUS OTHER MATTERS, MANY OF WHICH ARE BEYOND THE COMPANY’S CONTROL. SHOULD ONE OR MORE OF THESE RISKS OR UNCERTAINTIES OCCUR, OR SHOULD UNDERLYING ASSUMPTIONS PROVE TO BE INCORRECT, ACTUAL RESULTS MAY VARY MATERIALLY AND ADVERSELY FROM THOSE ANTICIPATED, BELIEVED, ESTIMATED, OR OTHERWISE INDICATED. CONSEQUENTLY, ALL OF THE FORWARD-LOOKING STATEMENTS MADE IN THIS FILING ARE QUALIFIED BY THESE CAUTIONARY STATEMENTS AND THERE CAN BE NO ASSURANCE OF THE ACTUAL RESULTS OR DEVELOPMENTS.

 

The following discussion and analysis of our financial condition and plan of operations should be read in conjunction with our financial statements and related notes appearing elsewhere herein. This discussion and analysis contains forward-looking statements including information about possible or assumed results of our financial conditions, operations, plans, objectives, and performance that involve risk, uncertainties, and assumptions. The actual results may differ materially from those anticipated in such forward-looking statements. For example, when we indicate that we expect to increase our product sales and potentially establish additional license relationships, these are forward-looking statements. The words expect, anticipate, estimate or similar expressions are also used to indicate forward-looking statements.

 

Plan of Operations

 

We believe we do not have adequate funds to fully execute our business plan for the next twelve months unless we obtain additional funding. However, should we not raise this capital, we will allocate our funding to first assure that all State, Federal and SEC requirements are met.

 

On November 2, 2023, the Company entered into a definitive agreement with Advanced Innovative Partners (“AIP”) for AIP to provide advice to Company and SMI HealthCare LLC (“SMIHC”) on the global design, strategy and execution of clinical trials, regulatory filings, intellectual property rights filings, and manufacturing for Project Amethyst™. Project Amethyst™ is a compound intended to treat neurodegeneration from multiple sclerosis (“MS”). GSTC is the exclusive worldwide licensee for Project Amethyst™, including all patents and patent applications relating thereto.

 

The Company and AIP agreement has been approved by the parties' respective boards and is immediately effective. AIP will initially advise the Company and SMIHC on the design and launch of an initial clinical trial in India and the associated regulatory approvals for GSTC's MS products in North America and Europe. A memorandum of understanding previously had been entered into by the Company and AIP to design and implement clinical trials for Project Amethyst™, subject to the execution of definitive agreement. Pursuant to the parties' agreement, the Company retains ownership of all intellectual property rights, and final approval of Project Amethyst™, including the right to engage additional advisors and subject matter experts. For its consulting services, AIP will be paid a monthly consulting fee and bonuses, a portion of which will be deferred and will become payable only if the Company secures FDA marketing approval. If AIP introduces the Company or SMIHC to potential customers, or strategic partners, subject to compliance with applicable law, AIP may also become entitled to receive commissions on certain revenues or profits derived from those relationships.

 

The agreement with AIP builds on the recent agreement of the Company with SMI HealthCare LLC (“SMIHC”) to manage an initial clinical trial, regulatory filings, intellectual property rights filings, manufacturing, sales and distribution in India, Southeast Asia, Africa, and the Middle East. On September 26, 2023, the Company entered into an agreement with SMIHC to manage an initial clinical trial, regulatory filings, intellectual property rights filings, manufacturing, sales and distribution in India, Southeast Asia, Africa, and the Middle East, excluding Israel and Iraq, and for government and private aid organizations, for the Company's patented

 

- 16 -

Table of Contents

 

Multiple Sclerosis treatment. The agreement with SMIHC was approved by the parties’ respective boards of directors. Implementation of the first phase is subject to the Company arranging financing. The first phase includes formation of the Company and SMIHC subsidiaries in India, the clinical trial, regulatory and intellectual property rights filings in India, identifying manufacturers, and planning for the commercial launch in India and countries in the region that accept Drug Controller General of India (“ DCGI”) approvals. Implementation of the second phase is expected to commence approximately nine months later, and is subject to receipt of DCGI marketing approval and the Company arranging financing. The second phase may continue for the duration of patent validity, and consists initially of sales, marketing and distribution in India and thereafter, countries in SMIHC’s territory that will permit sales and distribution based upon DCGI approval. After proof of market in those countries, the intention is to seek regulatory approvals elsewhere in SMIHC’s territory in order to expand the sales and distribution of the Company’s MS products. Pursuant to with SMIHC, the Company will receive a 5% royalty on any sales under the agreement by the company formed in India under this agreement, and 50% of any sublicense revenue from the India company formed under the agreement. The Company will pay the following (i) initial fees of between $15,000 - $22,500, and monthly fees of between $5,000 and $12,500 per month for Phase A (ii) monthly fees of $12,500, increase after six months to $17,500 per month, and to $25,000 per month after one year. The fee will increase by 5% per year thereafter for Phase B (iii) an initial management fee of $15,000 upon certain milestones and monthly management fee of $5,000 per month thereafter.

 

SMIHC is an affiliate of SMI Group LLC, a privately-held Los Angeles-based company. The chairman of SMI Group is a shareholder of the Company and consultant, though he did not advise the Company on this transaction and has waived fees payable to an SMI company for introducing SMIHC to the Company.

 

Results of Operations

 

Revenue

 

For the years ended September 30, 2023 and 2022 the Company had no revenue.

 

Cost of Goods Sold

 

We had no cost of goods sold for the years ended September 30, 2023 and 2022.

 

Sales, General, and Administrative Expenses

 

We recognized general and administrative expense of $1,864,370 for the year months ended September 30, 2023 compared to $1,265,065 for the comparable period of 2022. The increase in general and administrative expense was primarily related to an increase in stock -based compensation associated with common stock issued to a consultant, new option awards to officers in the current period and with expense related to the common stock warrant repricing, partially offset by a decrease in legal fees.

 

Loss on Settlement of Liabilities

 

We recognized a gain of $6,724 and a loss of $146,460 on the settlement of liabilities during the years ended September 30, 2023 and 2022, respectively. In the current period, the shares related to the settlement of royalty payable balance with 7 to Stand resulted in a loss of $3,442 and the settlement of accrued compensation with the Company’s CEO resulted in a gain of $10,165. In 2022, the loss was related to shares issued to settle $15,000 of advances.

 

Interest Expense

 

We recognized interest expense of $91,603 for the year ended September 30, 2023 compared to $70,346 for the comparable period of 2022. The increase was due primarily to the amortization of the discount on convertible notes payable and Series G Preferred Stock during the current period comparable to period of the prior year.

 

Net Loss

 

For the reasons above, our net loss for the year ended September 30, 2023 was $1,949,249 an increase of $461,439 or approximately 31% compared to a net loss of $1,487,810 for the year ended September 30, 2022.

 

- 17 -

Table of Contents

 

Liquidity and Capital Resources

 

At September 30, 2023, we had cash of $0 and a working capital deficit in the amount of $1,433,861. During the year ended September 30, 2023, we had cash used in operating activities of $205,760, consisting of our net loss of $1,949,249, partially offset by non-cash compensation of $464,878, gain on settlement of liabilities of $6,724, and amortization of discount on notes payable of $33,391. We have an accumulated deficit at September 30, 2023 in the amount of $20,454,025. We generated cash flows from financing activities in the amount of $72,500 of proceeds from the common stock subscribed, $55,000 from convertible notes payable, net, $4,395 from the related party advances and $73,000 from the sale of common stock, which were offset by the repayment of related party advances of $5,500.

 

We had no material commitments for capital expenditures or inventory purchases as of September 30, 2023. However, should we execute our business plan as anticipated, we will incur substantial capital expenditures and require financing in addition to what is required to fund our present operation.

 

We intend to pursue capital through public or private financing, as well as borrowing and other sources in order to finance our business activities. We cannot guarantee that additional funding will be available on favorable terms, if at all. If adequate funds are not available, then our ability to continue our operations may be significantly hindered.

 

Additional Financing

 

Additional financing is required to continue operations. Although actively searching for available capital, the Company does not have any current arrangements for additional outside sources of financing and cannot provide any assurance that such financing will be available.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

 

Critical Accounting Policies and Estimates

 

We prepare our financial statements in conformity with GAAP, which requires management to make certain estimates and assumptions and apply judgments. We base our estimates and judgments on historical experience, current trends, and other factors that management believes to be important at the time the financial statements are prepared; actual results could differ from our estimates and such differences could be material. We have identified below the critical accounting policies, which are assumptions made by management about matters that are highly uncertain and that are of critical importance in the presentation of our financial position, results of operations and cash flows. Due to the need to make estimates about the effect of matters that are inherently uncertain, materially different amounts could be reported under different conditions or using different assumptions. On a regular basis, we review our critical accounting policies and how they are applied in the preparation our financial statements.

 

Use of estimates - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Going concern - The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the year ended September 30, 2023, the Company had a net loss of $1,949,249 and generated negative cash flow from operating activities in the amount of $205,760. In view of these matters, there is substantial doubt regarding the Company’s ability to continue as a going concern, which is dependent upon its ability to achieve a level of profitability or to obtain additional capital to finance its operations. The Company intends on financing its future activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

- 18 -

Table of Contents

 

New Accounting Pronouncements

 

For a description of recent accounting standards, including the expected dates of adoption and estimated effects, if any, on our financial statements, see “Note 3: Significant Accounting Polices: Recently Issued Accounting Pronouncements” in Part II, Item 8 of this Form 10-K.

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

This item is not applicable to smaller reporting companies.

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

GlobeStar Therapeutics Corporation

 

Consolidated Financial Statements

 

September 30, 2023

 

Contents

 

Report of Independent Registered Public Accounting Firm (PCAOB ID: 5525) 20
Report of Independent Registered Public Accounting Firm (PCAOB ID: 2738) 22
Consolidated Balance Sheets 23
Consolidated Statements of Operations 24
Consolidated Statements of Stockholders’ Deficit 25
Consolidated Statements of Cash Flows 26
Notes to the Consolidated Financial Statements 27

 

- 19 -

Table of Contents

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Shareholders of Globestar Therapeutics Corp.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheet of Globestar Therapeutics Corp. (“the Company”) as of September 30, 2023, and the related consolidated statements of operations, statements of stockholders’ deficit, and cash flows for the year ended September 30, 2023, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of September 30, 2023 and the results of its operations and its cash flows for the year ended September 30, 2023, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has an accumulated deficit, net losses, and a working capital deficit. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

- 20 -

Table of Contents

 

Valuation of Stock Options and Warrants – Reference Note 6 to the Financial Statements.

 

As reflected in the Company’s financial statements, the Company utilizes the Black-Scholes option pricing model to determine the issue-date fair value of options and warrants. Auditing management’s calculation of the fair value of its equity instruments involves significant judgment and estimate in order to determine the appropriate fair value.

 

How the Critical Audit Matter Was Addressed in the Audit

 

Our principal audit procedures to evaluate management’s analysis on the valuation and calculations of fair value of equity instruments included, among other things, the following:

 

● Obtaining and evaluating the underlying issuance and sale agreements and approvals.
● Assessing the relevance and reliability of the inputs utilized in the Company’s estimates of fair value by developing independent expectations.

 

 

Fruci & Associates, II, PLLC – PCAOB ID #5525

We have served as the Company’s auditor since 2023.

 

 Spokane, Washington

January 19, 2024

 

- 21 -

Table of Contents

 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Stockholders of GlobeStar Therapeutics Corporation

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheet of GlobeStar Therapeutics Corporation (the Company) as of September 30, 2022, and the related consolidated statements of operations, stockholders’ deficit, and cash flows for the year ended September 30, 2022, and the related notes (collectively referred to as the financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of September 30, 2022, and the result of its consolidated operations and its cash flows for the year ended September 30, 2022, in conformity with accounting principles generally accepted in the United States of America.

 

The Company's Ability to Continue as a Going Concern

 

The accompanying financial states have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company suffered a net loss from operations and has a net capital deficiency, which raises substantial doubt about its ability to continue as a going concern. Management’s plans regarding those matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.

 

/s/ M&K CPAS, PLLC

We served as the Company’s auditor from 2012 to 2023.

 

The Woodlands, Texas

 

January 9, 2023

 

- 22 -

Table of Contents

 

GLOBESTAR THERAPEUTICS CORPORATION

CONSOLIDATED BALANCE SHEETS

               
    September 30,   September 30,  
    2023   2022  
CURRENT ASSETS              
Cash and cash equivalents   $ —   $ 6,365  
Prepaid expenses     —     3,550  
Total current assets     —     9,915  
               
TOTAL ASSETS   $ —   $ 9,915  
               
LIABILITIES AND STOCKHOLDERS’ DEFICIT              
Current Liabilities              
Accounts payable and accrued liabilities   $ 328,178   $ 380,735  
Accounts payable to related party     454,665     379,126  
Related party advances     6,295     12,400  
Advances payable     59,650     59,650  
Note payable     300,000     —  
Current portion of convertible notes payable     59,710     20,000  
Series G Preferred Stock Liability, net of discount of $0 and $12,581, respectively     —     126,294  
Accrued interest payable     225,363     226,270  
Total current liabilities     1,433,861     1,204,475  
               
TOTAL LIABILITIES     1,433,861     1,204,475  
               
COMMITMENTS AND CONTINGENCIES              
               
STOCKHOLDERS’ DEFICIT              
Common stock, $0.001 par value, unlimited shares authorized; 996,119,530 and 722,326,669 shares issued and outstanding at September 30, 2023 and 2022, respectively     996,119     722,325  
Preferred stock; 20,000,000 shares authorized:              
Series A Preferred Stock, $0.001 par value, 0 and 0 shares issued and outstanding at September 30, 2023 and 2022, respectively     —     —  
Series B Preferred Stock, $0.001 par value, 0 and 0 shares issued and outstanding at September 30, 2023 and 2022, respectively     —     —  
Series C Preferred Stock, $0.001 par value, 0 and 0 shares issued and outstanding at September 30, 2023 and 2022, respectively     —     —  
Series D Preferred Stock, $0.001 par value; 0 and 509,988 shares issued and outstanding at September 30, 2023 and 2022, respectively     —     510  
Series E Preferred Stock, $0.001 par value; 1,000,000 shares issued and outstanding at September 30, 2023 and 2022, respectively     1,000     1,000  
Series F Preferred Stock; $0.001 par value; 128,991 shares issued and outstanding at September 30, 2023 and 2022, respectively     129     129  
Additional paid-in capital     18,022,916     16,581,252  
Stock payable, consisting of 0 and 1,515,152 shares to be issued at September 30, 2023 and 2022, respectively     —     5,000  
Accumulated deficit     (20,454,025 )   (18,504,776 )
               
TOTAL STOCKHOLDERS’ DEFICIT     (1,433,861 )   (1,194,560 )
               
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT   $ —   $ 9,915  

 

The accompanying footnotes are an integral part of these financial statements.

 

- 23 -

Table of Contents

 

GLOBESTAR THERAPEUTICS CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

             
    Twelve Months Ended  
    September 30,  
    2022     2022  
             
REVENUE   $ —     $ —  
Cost of goods sold     —       —  
Gross profit (loss)     —       —  
                 
OPERATING EXPENSES                
General and administrative expenses     1,864,370       1,265,065  
Total operating expenses     1,864,370       1,265,065  
                 
LOSS FROM OPERATIONS     (1,864,370 )     (1,265,065 )
                 
OTHER INCOME (EXPENSE)                
Gain (loss) on settlement of liabilities, related party     6,724       (146,460 )
Loss on conversion of preferred stock liability     —       (5,939 )
Interest expense     (91,603 )     (70,346 )
Total other expenses     (84,879 )     (222,745 )
                 
Net loss   $ (1,949,249 )   $ (1,487,810 )
                 
Net loss per share available to common shareholders   $ (0.00 )   $ (0.00 )
                 
Weighted average shares outstanding - basic and diluted     827,324,789       628,539,782  

 

The accompanying footnotes are an integral part of these consolidated financial statements.

 

- 24 -

Table of Contents

 

GLOBESTAR THERAPEUTICS CORPORATION

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

                                                                   
                    Original              
        Series D   Series E   Series F   Additional           Total  
  Common stock   Preferred Stock   Preferred Stock   Preferred Stock   paid-in   Stock   Accumulated   Equity  
    Shares   Par   Shares   Amount   Shares   Amount   Shares   Amount   capital   Payable   Deficit   (Deficit)  
                                                                   
Balance, September 30, 2021   561,495,726   $ 561,494   509,988   $ 510   1,000,000   $ 1,000   386,975   $ 387   $ 15,228,254   $ 499,500   $ (17,016,966 ) $ (725,821 )
                                                                   
Common stock issued for conversion of convertible note payable and accrued interest   25,798,400     25,798   —     —   —     —   (257,984 )   (258 )   (25,540 )   —     —     —  
Common stock subscribed for cash proceeds   —     —   —     —   —     —   —     —     —     5,000     —     5,000  
Common stock issued for stock payable   19,980,000     19,980   —     —   —     —   —     —     479,520     (499,500 )   —     —  
Common stock issued for settlement liability   6,000,000     6,000   —     —   —     —   —     —     155,460     —     —     161,460  
Stock-based compensation   —     —   —     —   —     —   —     —     322,266     —     —     322,266  
Stock-based compensation, related parties   —     —   —     —   —     —   —     —     186,926     —     —     186,926  
Conversion of Series G Preferred Stock to common stock   109,052,543     109,053   —     —   —     —   —     —     234,366     —     —     343,419  
Net loss for the year ended September 30, 2022   —     —   —     —   —     —   —     —     —     —     (1,487,810 )   (1,487,810 )
Balance, September 30, 2022   722,326,669     722,325   509,988     510   1,000,000     1,000   128,991     129     16,581,252     5,000     (18,504,776 )   (1,194,560 )
                                                                   
Conversion of Series G Preferred Stock to common   100,712,968     100,713   —     —   —     —   —     —     136,380     —     —     237,093  
Common stock issued for stock payable   1,515,152     1,515   —     —   —     —   —     —     3,485     (5,000 )   —     —  
Common stock subscribed for cash proceeds   51,882,319     51,883   —     —       —   —     — —     25,617     —     —     77,500  
Conversion of Series D Preferred Stock to common   50,998,800     50,999   (509,988 )   (510 ) —     —   —     —     (50,489 )   —     —     —  
Common stock issued for the conversion of debt   2,000,000     2,000   —     —       —   —     — —     18,000     —     —     20,000  
Common stock issued for settlement of liability, related party   16,683,622     16,684   —     —       —   —     — —     88,694     —     —     105,378  
Stock-based compensation   50,000,000     50,000   —     —       —   —     — —     414,878     —     —     464,878  
Stock-based compensation, related parties   —     —   —     —       —   —     — —     805,098     —     —     805,098  
Net loss for the year ended September 30, 2023   —     —   —     —   —     —   —     —     —     —     (1,949,249 )   (1,949,249 )
Balance, September 30, 2023   996,119,530   $ 996,119   —   $ —   1,000,000   $ 1,000   128,991   $ 129   $ 18,022,916   $ 5,000   $ (20,454,025 ) $ (1,433,861 )

 

The accompanying footnotes are an integral part of these consolidated financial statements.

 

- 25 -

Table of Contents

 

GLOBESTAR THERAPEUTICS CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

                 
    Twelve Months Ended  
    September 30,  
    2023     2022  
CASH FLOW FROM OPERATING ACTIVITIES:                
Net loss   $ (1,949,249 )   $ (1,487,810 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Stock compensation     464,878       322,266  
Stock compensation, related parties     805,098       186,926  
Amortization of discount on convertible note payable     33,391       54,664  
(Gain) loss on settlement of liabilities, related party     (6,724 )     146,460  
Loss on conversion of preferred stock liability     —       5,939  
Changes in operating assets and liabilities                
Prepaid expenses     3,550       (3,550 )
Accounts payable and accrued liabilities     247,444       172,957  
Accounts payable and accrued liabilities to related party     187,641       259,471  
Accrued interest payable     8,211       15,682  
NET CASH USED IN OPERATING ACTIVITIES     (205,760 )     (326,995 )
                 
CASH FLOWS FROM FINANCING ACTIVITIES                
Proceeds from convertible notes payable     55,000       —  
Proceeds from sale of share-settled Series G preferred stock     73,000       310,000  
Proceeds from related party advances     4,395       28,900  
Repayment of related party advances     (5,500 )     (16,500 )
Proceeds from sale of common stock     72,500       5,000  
NET CASH PROVIDED BY FINANCING ACTIVITIES     199,395       327,400  
                 
NET INCREASE (DECREASE) IN CASH     (6,365 )     405  
                 
Cash at beginning of period     6,365       5,960  
                 
Cash at end of period   $ —     $ 6,365  
                 
Cash paid during the period for:                
Interest   $ —     $ —  
Taxes   $ —     $ —  
                 
Noncash investing and financing transactions:                
Conversion of Series D preferred stock   $ 50,999     $ —  
Conversion of Series F preferred stock   $ —     $ 25,798  
Conversion of Series G preferred stock   $ 227,975     $ 324,500  
Common stock issued for stock payable   $ 5,000     $ 499,500  
Common stock issued for settlement of liabilities   $ —     $ 15,000  
Common stock issued for the conversion of debt   $ 20,000     $ —  
Note payable issued for settlement of accounts payable   $ 300,000     $ —  

 

The accompanying footnotes are an integral part of these consolidated financial statements.

 

- 26 -

Table of Contents

 

GLOBESTAR THERAPEUTICS CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2023

 

Note 1. General Organization and Business

 

GlobeStar Therapeutics Corporation (the “Company”) was incorporated on April 29, 2016. The Company’s year-end is September 30. On October 4, 2019, the Company filed Articles of Continuance with the Secretary of State of Wyoming to continue its business in the state of Wyoming. As part of these Articles of Continuance, effective October 4, 2019, the Company has no limit on the authorized shares of common stock that can be issued. The Company filed its Certificate of Dissolution with the Secretary of State of Nevada on October 21, 2019 because it is no longer a Nevada corporation.

 

The Company is developing an expanded platform of products that include addition of treatment for Multiple Sclerosis and other neurodegenerative diseases. The potential pharmaceutical products related to treatment for multiple sclerosis are licensed to the Company through the worldwide licensing agreement described in Note 8.

 

Note 2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The consolidated financial statements of the Company include the accounts of the Company and its wholly owned subsidiaries, SomaCeuticals, Inc., First Titan Energy, LLC and First Titan Technical, LLC from the date of their formations or acquisition. Significant intercompany transactions have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

Fair Value of Financial Instruments

 

The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization. 

 

FASB Accounting Standards Codification (ASC) 820 Fair Value Measurements and Disclosures (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
   
Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
   
Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2023. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accounts payable and accrued expenses.

 

Effective June 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to each performance obligation in the contract; and (5) recognizing revenue when each performance obligation is satisfied.

 

Advertising and Marketing Costs

 

We expense advertising and marketing costs as incurred. Advertising and marketing costs were $3,900 and $43,031 for the years ended September 30, 2023 and 2022, respectively.

 

Research and Development Costs

 

Research and development costs are expensed as incurred. The Company incurred no research and development costs during the years ended September 30, 2023 and 2022.

 

Cash and Cash Equivalents

 

All cash is maintained with a major financial institution in the United States. Deposits with this bank may occasionally exceed the amount of insurance provided on such deposits. For the purpose of the financial statements, cash includes cash in banks. Cash was $0 and $6,365 as of September 30, 2023 and 2022, respectively. There were no cash equivalents as of September 30, 2023 and 2022.

 

Income Taxes

 

The Company accounts for income taxes under ASC 740 Income Taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized as of September 30, 2023 and 2022.

 

Commitments and Contingencies

 

The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. There are no known commitments or contingencies as of September 30, 2023 or 2022.

 

Recently Issued Accounting Pronouncements

 

Accounting standards promulgated by the Financial Accounting Standards Board (the “FASB”) are subject to change. Changes in such standards may have an impact on our future financial statements. The following are a summary of recent accounting developments.

 

In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification; and (3) revises the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The Company adopted this guidance early on October 1, 2023 with no impact to the consolidated financial statements or results of operations of the Company.

 

There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on our consolidated financial position, results of operations or cash flows.

 

Note 3. Going Concern

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. For the year ended September 30, 2023, the Company had a net loss of $1,949,249. As of September 30, 2023, the Company had a working capital deficit of $1,433,861 and an accumulated deficit of $20,454,025. The Company has no revenue. Without additional capital, the Company will not be able to remain in business.

 

These factors raise a substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

 

Management has plans to address the Company’s financial situation as follows:

 

In the near term, management plans to continue to focus on raising the funds necessary to implement the Company’s business plan. Management will continue to seek out debt financing to obtain the capital required to meet the Company’s financial obligations. There is no assurance, however, that lenders will advance capital to the Company or that the new business operations will be profitable. The possibility of failure in obtaining additional funding and the potential inability to achieve profitability raise doubts about the Company’s ability to continue as a going concern.

 

In the long term, management believes that the Company’s projects and initiatives will be successful and will provide cash flow to the Company, which will be used to finance the Company’s future growth. However, there can be no assurances that the Company’s planned activities will be successful, or that the Company will ultimately attain profitability. The Company’s long-term viability depends on its ability to obtain adequate sources of debt or equity funding to meet current commitments and fund the continuation of its business operations, and the ability of the Company to achieve adequate profitability and cash flows from operations to sustain its operations.

 

Note 4. Related Party Transactions

 

For the year ended September 30, 2023

 

As of September 30, 2023 and September 30, 2022, the Company owed $454,665 and $379,126 to officers of the Company for compensation which are recorded as accounts payable related party. Additionally, during the years ended September 30, 2023 and 2022 the Company received short term, unsecured, non-interest bearing advances from the Company’s CEO totaling $21,200 and $2,500, respectively. As of September 30, 2023 and 2022, the Company owed $6,295 and $12,400 on these related party advances, respectively.

 

In February 2022, the Company entered into an amended and restatement employment agreement with Jim Katzaroff, the CEO. Mr. Katzaroff is entitled to an annual salary of $180,000 and a bonus as determined by the Board of Directors. Mr. Katzaroff may elect to receive payment in shares of stock based on the average of the three lowest trading prices for the 15 days prior to election of payment in stock. Further, in the event of a change of control of the Company, Mr. Katzaroff is entitled to a payment equal to 2.99 multiplied by the larger of the total compensation paid to Mr. Katzaroff over the prior 12-month period or the average compensation paid or payable to the Consultant over the prior three years.

 

The Company awarded Mr. Katzaroff a total of 35,000,000 common stock options with an exercise price of $0.009 per share, an exercise term of five years. The options vest 50% immediately, and the remainder on monthly basis over two years. Mr. Katzaroff is also entitled to additional options in the event of the Company issuing equity or equity equivalents in the future, with him receiving an amount of options equal to 3% of future options or warrants issued, excluding grants to officers. The exercise price of these additional options will be 110% of the price per equity equivalent. To date, a total of 11,632,356 additional options were issued to Mr. Katzaroff pursuant to the agreement terms. The total fair value of these option grants at issuance was $53,117. During the years ended September 30, 2023 and 2022, the Company recognized $108,802 and $186,926 of stock-based compensation, related to outstanding stock options under this agreement, respectively. At September 30, 2023, the Company had $42,228 of unrecognized expense related to options.

 

Additionally, Mr. Katzaroff will earn a fee related to any strategic transaction, as defined in the agreement, including but not limited to acquisitions, divestitures, partnerships or joint ventures, of at least 2% for any transactions not introduced by Mr. Katzaroff, or 4% for any introduced by Mr. Katzaroff of up to $20,000,000, and an additional 0.75% - 3.5% for amounts above that threshold. As of June 30, 2023, no amounts have been earned or paid.

 

Mr. Katzaroff will also receive an activity fee of 3% of gross revenues related to activities including securing a variety of vendor, sales or advertising relationships, or any new revenue generating activity. If such activity is a cost saving initiative instead of revenue generating, Mr. Katzaroff will receive 10% of the cost savings. As of September 30, 2023, no amounts have been earned or paid.

 

On April 4, 2023, the Company issued 7,422,535 shares to James Katzaroff to settle $50,000 of accrued compensation. The Company recognized a loss of $3,442 on this issuance based on the fair value of the shares issued.

 

On August 4, 2023, the Company issued 2,000,000 shares to its CFO Robert Chicoski to settle $12,000 of accrued compensation. The shares had a fair value of $3,600. No gain was recognized due to the related party nature of the transaction, with the Company recognizing the settlement in additional paid in capital.

 

On September 26, 2023, the Company entered into an agreement with SMI HealthCare LLC (“SMIHC”) to manage an initial clinical trial, regulatory filings, intellectual property rights filings, manufacturing, sales and distribution in India, Southeast Asia, Africa, and the Middle East, excluding Israel and Iraq, and for government and private aid organizations, for the Company's patented Multiple Sclerosis treatment. The agreement with SMIHC was approved by the parties’ respective boards of directors. Implementation of the first phase is subject to the Company arranging financing. The first phase includes formation of the Company and SMIHC subsidiaries in India, the clinical trial, regulatory and intellectual property rights filings in India, identifying manufacturers, and planning for the commercial launch in India and countries in the region that accept Drug Controller General of India (“DCGI”) approvals. Implementation of the second phase is expected to commence approximately nine months later, and is subject to receipt of DCGI marketing approval and the Company arranging financing. The second phase may continue for the duration of patent validity, and consists initially of sales, marketing and distribution in India and thereafter, countries in SMIHC’s territory that will permit sales and distribution based upon DCGI approval. After proof of market in those countries, the intention is to seek regulatory approvals elsewhere in SMIHC’s territory in order to expand the sales and distribution of the Company’s MS products. Pursuant to with SMIHC, the Company will receive a 5% royalty on any sales under the agreement by the company formed in India under this agreement, and 50% of any sublicense revenue from the India company formed under the agreement. The Company will pay the following (i) initial fees of between $15,000 - $22,500, and monthly fees of between $5,000 and $12,500 per month for Phase A (ii) monthly fees of $12,500, increase after six months to $17,500 per month, and to $25,000 per month after one year. The fee will increase by 5% per year thereafter for Phase B (iii) an initial management fee of $15,000 upon certain milestones and monthly management fee of $5,000 per month thereafter.

 

SMIHC is an affiliate of SMI Group LLC, a privately-held Los Angeles-based company. Kevin Spivak, a shareholder of the Company and consultant is the chairman of SMI Group though he did not advise the Company on this transaction and has waived fees payable to an SMI company for introducing SMIHC to the Company.

 

On September 19, 2023, the Company entered into a supplement to employment agreement with Jim Katzaroff, the CEO. For Mr. Katzaroff’s contribution to the SMIHC transaction, he will be paid the following (i) during the term of the agreement with SMIHC, a fee of 3% of any SMIHC generated revenue and (ii) not less than ¼ of the participation in Pro Forma Profits Before Tax to be payable to the Company at its senior executive pursuant to the SMIHC translation. Additionally, for Mr. Katzaroff’s contribution to the AIP transaction, he will be paid the following (i) if the Company invests in AIP, or merges with AIP, Mr. Katzaroff will receive a fee ranging from 1.5% - 4% during on the aggregate consideration of the AIP transaction and (ii) if AIP generated any revenue for the Company by reason of introductions, sales agency, distribution or other similar activities, he will receive a 3% fee for the term of the AIP transaction.

 

Note 5. Convertible Notes Payable and Advances

 

Convertible notes payable consisted of the following at September 30, 2023 and 2022:

                 
    September 30,
2023		     September 30,
2022		  
Convertible note dated April 13, 2017 in the original principal amount of $20,000, no stated maturity date, bearing interest at 3% per year, convertible into common stock at a rate of $0.01 per share.   $ —     $ 20,000  
Convertible note dated May 10, 2023 in the original principal amount of $21,300 maturing May 10, 2024, bearing interest at 12%, convertible beginning six months from issuance into common stock at a rate of 61% of the lowest trading price during the 20 days prior to conversion.     21,300       —  
Convertible note dated July 3, 2023 in the original principal amount of $47,250 maturing April 15, 2024, bearing interest at 12%, convertible beginning six months from issuance into common stock at a rate of 61% of the lowest trading price during the 20 days prior to conversion.     47,250       —  
Total convertible notes payable     68,550       20,000  
Unamortized discount     (8,840 )     —  
                 
Total current convertible notes payable, net of discount   $ 59,710     $ 20,000  

 

All principal along with accrued interest is payable on the maturity date. The notes are convertible into common stock at the option of the holder. The holder of the notes cannot convert the notes into shares of common stock if that conversion would result in the holder owning more than 4.9% of the outstanding stock of the Company.

 

On May 10, 2023, the Company entered into a Securities Purchase Agreement (the “May 2023 Securities Purchase Agreement”) with 1800 Diagonal Lending LLC (“1800 Diagonal”). Pursuant to the terms of the May 2023 Securities Purchase Agreement, the Company issued a convertible promissory note (the “May 2023 Note”) to 1800 Diagonal in the aggregate principal amount of $21,300 with the Company receiving $15,000 in cash proceeds. Effective May 10, 2023, the Company issued the May 2023 Note to 1800 Diagonal consistent with the terms of the May 2023 Securities Purchase Agreement. The May 2023 Note bears interest at 12%, with a 22% rate in the event of default, with an Original Issue Discount of $1,050 and matures on May 10, 2024. Pursuant to the terms of the May 2023 Note, the outstanding principal and accrued interest on the note shall be convertible beginning six months from issuance into shares of the Company’s common stock at 61% of the lowest trading price of the Company’s common stock during the 20 days prior to conversion. The Company recognized $6,300 of discount and deferred finance costs and amortized $2,462 during the six months ended June 30, 2023. The conversion option on the note payable was not bifurcated as a derivative under ASC 815 due to sufficient authorized shares being available to settle the conversion feature.

 

On July 3, 2023, the Company entered into a Securities Purchase Agreement (the “July 2023 Securities Purchase Agreement”) with 1800 Diagonal Lending LLC (“1800 Diagonal”). Pursuant to the terms of the July 2023 Securities Purchase Agreement, the Company issued a convertible promissory note (the “May 2023 Note”) to 1800 Diagonal in the aggregate principal amount of $47,250 with the Company receiving $40,000 in cash proceeds. Effective July 3, 2023, the Company issued the July 2023 Note to 1800 Diagonal consistent with the terms of the July 2023 Securities Purchase Agreement. The July 2023 Note bears interest at 12%, with a 22% rate in the event of default, with an Original Issue Discount of $2,250 and matures on April. 15, 2024. Pursuant to the terms of the July 2023 Note, the outstanding principal and accrued interest on the note shall be convertible beginning six months from issuance into shares of the Company’s common stock at 61% of the lowest trading price of the Company’s common stock during the 20 days prior to conversion. The Company recognized $7,250 of discount and deferred finance costs and amortized $2,248 during the year ended September 30, 2023. The conversion option on the note payable was not bifurcated as a derivative under ASC 815 due to sufficient authorized shares being available to settle the conversion feature.

 

As of September 30, 2023 and September 30, 2022, accrued interest on convertible notes payable was $225,363 and $225,953, respectively.

 

Conversions to Common Stock

 

During the year ended September 30, 2023, the holders of the April 2017 convertible note payable elected to convert principal of $20,000 into 2,000,000 shares of common stock. The conversion was in accordance with the terms of the agreement and no gain or loss was recognized.

 

Advances

 

As of September 30, 2023 and 2022, the Company had non-interest bearing advances payable to third parties of $59,650. These advances are payable on demand.

 

Note 6. Stockholders’ deficit

 

Preferred Stock

 

Our authorized preferred stock consists of 20,000,000 shares of $0.001 par value preferred stock.

 

Series A Preferred Stock – Our board of directors has designated up to 6,000,000 shares of Series A Preferred Stock. The Series A Preferred Stock has a liquidation value of $2.00 per share. The initial number issued is 5,000,000 with additional shares to be issued as a dividend not to exceed a total of 6,000,000 shares. The rank of the Series A is prior to all common and preferred shares. In addition, the Series A Preferred Stock retains protective provisions to maintain their seniority with respect to liquidation or dissolution. The Series A Preferred Stock holds no voting rights and earns an 8% per annum dividend, payable in additional shares of Series A Preferred Stock. At September 30, 2023 and 2022, there were no shares of our Series A Preferred Stock outstanding, respectively.

 

Series B Preferred Stock – Our board of directors has designated up to 1,000,000 shares of Series B Preferred Stock. The Series B Preferred Stock has a liquidation value of $1.00 per share. The holders of the Series B Preferred Stock are entitled to dividends of 8% per year payable quarterly in cash or in shares of common stock at the option of the Company. The holders of the Series B Preferred Stock have no voting rights. The Series B Preferred Stock is redeemable at the option of the Company at a price of $1.00 per share. At September 30, 2023 and 2022, there were no shares of our Series B Preferred Stock outstanding.

 

Series C Preferred Stock – On September 12, 2017, our board of directors designated up to 1,200,000 shares of Series C Preferred Stock with a liquidation value of $0.50 per share. The holders of the Series C Preferred Stock have no voting rights. The Series C Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of one share of common stock for each share of Series C Preferred Stock. The Series C Preferred Stock is redeemable at the option of the Company at a price of $0.50 per share. The Series C Preferred Stock has been canceled, and there are no shares of Series C Preferred Stock outstanding as of September 30, 2023 and 2022.

 

Series D Preferred Stock – On September 21, 2017, our board of directors designated up to 539,988 shares of Series D Preferred Stock with a liquidation value of $1.00 per share. The holders of the Series D Preferred Stock have no voting rights. The Series D Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock. The Series D Preferred Stock is not redeemable. In July 2023, the Company issued 50,998,800 shares to the holder of the Series D Preferred Stock for Full conversion of 509,988 shares outstanding. At September 30, 2023 and 2022, there were 0 and 509,988 shares of Series D Preferred Stock outstanding, respectively.

 

Series E Preferred Stock – On August 3, 2015, our board of directors designated 1,000,000 shares of Series E Preferred stock. The Series E Preferred stock is subordinate to our common stock. It does not receive dividends and does not participate in equity distributions. The Series E Preferred stock retained 2/3 of the voting rights in the Company.

 

At September 30, 2023 and 2022, there were 1,000,000 shares of Series E Preferred stock outstanding. Dividends, when, as and if declared by the Board of Directors, shall be paid out of funds at the time legally available for such purposes.

 

Series F Preferred Stock – On September 21, 2017, our board of directors designated up to 501,975 shares of Series F Preferred Stock with a liquidation value of $1.00 per share. The holders of the Series F Preferred Stock have no voting rights. The Series F Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock. The Series F Preferred Stock is not redeemable. At September 30, 2021, 386,975 shares of the Series F Preferred Stock were issued and outstanding. During the year ended September 30, 2022, 257,984 shares of Series F Preferred Stock was converted into 25,798,400 shares of common stock. At September 30, 2023 and 2022, 128,991 shares of the Series F Preferred Stock were issued and outstanding.

 

Conversions to Common Stock of Convertible Notes Payable

 

During the year ended September 30, 2023, the holders of the April 2017 convertible note payable elected to convert principal of $20,000 into 2,000,000 shares of common stock. The conversion was in accordance with the terms of the agreement and no gain or loss was recognized.

 

Common stock issued for Services

 

On April 6, 2023, the Company issued 50,000,000 shares to a consultant for services rendered to the Company. The shares had a fair value of $360,000. 

 

Common stock issued for settlement of liabilities

 

During the year ended September 30, 2022, the Company issued 6,000,000 shares of common stock and 900,000 warrants for the settlement of liabilities totaling $15,000. The Company recorded a $146,460 loss on settlement of liabilities related to this transaction.

 

On April 4, 2023, the Company issued 7,422,535 shares to James Katzaroff to settle $50,000 of accrued compensation. The Company recognized a loss of $3,442 on this issuance based on the fair value of the shares issued.

 

On April 25, 2023, the Company issued 7,261,087 shares of common stock to 7 to Stand to settle the outstanding royalty balance of $50,102 under the License Agreement. The Company recognized a gain of $10,166 on the issuance related to the fair value of the shares. See Note 7.

 

Common stock issued for stock payable

 

In July 2023, the Company also issued a total of 1,512,152 shares to settle subscription payables of $5,000.

 

In December 2021, the Company issued 19,980,000 shares of common stock as part of the common stock unit sales that occurred during the year ended September 30, 2021. As of September 30, 2022, no shares are remaining to be issued for these unit sales.

 

In September 2022, the Company received two subscriptions of $5,000 in cash for 1,515,152 shares of common stock and an equal number of warrants to purchase common stock at an exercise price of $0.01 for one year. In December 2022, the Company received $5,000 of cash as a subscription for an additional 1,515,152 shares of common stock and an equal number of warrants to purchase common stock at an exercise price of $0.01 for one year. The warrants had a fair value of $4,067 based on a Black-Scholes pricing model using the following assumptions: 1) volatility of 176.37%; 2) risk free rate of 4.74%; 3) dividend yield of 0% and 4) expected term of 1 year. In February 2023, the Company received $8,000 of cash and $7,000 of expenses paid on the Company’s behalf as a subscription for 7,500,000 shares of common stock. The common shares were issued in May 2023.

 

Common Stock Warrants

 

During the year ended September 30, 2023, the Company amended the exercise price of the common stock warrants issued to investors in its 2021 private placement to reduce the price from $0.03 per share to $0.01 per share. In accordance with ASC 718, the Company estimated the incremental value of the warrants based on terms immediately preceding the amendment, and immediately after the amendment, using the follow range of assumptions in a Black-Scholes option price model: 1) volatility of 203%; 2) expected term of approximately one year; 3) risk-free rate of 5.05%; 5) a common stock price at the date of grant of $0.086 and 6) a dividend yield of 0%. The Company recognized stock-based compensation expense of $51,761 related to the repricing.

 

In February 2022, the Company entered into a consulting agreement with Spivak Management, Inc. (the “Consultant”). Under the agreement, the Consultant will provide business strategy advice and introductions to the Company for a period of five years unless mutually terminated sooner. The Consultant is also entitled to additional warrants in the event of the Company issuing equity or equity equivalents in the future, with him receiving an number of warrants equal to 3% of future warrants issued, excluding grants to officers. The exercise price of these additional warrants will be 110% of the price per equity equivalent. The total fair value of these option grants at issuance was $53,117 using the follow range of assumptions in a Black-Scholes option price model volatility of 215.45 % - 253.78% ; 2) risk free rate of 2.37% - 4.46%; 3) dividend yield of 0% and 4) expected term of 5.0 years. During the years ended September 30, 2023 the Company recognized $53,117, related to this agreement, respectively.

 

The Company recognized $322,266 of expense related to these warrants during the year ended September 30, 2022. The Company estimated the fair value of the warrants based on a Black-Scholes pricing model using the following assumptions: 1) volatility of 254.43%; 2) risk free rate of 1.76%; 3) dividend yield of 0% and 4) expected term of 5 years.

 

The following table summarizes the stock warrant activity for the years ended September 30, 2023 and 2022:

 

    Warrants     Weighted-Average
Exercise Price
Per Share		  
Outstanding, September 30, 2021     29,970,000     $ 0.03  
Granted     41,415,152       0.01  
Exercised     —       —  
Forfeited     —       —  
Expired     —       —  
Outstanding, September 30, 2022     71,385,152     $ 0.02  
Granted     90,181,342       0.002  
Exercised     —       —  
Forfeited     —       —  
Expired     (3,030,304 )     0.01  
Outstanding, September 30, 2023     158,536,190     $ 0.01  

 

As of September 30, 2023, the outstanding warrants had an expected remaining life of 1.60 years and have an intrinsic value of $69,300.

 

Common Stock Options

 

As discussed in Note 4, The Company awarded common stock options to Mr. Katzaroff in connection with his amended and restated employment agreement. During the year ended September 30, 2023, the Company estimated the fair value of the options to be $53,117, using the following assumptions range: 1) volatility of 215.45 % - 253.78% ; 2) risk free rate of 2.37% - 4.46%; 3) dividend yield of 0% and 4) expected term of 5.0 years. The Company recognized $108,802 of expense related to the fair value of options vesting during the year ended September 30, 2023. The Company recognized $186,926 of expense related to the fair value of options vesting during the year ended September 30, 2022. The Company expects to recognize an additional $42,229 of expense related to these options assuming all vest.

 

The Company also recognized $696,294 of expense related to the estimated fair value of stock options awarded to officers of the Company. The Company awarded 50,000,000 options with a $0.01 exercise price to the Company’s CFO Robert Chicoski that expire in May 2026, and awarded 20,000,000 options with an exercise price of $0.01 each to Mr. Farley and Mr. Penderghast which expire in April 2026. The fair value was estimated using a Black-Scholes option pricing model and the following assumptions: 1) volatility of 184%; 2) expected term of approximately three years; 3) risk-free rate of 4.52%; 5) a common stock price at the date of grant of $0.086 and 6) a dividend yield of 0%. The option wards vested immediately.

 

At September 30, 2023, the Company had $42,229 of unrecognized expenses related to options.

 

The following table summarizes the stock option activity for the years ended September 30, 2023 and 2022:

 

    Options     Weighted-Average
Exercise Price
Per Share		  
Outstanding, September 30, 2021     70,000,000     $ 0.03  
Granted     35,000,000       0.01  
Exercised     —       —  
Forfeited     —       —  
Expired     —       —  
Outstanding, September 30, 2022     105,000,000       0.02  
Granted     101,632,356       0.01  
Exercised     —       —  
Forfeited     —       —  
Expired     (70,000,000 )     0.03  
Outstanding, September 30, 2023     136,632,356     $ 0.01  

 

As of September 30, 2023, the aggregate intrinsic value of options vested and outstanding were $0. As of September 30, 2023, the outstanding options had a weighted average remaining term of 2.94 years.

 

Note 7. Series G Preferred Stock

 

On August 11, 2021, our board of directors designated up to 1,000,000 shares of Series G Preferred Stock with a liquidation value of $1.00 per share. The holders of the Series G Preferred Stock have no voting rights except on matters related specifically to the Series G Preferred Stock. The Series G Preferred Stock carries a dividend of 8% of the stated value per share, which is cumulative and payable upon redemption, liquidation or conversion, and increases to 22% in case of default. The Series G Preferred Stock and accrued dividends are convertible beginning 180 days from issuance at the option of the holder into shares of common stock at a rate of a conversion price of 75% of the average three lowest trading prices during the 15 days prior to conversion. The Company will be required to redeem the Series G Preferred Stock upon the earlier of 15 months from issuance date or upon on event of default as defined in the agreement.

 

Based on the economic characteristics of the Series G Preferred Stock, the Company determined that the Series G should be accounted for as a liability under ASC 480-10, based on the discounted conversion price providing an effectively fixed monetary amount that the preferred stock is convertible into.

 

During the year ended September 30, 2023, the Company sold an aggregate of 89,100 shares of Series G Preferred Stock for net cash proceeds of $73,000. The Company recorded a debt discount of $16,100 for the difference between the cash proceeds and the total amount to be redeemed by the holder of $89,100. The Company amortized $28,681 of discount related to Series G Preferred Stock for the year ended September 30, 2023. The dividends on the Series G Preferred Stock are accrued as interest. The Company recognized $5,039 of interest on the Series G Preferred Stock and had an accrued interest balance of $3,556 and $3,983 as of September 30, 2023 and September 30, 2022, respectively. During the year ended September 30, 2023, the holder of the Series G converted 227,975 shares of Series G and $9,119 of dividends into 100,712,968 shares of common stock. The conversions were in accordance with the terms of the agreement and no gain or loss was recognized.

 

During the year ended September 30, 2022, the Company sold an aggregate of 369,875 shares of Series G Preferred Stock for net cash proceeds of $310,000. The Company recorded a debt discount of $59,875 for the difference between the cash proceeds and the total amount to be redeemed by the holder of $369,875. The Company amortized $54,664 of discount related to Series G Preferred Stock for the year months ended September 30, 2022. The dividends on the Series G Preferred Stock are accrued as interest. The Company recognized $15,852 of interest on the Series G Preferred Stock and had an accrued interest balance of $3,983 and $1,281 as of September 30, 2022 and September 30, 2021, respectively. During the year ended September 30, 2022, the holder of the Series G converted 324,500 shares of Series G and $12,980 of dividends into 109,052,543 shares of common stock, and the Company recognized a loss of $5,939.

 

As of September 30, 2023 and September 30, 2022, 0 and 138,875 shares of the Series G Preferred Stock were issued and outstanding, respectively. The balance of the Series G Preferred stock liability was $0 and $126,294, respectively, net of unamortized discount of $0 and $12,581, respectively.

 

Note 8. Commitments and Contingent Liabilities

 

In February 2022, the Company entered into a consulting agreement with Spivak Management, Inc. (the “Consultant”). Under the agreement, the Consultant will provide business strategy advice and introductions to the Company for a period of five years unless mutually terminated sooner. Concurrently, Kenin Spivak, who controls Spivak Management, Inc., entered into a stock purchase agreement with the Company to purchase 6,000,000 shares of common stock for $25,000 cash. The purchase and issuance of the shares was to be completed by June 30, 2022.

 

The Consultant will be paid a signing bonus of $25,000 upon receipt by the Company of the $25,000 cash under the stock purchase agreement described above. The Consultant will also receive the larger of $12,500 per month, or 50% of the CEO’s fixed cash compensation under the amended employment agreement described in Note 4. The Consultant may elect to receive this payment in stock.

 

In July 2022, the consultant agreement and the stock purchase agreement were amended to reduce the subscription amount to $17,500. In August 2022, $17,500 was placed in escrow by Mr. Spivak for the Company’s Benefit, and the Company paid $17,500 to the Consultant from the escrow account. The 6,000,000 shares owed to Mr. Spivak were not issued by June 30, 2023, and were issued in August 2023.

 

The Consultant may also receive a bonus in each calendar year of the agreement equal to the larger of any bonus awarded by the Board of Directors to the Consultant or 50% of the largest bonus payable by the Company to anyone other than the Consultant. If the agreement is terminated with one year of a change of control of the Company, the Consultant will be entitled to receive a payment equal to 2.99 times the larger of the total compensation paid to the Consultant over the prior 12 month period or the average compensation paid or payable to the Consultant over the prior three years. On September 19, 2023, the Company entered into a second supplement to consulting agreement. Pursuant to the agreement, in In lieu of Base Fees accrued through September 2023 and interest on late payment thereof, the Company shall pay to the Consultant, the sum of $300,000 in installments on and from the first to occur of the following until the full $300,000 is paid in full. The Company will continue to pay the Consultant a fee of $12,500 per month. The Company reclassified $250,000 of fee accrued in accounts payable owed to the Consultant and interest expense of $50,000 to a note payable. As of September 30, 2023 and September 30, 2022, the Company owed the consultant $337,500 and $100,000, which included accounts payable and accrued liabilities of $37,500 and $100,000 and notes payable of $300,000 and $0, respectively.

 

On August 10, 2023, the Company entered into a consulting agreement with Valerian Capital, LLC ( “Valerian”). Under the agreement, Valerian will provide management consulting, business advisory, shareholder information and public relations to the Company for a period of six months unless mutually terminated sooner. Upon execution of the agreement, Valerian will purchase 33,333,333 shares of the Company’s stock for a total purchase price of $25,000 and have the option to purchase an additional 33,333,333 shares for $25,000 during the first 45 days of the agreement. Lastly, Valerian will have the right to purchase 66,000,000 warrants with an exercise price of $0.00075 for up to one year following the agreement. As of September 30, 2023, the Company received $25,000 and issued 33,333,333 shares of common stock to Valerian.

 

Litigation

 

From time to time, the Company may be subject to routine litigation, claims, or disputes in the ordinary course of business. In the opinion of management, no pending or known threatened claims, actions or proceedings against the Company are expected to have a material adverse effect on the Company’s financial position, results of operations or cash flows. The Company cannot predict with certainty, however, the outcome or effect of any of the litigation or investigatory matters specifically described above or any other pending litigation or claims. There can be no assurance as to the ultimate outcome of any lawsuits and investigations.

 

Note 9. License Agreement

 

Effective August 23, 2020 the Company’s wholly-owned subsidiary, SomaCeuticals, Inc. entered into an exclusive global license agreement with 7 to Stand, Inc. for the rights to U.S. patent 10,610,592 issued to Fabrizio de Silvestri, Terni, Italy, as inventor, April 7, 2020 for treatment of Multiple Sclerosis. In consideration for the license agreement, SomaCeuticals agreed to pay 7 to Stand a royalty of 7.1% of the net sales of any product developed under the patent on a worldwide basis. Additionally, the Company will issue shares of common stock to 7 to Stand upon completion of the following milestones:

 

● Common shares representing 5% of total number of outstanding common shares of the Company immediately following any change of control of the Company; the Company issued 29,130,167 shares of common stock as a result of the change of control discussed in Note 5. These shares were issued in July 2021.
   
● 29,130,167 Common shares immediately following the first round of funding under a private offer of equity or debt securities; These shares were issued in July 2021.
   
● 29,130,167 Common shares immediately following the commencement of clinical trials for Federal Drug Administration clearance of the product; and
   
● Common shares representing an adjustment to increase 7 to Stand’s total ownership to 19.99% of total number of outstanding common shares of the Company immediately following FDA clearance of the product for sale. The Company expects to issue 29,130,166 shares of common stock related to this provision if met.
   
● $40,000 of royalties to be paid to 7 to Stand annually, on a quarterly basis. The license agreement may be terminated by 7 to Stand if 1) SomaCeuticals does not begin clinical trials within one year of the agreement; 2) if SomaCeuticals terminates the continuation of the clinical trials; or 3) shall not commence marketing the product within reasonable time after obtaining FDA approval.

 

The Company paid no royalties and accrued $43,851 of royalties and late fees during the year ended September 30, 2023. During the year ended September 30, 2023, the Company and 7 to Stand agreed to settle a total of $50,102 by issuance of 7,261,087 shares of common stock. The Company recognized a gain of $10,166 based on the fair value of the shares issued.

 

The Company owed $20,000 of royalties and late fees under this agreement as of September 30, 2023 and $26,250 as of September 30, 2022.

 

Note 10. Income Taxes

 

There is no current or deferred income tax expense or benefit for the period ended September 30, 2023 and 2021. The Company currently has net operating loss carryforwards aggregating approximately $5,217,000 which expire beginning in 2033. The deferred tax asset related to the net operating loss carryforwards has been fully reserved.

 

The provision for income taxes is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes. The items causing this difference for the period from April 29, 2016 (date of inception) through September 30, 2023 and 2022 is the valuation allowance as follows.

 

    September 30, 2023   September 30, 2022  
Net operating loss carryforward at statutory tax rate   $ 1,096,000   $ 962,000  
Valuation allowance     (1,096,000 )   (962,000 )
Deferred tax benefit, net   $ —   $ —  

 

The Company has not recognized an income tax benefit for the period based on uncertainties concerning its ability to generate taxable income in future periods. The tax benefit for the current period presented is offset by a valuation allowance (100%) established against deferred tax assets arising from operating losses and other temporary differences, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not.

 

The tax returns for fiscal year 2017 and forward are still open for review by the Internal Revenue Service.

 

Note 11. Subsequent Events

 

On November 2, 2023, the Company entered into a consulting agreement with Advanced Innovate Partners (“AIP”) under which AIP will provide advice to GlobeStar and SMIHC on the global design, strategy and execution of clinical trials. Pursuant to the agreement, the Company will pay the following (i) AIP $5,000 per month during Phase A period, if the Company receives regulatory approval to manufacture, sell and distribute products in India or the United States within 60 days of the agreement (ii) AIP $6,000 per month during Phase B period (iii) AIP a sales commission of between 10% and 15% related to any customers, distributors or sales agents introduced to the Company by AIP and (iv) a commission of 4% of any proceeds from equity investments to the Company introduced by AIP, or 2% of any loan proceeds from lenders introduced by AIP.

 

Subsequent to September 30, 2023, the holder of the May 10, 2023 convertible note was issued 30,297,790 shares of common stock upon conversion of all $21,300 of principal and $1,278 of accrued interest.

 

- 37 -

Table of Contents

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

Changes in Accountants

 

None.

 

Disagreements with Accountants

 

None.

 

ITEM 9A. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our management evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2023 (the “Evaluation Date”). The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2023, our management concluded that, as of such date, our disclosure controls and procedures were not effective at the reasonable assurance level.

 

Limitations on Systems of Controls

 

Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. To address the material weaknesses identified in our evaluation, we performed additional analysis and other post-closing procedures in an effort to ensure our consolidated financial statements included in this annual report have been prepared in accordance with generally accepted accounting principles. Accordingly, management believes that the financial statements included in this report fairly present in all material respects our financial condition, results of operations and cash flows for the periods presented.

 

Management’s Report on Internal Control over Financial Reporting

 

Management’s Annual Report on Internal Control Over Financial Reporting

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Management has conducted an assessment, including testing of the effectiveness, of our internal control over financial reporting as of Evaluation Date. Management’s assessment of internal control over financial reporting was conducted using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control — Integrated Framework (2013 Framework).

 

- 38 -

Table of Contents

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Because of the inherent limitations of internal control, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

 

As of September 30, 2023, management assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) and SEC guidance on conducting such assessments. Based on that evaluation, they concluded that, during the period covered by this report, such internal controls and procedures were not effective to detect the inappropriate application of US GAAP rules as more fully described below. This was due to deficiencies that existed in the design or operation of our internal controls over financial reporting that adversely affected our internal controls and that may be considered to be material weaknesses.

 

The matters involving internal controls and procedures that our management considered to be material weaknesses under the standards of the Public Company Accounting Oversight Board were: inadequate segregation of duties consistent with control objectives; and, management is dominated by a single individual. The aforementioned material weaknesses were identified by our Chief Executive Officer in connection with the review of our financial statements as of September 30, 2023.

 

The Company recognizes the following weaknesses and deficiencies of the Company as of September 30, 2023:

 

We recognized the following deficiencies that we believe to be material weaknesses:

 

- The Company has not fully designed, implemented or assessed internal controls over financial reporting. Due to the Company being a development stage company, management’s assessment and conclusion over internal controls were ineffective this year.

 

We recognized the following deficiencies that we believe to be significant deficiencies:

 

- The Company has no formal control process related to the identification and approval of related party transactions.

 

- No formal written policy for the approval, identification and authorization of related party transactions currently exists.

 

Management believes that the material weaknesses set forth above did not have an effect on our financial results. However, management believes that the lack of a functioning audit committee and the lack of a majority of outside directors on our board of directors results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods.

 

ITEM 9B. OTHER INFORMATION

 

None

 

- 39 -

Table of Contents

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

Our officer and directors will serve until successors are elected and qualified. Our officers are elected by the board of directors to a term of one (1) year and serve until their successors are duly elected and qualified, or until they are removed from office. The board of directors has an auditing committee but no nominating or compensation committees.

 

The name, address, age and position of our president, secretary/treasurer, and director and vice president is set forth below:

 

Name   Age   Position
James C. Katzaroff
719 Jadwin Avenue, Richland, WA, 99352 		   66   Chief Executive Officer, President, Secretary,
 Principal Executive Officer, and Chairman of the Board
         
Robert Chicoski, CPA   81   Chief Financial officer, Treasurer, Principal Financial Officer
         
William Farley   68   Director
         
Steven Penderghast       Director

 

James C. Katzaroff. From 2007 through 2016 was Chief Executive Officer and controlling shareholder is the founder of Advanced Medical Isotope Corp. (now Vivos, Inc) a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of unresectable tumors. Effective May 2020, Mr. Katzaroff became the Chief Executive officer and controlling shareholder of Poverty Dignified, Inc. (OTC PVDG).

 

Robert Chicoski. From 1973 to 2021 was a practicing Certified Public Accountant, beginning with KPMG and continuing as a contract Controller and Interim CFO of client companies. He was CFO and co-founder of Oceanside Energy in Worcester, MA a pioneer in an on-line reverse-auction trading platform for the purchase of substantial amounts of electricity and natural gas. In the early 2000’s Oceanside Energy enjoyed its IPO as World Energy Solutions (OTC XWES).

 

William Farley has over 35 years’ experience in the Business Development, Sales and leading efforts in drug discovery, development and partnering.  Mr. Farley holds a senior leadership position at Sorrento Therapeutics. He began his career at Johnson and Johnson and has held positions at Pfizer and HitGen Ltd., at WuXi Apptec creating, building and leading global BD teams, VP of BD at ChemDiv where he leads numerous efforts to create new therapeutic companies in CNS, Oncology and Anti infectives. Mr. Farley serves on the BOD of GlobeStar and Xortex. Bill serves  as a consultant to various executive management teams as well as advising several BODs on commercialization of assets. Mr. Farley has spoken at numerous conferences and is published in variety of journals, received his Bachelor of Science degree in Chemistry from State University of New York , Oswego and has taken graduate courses at Rutgers and UC Irvine.

 

Steven Penderghast Medical device & technology professional with over 25 years experience in Corporate National Accounts, Sales & Management, Product Management, Marketing Management, Clinical Research and Regulatory Affairs. Since 2013, as Corporate Vice President, National Accounts as well as Corporate Regional Vice President/SCG for BD/CR Bard Inc., Corporate Customer Group, Franklin Lakes, New Jersey, has responsibility for Strategic account corporate relationships IDN and regional purchasing groups in Western USA; Strategic oversight of national and regional GPO business contracting and product segment agreements; Corporate guidance over product segment commercialization and technology introductions.

 

Family Relationships

 

There are no family relationships among our directors, executive officers or persons nominated to become executive officers or directors.

 

Involvement in Certain Legal Proceedings

 

During the past ten (10) years, none of our directors, persons nominated to become directors, executive officers, promoters or control persons was involved in any of the legal proceedings listen in Item 401 (f) of Regulation S-K.

 

- 40 -

Table of Contents

 

Arrangements

 

There are no arrangements or understandings between an executive officer, director or nominee and any other person pursuant to which he was or is to be selected as an executive officer or director.

 

Committees of the Board of Directors

 

There are no members of the established Audit Committee. 

 

We do not have a policy regarding the consideration of any director candidates that may be recommended by our stockholders, including the minimum qualifications for director candidates, nor have our directors established a process for identifying and evaluating director nominees. We have not adopted a policy regarding the handling of any potential recommendation of director candidates by our stockholders, including the procedures to be followed. Our directors have not considered or adopted any of these policies, as we have never received a recommendation from any stockholder for any candidate to serve on our Board of Directors. Given our relative size and lack of directors and officers insurance coverage, we do not anticipate that any of our stockholders will make such a recommendation in the near future.

 

While there have been no nominations of additional directors proposed, in the event such a proposal is made, all current members of our Board will participate in the consideration of director nominees.

 

Our directors are not “committee financial experts” within the meaning of Item 401(e) of Regulation S-K. In general, an “audit committee financial expert” is an individual member of the audit committee or Board of Directors who:

 

  ● understands generally accepted accounting principles and financial statements,
     
  ● is able to assess the general application of such principles in connection with accounting for estimates, accruals and reserves,
     
  ● has experience preparing, auditing, analyzing or evaluating financial statements comparable to the breadth and complexity to our financial statements,
     
  ● understands internal controls over financial reporting, and
     
  ● understands audit committee functions

 

Our Board of Directors is comprised of Ms. Blankenship who is involved in our day-to-day operations. On February 23, 2018, the Company was notified that Robert W. Fryer tendered his resignation as an independent director. We would prefer to have an audit committee financial expert on our board of directors. As with most small, early-stage companies until such time our company further develops its business, achieves a stronger revenue base and has sufficient working capital to purchase directors and officers insurance, the Company does not have any immediate prospects to attract independent directors. When the Company is able to expand our Board of Directors to include one or more independent directors, the Company intends to establish an Audit Committee of our Board of Directors. It is our intention that one or more of these independent directors will also qualify as an audit committee financial expert. Our securities are not quoted on an exchange that has requirements that a majority of our Board members be independent and the Company is not currently otherwise subject to any law, rule or regulation requiring that all or any portion of our Board of Directors include “independent” directors, nor are we required to establish or maintain an Audit Committee or other committee of our Board of Directors.

 

WE DO NOT HAVE ANY INDEPENDENT DIRECTORS AND THE COMPANY HAS NOT VOLUNTARILY IMPLEMENTED VARIOUS CORPORATE GOVERNANCE MEASURES, IN THE ABSENCE OF WHICH, STOCKHOLDERS MAY HAVE MORE LIMITED PROTECTIONS AGAINST INTERESTED DIRECTOR TRANSACTIONS, CONFLICTS OF INTEREST, AND SIMILAR MATTERS.

 

Code of Business Conduct and Ethics

 

We have adopted a code of ethics meeting the requirements of Section 406 of the Sarbanes-Oxley Act of 2002. We believe our code of ethics is reasonably designed to deter wrongdoing and promote honest and ethical conduct; provide full, fair, accurate, timely, and understandable disclosure in public reports; comply with applicable laws; ensure prompt internal reporting of violations; and provide accountability for adherence to the provisions of the code of ethic.

 

- 41 -

Table of Contents

 

ITEM 11. EXECUTIVE COMPENSATION

 

Prior to her separation from the Company in March 2021, Ms. Blankenship was paid $5,000 per month for her services to the company. The Company’s CEO is paid $15,000 per month, and the Company’s CFO is paid $7,000 per month. No amounts were paid in cash during the years ended September 30, 2021 and 2022.

 

The table below summarizes all compensation awards paid or accrued to our named executive officer for all service rendered in all capacities to us for the fiscal periods ended September 30, 2022 and 2023.

 

SUMMARY COMPENSATION TABLE

 

Name and Principal Position   Fiscal
Year		   Salary
($)		     Bonus
($)		   Stock
Awards
($)		     Option
Awards
($)		   Non-Equity
Incentive Plan
Compensation
($)		   Nonqualified
Deferred
Compensation
($)		   All Other
Compensation
($)		   Total ($)  
James C. Katzaroff   2023   $ 180,000 (a)     —   $ —     $ 53,117 (b)   —     —     —   $ 231,117  
    2022   $ 177,933 (a)     —   $ —     $ 284,840 (b)   —     —     —   $ 462,773  
                                                           
Robert R. Chicoski   2023   $ 84,000       —   $ —     $ 387,238     —     —     —   $ 468,238  
    2022   $ 84,000       —   $ —     $ —     —     —     —   $ 84,000  
                                                           
Alex Blankenship   2022   $ — (a)     —   $ —       —     —     —     —   $ —  

__________

  (a) Includes amount accrued during the year;
     
  (b) Includes 11,632,356 options issued to Mr. Katzaroff pursuant to amended employment agreement. Includes 50,000,000 options issued Robert Chicoski on February 24, 2023

 

 

OUTSTANDING EQUITY AWARDS AT SEPTEMBER 30, 2023

 

    Option Awards   Stock Awards  
Name   Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable		   Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable		   Equity
Incentive
Plan
Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options (#)		   Option
Exercise
Price ($)		   Option
Expiration
Date		   Number of
Shares of
Stock That
Have Not
Vested (#)		   Market
Value of
Shares of
Stock That
Have Not
Vested ($)		   Equity
Incentive
Plan Awards:
Number of
Unearned
Shares or
Other Rights
That Have
Not Vested
(#)		   Equity
Incentive Plan
Awards:
market or
Payout Value
of Unearned
Shares or
Other Rights
That Have
Not Vested
($)		  
James C. Katzaroff     46,632,356     6,807,977     —     $0.002 - $0.011     February 7, 2027 - September 16, 2028     —     —     —     —  
Robert Chicoski     50,000,000     —     —     $0.01     February 24, 2023     —     —     —     —  

 

Employment Agreements & Retirement Benefits

 

None of our executive officers is subject to employment agreements, but we may enter into such agreements with them in the future. We have no plans providing for the payment of any retirement benefits.

 

- 42 -

Table of Contents

 

Director Compensation

 

Directors receive no compensation for serving on the Board. We have no non-employee directors.

 

Our Board of Directors is comprised of James C. Katzaroff who also serves as the CEO of the Company, William Farley and Steven Penderghast. None of our directors has or had a compensation arrangement with the Company for director services, nor have any of them been compensated for director services since the Company’s inception.

 

We reimburse our directors for all reasonable ordinary and necessary business related expenses, but we did not pay director’s fees or other cash compensation for services rendered as a director in the period ended September 30, 2023 to any of the individuals serving on our Board during that period. We have no standard arrangement pursuant to which our directors are compensated for their services in their capacity as directors. We may pay fees for services rendered as a director when and if additional directors are appointed to the Board of Directors.

 

Director Independence

 

We currently have two independent directors and we do not anticipate appointing additional directors in the foreseeable future.

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

We do not currently have a stock option plan in favor of any director, officer, consultant, or employee of our company. No individual grants of stock options, whether or not in tandem with stock appreciation rights known as SARs or freestanding SARs have been made to our directors and officer since our inception; accordingly, no stock options have been granted or exercised by our directors and officer since we were founded.

 

The following table sets forth certain information as of January 16, 2023, with respect to the beneficial ownership of our common stock by each beneficial owner of more than 5% of the outstanding shares of common stock of the Company, each director, each executive officer named in the “Summary Compensation Table” and all executive officers and directors of the Company as a group, and sets forth the number of shares of common stock owned by each such person and group. Unless otherwise indicated, the owners have sole voting and investment power with respect to their respective shares.

 

Name of Beneficial Owner   Number of Shares
Beneficially Owned		       Percentage of
Outstanding
Common Stock
Owned		  
                   
Robert Chicoski     11,000,000         1.07 %
                   
James C. Katzaroff     17,422,535   (1)     1.70 %
                   
2021 Pharma Associates LLC (7 to Stand)     58,260,334         5.68 %
                   
All directors and executive officers as a group (2) persons.     28,422,535         2.77 %

__________

(1) Does not include shares of common stock underlying 1,000,000 shares of the Company’s Series E Preferred Stock owned by Mr. Katzaroff. The Series E Preferred Stock carries two votes for each outstanding share of the Company’s common stock and, as a result, has 2/3 voting control over any shareholder votes.

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

None.

 

- 43 -

Table of Contents

 

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

 

The following table summarize the fees billed to the Company by its independent accountants, Fruci & Associates II, PLLC for the year ended September 30, 2023 and M&K CPAs PLLC, for the years ended September 30, 2022:

 

    2023   2022  
Audit Fees   $ 31,500   $ 23,500  
               
Audit Related Fees (1)   $ —   $ —  
               
Tax Fees (2)   $ —   $ —  
               
All Other Fees (3)   $ —   $ —  
               
Total Fees   $ 31,500   $ 23,500  

 

Notes to the Accountants Fees Table:

 

  (1) Consists of fees for assurance and related services by our principal accountants that are reasonably related to the performance of the audit or review of the Company’s financial statements and are not reported under “Audit Fees.”
     
  (2) Consists of fees for professional services rendered by our principal accountants for tax related services.
     
  (3) Consists of fees for products and services provided by our principal accountants, other than the services reported under “Audit Fees,” “Audit-Related Fees” and “Tax Fees” above.

 

As part of its responsibility for oversight of the independent registered public accountants, the Board has established a pre-approval policy for engaging audit and permitted non-audit services provided by our independent registered public accountants. In accordance with this policy, each type of audit, audit-related, tax and other permitted service to be provided by the independent auditors is specifically described and each such service, together with a fee level or budgeted amount for such service, is pre-approved by the Board. All of the services provided by Fruci & Associates, II, PLLC and M&K CPAs PLLC described above were approved by our Board.

 

The Company’s principal accountant did not engage any other persons or firms other than the principal accountant’s full-time, permanent employees.

 

- 44 -

Table of Contents

 

PART IV

 

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

 

3.1 Articles of Incorporation (1)
3.2 Bylaws (2)
14.1 Code of Ethics (3)
21 Subsidiaries of the Registrant (4)
31.1 Rule 13(a)-14(a)/15(d)-14(a) Certification of principal executive officer (4)
31.2 Rule 13(a)-14(a)/15(d)-14(a) Certification of principal financial officer (4)
32.1 Section 1350 Certification of principal executive officer (4)
32.2 Section 1350 Certification of principal financial officer (4)
101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. (5)
101.SCH Inline XBRL Taxonomy Extension Schema Document (5)
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document (5)
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document (5)
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document (5)
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document (5)
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) (5)

__________

(1) Incorporated by reference to our Definitive Proxy Statement on Schedule 14A filed on April 8, 2015.
(2) Incorporated by reference to our Form 10-K/A Amendment No. 1 for the year ended September 30, 2015 filed on January 22, 2016.
(3) Incorporated by reference to our Form S-1 filed with the Securities and Exchange Commission on November 3, 2010.
(4) Filed or furnished herewith.
(5) In accordance with Regulation S-T, the Interactive Data Files in Exhibit 101 to the Annual Report on Form 10-K shall be deemed “furnished” and not “filed.”

 

- 45 -

Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  GlobeStar Therapeutics Corporation
   
Date: January 19, 2024 BY: /s/ James C. Katzaroff
  James C. Katzaroff
  Chief Executive Officer, President, Secretary, Principal Executive Officer, and Director
   
Date: January 19, 2024 BY: /s/ Robert Chicoski
  Robert Chicoski
  Chief Financial Officer, Treasurer, Secretary, Principal Financial And Accounting Officer

 

- 46 -

 EX-21 2 ex_21.htm SUBSIDIARIES OF THE REGISTRANT

 

Exhibit 21

 

SUBSIDIARIES OF THE REGISTRANT

 

SomaCeuticals, Inc. (a Texas corporation)

 

First Titan Energy, LLC, (a Nevada limited liability company)

 

First Titan Technical, LLC, (a Nevada limited liability company)

 

 EX-31 3 ex_31-1.htm RULE 13(A)-14(A)/15(D)-14(A) CERTIFICATION

 

Exhibit 31.1

 

RULE 13A-14(A)/15D-14(A) CERTIFICATION

 

I, James C. Katzaroff, certify that:

 

1. I have reviewed this annual report on Form 10-K for the fiscal year ended September 30, 2023 of GlobeStar Therapeutics Corporation.

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15-d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: January 19, 2024

BY: /s/ James C. Katzaroff

 

James C. Katzaroff

 

Chief Executive Officer, President, Secretary, Principal Executive Officer and Chairman of the Board

 

 EX-31 4 ex_31-2.htm RULE 13(A)-14(A)/15(D)-14(A) CERTIFICATION

 

Exhibit 31.2

 

RULE 13A-14(A)/15D-14(A) CERTIFICATION

 

I, Robert Chicoski, certify that:

 

1. I have reviewed this annual report on Form 10-K for the fiscal year ended September 30, 2023 of GlobeStar Therapeutics Corporation.

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15-d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: January 19, 2024

BY: /s/ Robert Chicoski

 

Robert Chicoski

 

Chief Financial officer, Treasurer, Principal Financial Officer

 

 EX-32 5 ex_32-1.htm SECTION 1350 CERTIFICATION

 

Exhibit 32.1

 

SECTION 1350 CERTIFICATION

 

In connection with the annual report of GlobeStar Therapeutics Corporation. (the “Company”) on Form 10-K for the period ended September 30, 2023 as filed with the Securities and Exchange Commission (the “Report”), I, James C. Katzaroff, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. SS. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: January 19, 2024

BY: /s/ James C. Katzaroff

 

James C. Katzaroff

 

Chief Executive Officer, President, Secretary, Principal Executive Officer and Chairman of the Board

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 EX-32 6 ex_32-2.htm SECTION 1350 CERTIFICATION

 

Exhibit 32.2

 

SECTION 1350 CERTIFICATION

 

In connection with the annual report of GlobeStar Therapeutics Corporation. (the “Company”) on Form 10-K for the period ended September 30, 2023 as filed with the Securities and Exchange Commission (the “Report”), I, Robert Chicoski, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. SS. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: January 19, 2024

BY: /s/ Robert Chicoski

 

Robert Chicoski

 

Chief Financial Officer, Treasurer, Principal Financial Officer

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 EX-101.SCH 7 gstc-20230930.xsd INLINE XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - General Organization and Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Convertible Notes Payable and Advances link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Stockholders’ deficit link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Series G Preferred Stock link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments and Contingent Liabilities link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - License Agreement link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Convertible Notes Payable and Advances (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Stockholders’ deficit (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Convertible notes payable consisted of the following at September 30, 2023 and 2022: (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Convertible Notes Payable and Advances (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - The following table summarizes the stock warrant activity for the years ended September 30, 2023 and 2022: (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - The following table summarizes the stock option activity for the years ended September 30, 2023 and 2022: (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Stockholders’ deficit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Series G Preferred Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Commitments and Contingent Liabilities (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - License Agreement (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Schedule of provision for income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 gstc-20230930_cal.xml INLINE XBRL CALCULATION FILE EX-101.DEF 9 gstc-20230930_def.xml INLINE XBRL DEFINITION FILE EX-101.LAB 10 gstc-20230930_lab.xml INLINE XBRL LABEL FILE Class of Stock [Axis] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Series C Preferred Stock [Member] Series D Preferred Stock [Member] Series E Preferred Stock [Member] Series F Preferred Stock [Member] Series G Preferred Stock [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Stock Payable [Member] Retained Earnings [Member] Title of Individual [Axis] Officer [Member] Chief Executive Officer [Member] Related Party, Type [Axis] Mr Katzaroff [Member] Board of Directors Chairman [Member] Robert Chicoski [Member] Chief Financial Officer [Member] Debt Instrument [Axis] Convertible Note Date April 13 2017 [Member] Convertible Note Date May 10 2023 [Member] Convertible Note Date July 3, 2023 [Member] Short-Term Debt, Type [Axis] Convertible Debt [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] May 2023 Securities Purchase Agreement [Member] July 2023 Securities Purchase Agreement [Member] Convertible Debt One [Member] Advance [Member] Director [Member] Convertible Notes Payable [Member] Warrant [Member] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] License Agreement Terms [Member] Sale of Stock [Axis] Private Placement [Member] Statistical Measurement [Axis] Maximum [Member] Minimum [Member] Common Stock Warrants [Member] Spivak Management Inc [Member] Mr Farley [Member] Mr Penderghast [Member] Subscription Arrangement [Member] Deferred Revenue Arrangement Type [Axis] Mr Spivak [Member] Financial Instrument [Axis] Accrued Liabilities [Member] Notes Payable, Other Payables [Member] Consultant Agreement [Member] License Agreement [Member] Finite-Lived Intangible Assets by Major Class [Axis] Patents [Member] Fabrizio De Silvestri [Member] Royalty Arrangement [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Document Financial Statement Error Correction [Flag] Auditor Name Auditor Firm ID Auditor Location Statement [Table] Statement [Line Items] CURRENT ASSETS Cash and cash equivalents Prepaid expenses Total current assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ DEFICIT Current Liabilities Accounts payable and accrued liabilities Accounts payable to related party Related party advances Advances payable Note payable Current portion of convertible notes payable Series G Preferred Stock Liability, net of discount of $0 and $12,581, respectively Accrued interest payable Total current liabilities TOTAL LIABILITIES COMMITMENTS AND CONTINGENCIES STOCKHOLDERS’ DEFICIT Common stock, $0.001 par value, unlimited shares authorized; 996,119,530 and 722,326,669 shares issued and outstanding at September 30, 2023 and 2022, respectively Preferred stock, value Additional paid-in capital Stock payable, consisting of 0 and 1,515,152 shares to be issued at September 30, 2023 and 2022, respectively Accumulated deficit TOTAL STOCKHOLDERS’ DEFICIT TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT Preferred stock liability Common stock, par value (in dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Preferred stock, shares authorized Preferred stock, par value (in dollars per share) Preferred stock, issued Preferred stock, shares outstanding Stock payable, shares Income Statement [Abstract] REVENUE Cost of goods sold Gross profit (loss) OPERATING EXPENSES General and administrative expenses Total operating expenses LOSS FROM OPERATIONS OTHER INCOME (EXPENSE) Gain (loss) on settlement of liabilities, related party Loss on conversion of preferred stock liability Interest expense Total other expenses Net loss Net loss per share available to common shareholders Weighted average shares outstanding - basic and diluted Beginning balance, value Shares, Outstanding, Beginning Balance Common stock issued for conversion of convertible note payable and accrued interest Stock Issued During Period, Shares, Conversion of Convertible Securities Common stock subscribed for cash proceeds Stock Issued During Period, Shares, Other Common stock issued for stock payable Stock Issued During Period, Shares, New Issues Common stock issued for settlement liability Settlement of Accounts Payable with Related Party Shares Stock-based compensation Stock Issued During Period, Shares, Employee Benefit Plan Stock-based compensation, related parties Conversion of Series G Preferred Stock to common Conversion of Series G Preferred Stock to Common Shares Net loss Conversion of Series D Preferred Stock to common Conversion of Series D Preferred Stock to Common Shares Common stock issued for the conversion of debt Common Stock Issued for The Conversion of Debt Shares Common stock issued for settlement of liability, related party Common Stock Issued for Settlement of Liability Related Party in Shares Ending balance, value Shares, Outstanding, Ending Balance Statement of Cash Flows [Abstract] CASH FLOW FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash used in operating activities: Stock compensation Stock compensation, related parties Amortization of discount on convertible note payable (Gain) loss on settlement of liabilities, related party Loss on conversion of preferred stock liability Changes in operating assets and liabilities Prepaid expenses Accounts payable and accrued liabilities Accounts payable and accrued liabilities to related party Accrued interest payable NET CASH USED IN OPERATING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from convertible notes payable Proceeds from sale of share-settled Series G preferred stock Proceeds from related party advances Repayment of related party advances Proceeds from sale of common stock NET CASH PROVIDED BY FINANCING ACTIVITIES NET INCREASE (DECREASE) IN CASH Cash at beginning of period Cash at end of period Cash paid during the period for: Interest Taxes Noncash investing and financing transactions: Conversion of Series D preferred stock Conversion of Series F preferred stock Conversion of Series G preferred stock Common stock issued for stock payable Common stock issued for settlement of liabilities Common stock issued for the conversion of debt Note payable issued for settlement of accounts payable Organization, Consolidation and Presentation of Financial Statements [Abstract] General Organization and Business Accounting Policies [Abstract] Summary of Significant Accounting Policies Going Concern Related Party Transactions [Abstract] Related Party Transactions Debt Disclosure [Abstract] Convertible Notes Payable and Advances Equity [Abstract] Stockholders’ deficit Series G Preferred Stock Series G Preferred Stock Commitments and Contingencies Disclosure [Abstract] Commitments and Contingent Liabilities License Agreement License Agreement Income Tax Disclosure [Abstract] Income Taxes Subsequent Events [Abstract] Subsequent Events Basis of Presentation Use of Estimates Fair Value of Financial Instruments Advertising and Marketing Costs Research and Development Costs Cash and Cash Equivalents Income Taxes Commitments and Contingencies Recently Issued Accounting Pronouncements Convertible notes payable consisted of the following at September 30, 2023 and 2022: The following table summarizes the stock warrant activity for the years ended September 30, 2023 and 2022: The following table summarizes the stock option activity for the years ended September 30, 2023 and 2022: Schedule of provision for income taxes Advertising and marketing costs Research and development Cash Cash equivalents Net loss Working capital deficit Accumulated deficit Revenue Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Compensation Compensation Related party advances Annual fees Payable to consultant term Exercise price, per shares Exercise term Description of options Description of additional options Issuance of common stock Settelment amount Recognized loss Fair value Royalty on any sales under the agreement Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Dated Amount Interest Conversion price Total current convertible notes payable, net of discount Maturity date Total convertible notes payable Unamortized discount Beneficial conversion discount on convertible note payable Common stock issued for stock payable Cash proceeds Interest rate Debt discount Conversion of stock description Recognized of discount Deferred finance costs Accounts payable and accrued liabilities Principal amount Conversion of shares Warrants outstanding, beginning Warrants outstanding, beginning (in per shares) Granted Granted (in per shares) Expired Expired (in per shares) Warrants outstanding, ending Warrants outstanding, ending (in per shares) Option outstanding, beginning Option outstanding, beginning (in per shares) Granted Granted (in per shares) Exercised Exercised (in per shares) Forfeited Forfeited (in per shares) Expired Expired (in per shares) Option outstanding, ending Option outstanding, ending (in per shares) Schedule of Stock by Class [Table] Class of Stock [Line Items] Preferred stock authorized Preferred stock shares designated Preferred stock liquidation preference Additional share to be issued Preferred stock dividends Preferred stock dividend rate Preferred stock redemption price per share Preferred stock, conversion basis Preferred stock, shares issued Description of voting rights Convertible preferred stock shares Principal amount Shares converted Common stock issued Fair value of shares issued Stock issued during period, shares, conversion of convertible securities Stock issued during period, shares, conversion of convertible securities Settlement of liabilities Gain (loss) related to settlement of liabilities Royalty expense Recognized gain Shares issued to settle subscription payables Subscription payables settle Exercise price to purchase common stock Fair value of warrants Volatility rate Risk free rate Dividend yield Expected term Cash received Expenses paid Number of shares subscribe Amended the exercise price Grant stock price, per share Stock based compensation related to repricing Fair value of option grants Expenses related to warrants Expected remaining life Aggregate intrinsic value Expenses related to the fair value Additional expenses Exercise price Other description Unrecognized expenses related to options Aggregate intrinsic value Preferred stock, shares designated Number of share sold Net cash proceeds Amortization of debt discount Interest recognized Accrued interest Conversion of stock shares converted Dividend value Recognized loss Liabilities related to stock Unamortized discount Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Shares issue Value of share issue Description of commitment Description of purchase agreement Obligation benefits paid Accrued fees Consultant fees Fee accrued in accounts payable Interest expense to a note payable Accounts payable and accrued liabilities Notes payable Purchase Commitment, Description Common stock, value Rights to issued Royalty of net sales Description of milestone Description of milestone one Description of milestone two Description of milestone three Description of milestone four Paid for royalties Royalties and late fess Agreed to settle Recognized gain Net operating loss carryforward at statutory tax rate Valuation allowance Deferred tax benefit, net Operating loss carryforwards Subsequent Event [Table] Subsequent Event [Line Items] Consulting agreement Conversion of all of principal Accrued interest The element represents related party advances. The element represents preferred stock liability. The element represents stock payable. The element represents share based compensation arrangement warrant outstanding weighted average exercise price. The element represents share based compensation arrangement warrant granted numberone. The element represents loss on conversion of preferred stock liability. The element represents earnings per shares basic and diluted. The element represents weighted average shares outstanding basic and diluted. The element represents schedule of share based compensation stock warrants activity table text block. The element represents share based compensation arrangement warrant outstanding number one. The element represents series g preferred stock disclosure text block. The element represents license agreement disclosure text block. The element represents stock compensation related parties. The element represents conversion of series f preferred stock. The element represents common stock issued for stock payable. The element represents common stock issued for settlement of liabilities. The element represents proceeds from sale of sharesettled series g preferred stock. The element represents stock payable member. The element represents conversion of series g preferred stock to common. The element represents settlement of accounts payable with related party shares. The element represents conversion of series g preferred stock to common shares. The element represents working capital. The element represents payable to consultant term. The element represents stock payable shares. The element represents description of options. The element represents additional share to be issued. The element represents preferred stock shares designated. The element represents share based compensation arrangement warrant exercised weighted average two exercise price. The element represents net cash proceeds. The element represents interest recognized. The element represents royalty of net sales percentage. The element represents description of milestones. The element represents description of milestones1. The element represents description of milestones2. The element represents description of milestones3. The element represents description of milestones4. The element represents convertible note date member. The element represents advance member. The element represents mr katzaroff member. The element represents stock based compensation related parties. The element represents license agreement member. The element represents common stock issued for the conversion of debt shares. The element represents common stock issued for the conversion of debt. The element represents convertible note date may 102 023 member. The element represents fabrizio de silvestri member. The element represents common stock warrants member. The element represents stock issued during period value common stock issued for settlement of liability. The element represents loss on settlement of labilities related party. The element represents cash proceeds. The element represents robert chicoski member. The element represents mr farley member. The element represents conversion of series g preferred stock. The element represents description of additional options. The element represents convertible note date july 3 2023 member. The element represents may 2023 securities purchase agreement member. The element represents july 2023 securities purchase agreement member. The element represents convertible debt one member. The element represents conversion of stock description other. The element represents exercise price. The element represents cash receive on subscription. The element represents exercise price 1. The element represents conversion of series d preferred stock. The element represents common stock issued for conversion of debt. The element represents note payable issued for settlement of accounts payable. The element represents conversion of series d preferred stock to common. The element represents common stock issued for settlement of liability related party. The element represents common stock issued for settlement of liability related party in shares. The element represents conversion of series d preferred stock to common shares. The element represents description indefinite lived license agreements. The element represents share based compensation arrangement warrant expiration weighted average two exercise price. The element represents Mr Spivak member. The element represents consultant agreemen member. The element represents spivak management inc member. The element represents optiong grants value. The element represents fair value expenses. The element represents stock issued during period shares conversion of convertible securities1. Assets, Current Assets Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Gross Profit Operating Costs and Expenses Operating Income (Loss) Nonoperating Income (Expense) Shares, Outstanding Gain (Loss) on Extinguishment of Debt Increase (Decrease) in Prepaid Expense Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Interest Payable, Net Net Cash Provided by (Used in) Operating Activities Repayments of Related Party Debt Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Common Stock Issued for Stock Payable Common Stock Issued for Conversion of Debt Series G Preferred Stock Disclosure [Text Block] License Agreement Disclosure[Text Block] Income Tax, Policy [Policy Text Block] Increase (Decrease) in Due to Other Related Parties, Current Accounts Payable and Accrued Liabilities Share Based Compensation Arrangement Warrant Outstanding Number One Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Gain (Loss) on Fair Value Hedges Recognized in Earnings Accounts Payable and Other Accrued Liabilities Former Gain Contingency, Recognized in Current Period Income Tax Expense (Benefit) EX-101.PRE 11 gstc-20230930_pre.xml INLINE XBRL PRESENTATION FILE GRAPHIC 12 fruci_logo.jpg GRAPHIC begin 644 fruci_logo.jpg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fruci_signature.jpg GRAPHIC begin 644 fruci_signature.jpg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end GRAPHIC 14 mkcpas_logo.jpg GRAPHIC begin 644 mkcpas_logo.jpg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end XML 15 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover - USD ($)
 12 Months Ended
Sep. 30, 2023
Jan. 16, 2024
Mar. 31, 2023
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Sep. 30, 2023    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2023    
Current Fiscal Year End Date --09-30    
Entity File Number 333-170315    
Entity Registrant Name GlobeStar Therapeutics Corporation    
Entity Central Index Key 0001502152    
Entity Tax Identification Number 27-3480481    
Entity Incorporation, State or Country Code WY    
Entity Address, Address Line One 719 Jadwin Avenue    
Entity Address, City or Town Richland    
Entity Address, State or Province WA    
Entity Address, Postal Zip Code 99352    
City Area Code 206    
Local Phone Number 451-1970    
Title of 12(b) Security Common stock, $0.001 par value    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period false    
Entity Shell Company false    
Entity Public Float     $ 4,851,851
Entity Common Stock, Shares Outstanding   1,026,417,320  
Document Financial Statement Error Correction [Flag] false    
Auditor Name Fruci & Associates, II, PLLC    
Auditor Firm ID 5525    
Auditor Location Spokane, Washington    

XML 16 R2.htm IDEA: XBRL DOCUMENT v3.23.4
CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2023
Sep. 30, 2022
CURRENT ASSETS    
Cash and cash equivalents $ 6,365
Prepaid expenses 3,550
Total current assets 9,915
TOTAL ASSETS 9,915
Current Liabilities    
Accounts payable and accrued liabilities 328,178 380,735
Accounts payable to related party 454,665 379,126
Related party advances 6,295 12,400
Advances payable 59,650 59,650
Note payable 300,000
Current portion of convertible notes payable 59,710 20,000
Series G Preferred Stock Liability, net of discount of $0 and $12,581, respectively 126,294
Accrued interest payable 225,363 226,270
Total current liabilities 1,433,861 1,204,475
TOTAL LIABILITIES 1,433,861 1,204,475
STOCKHOLDERS’ DEFICIT    
Common stock, $0.001 par value, unlimited shares authorized; 996,119,530 and 722,326,669 shares issued and outstanding at September 30, 2023 and 2022, respectively 996,119 722,325
Additional paid-in capital 18,022,916 16,581,252
Stock payable, consisting of 0 and 1,515,152 shares to be issued at September 30, 2023 and 2022, respectively 5,000
Accumulated deficit (20,454,025) (18,504,776)
TOTAL STOCKHOLDERS’ DEFICIT (1,433,861) (1,194,560)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT 9,915
Series A Preferred Stock [Member]    
STOCKHOLDERS’ DEFICIT    
Preferred stock, value 0 0
Series B Preferred Stock [Member]    
STOCKHOLDERS’ DEFICIT    
Preferred stock, value 0 0
Series C Preferred Stock [Member]    
STOCKHOLDERS’ DEFICIT    
Preferred stock, value 0 0
Series D Preferred Stock [Member]    
STOCKHOLDERS’ DEFICIT    
Preferred stock, value 0 510
TOTAL STOCKHOLDERS’ DEFICIT 510
Series E Preferred Stock [Member]    
STOCKHOLDERS’ DEFICIT    
Preferred stock, value 1,000 1,000
TOTAL STOCKHOLDERS’ DEFICIT 1,000 1,000
Series F Preferred Stock [Member]    
STOCKHOLDERS’ DEFICIT    
Preferred stock, value 129 129
TOTAL STOCKHOLDERS’ DEFICIT $ 129 $ 129
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.23.4
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Preferred stock liability $ 126,294
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized Unlimited Unlimited
Common stock, shares issued 996,119,530 722,326,669
Common stock, shares outstanding 996,119,530 722,326,669
Preferred stock, shares authorized 20,000,000 20,000,000
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Stock payable, shares 0 1,515,152
Series G Preferred Stock [Member]    
Preferred stock liability $ 0 $ 12,581
Preferred stock, issued 0 138,875
Preferred stock, shares outstanding 0 138,875
Series A Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, issued 0 0
Preferred stock, shares outstanding 0 0
Series B Preferred Stock [Member]    
Preferred stock, shares authorized 1,000,000  
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, issued 0 0
Preferred stock, shares outstanding 0 0
Series C Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, issued 0 0
Preferred stock, shares outstanding 0 0
Series D Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, issued 0 509,988
Preferred stock, shares outstanding 0 509,988
Series E Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, issued 1,000,000 1,000,000
Preferred stock, shares outstanding 1,000,000 1,000,000
Series F Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, issued 128,991 128,991
Preferred stock, shares outstanding 128,991 128,991
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.23.4
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
REVENUE
Cost of goods sold
Gross profit (loss)
OPERATING EXPENSES    
General and administrative expenses 1,864,370 1,265,065
Total operating expenses 1,864,370 1,265,065
LOSS FROM OPERATIONS (1,864,370) (1,265,065)
OTHER INCOME (EXPENSE)    
Gain (loss) on settlement of liabilities, related party 6,724 (146,460)
Loss on conversion of preferred stock liability (5,939)
Interest expense (91,603) (70,346)
Total other expenses (84,879) (222,745)
Net loss $ (1,949,249) $ (1,487,810)
Net loss per share available to common shareholders $ (0.00) $ (0.00)
Weighted average shares outstanding - basic and diluted 827,324,789 628,539,782
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.23.4
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Stock Payable [Member]
Retained Earnings [Member]
Series D Preferred Stock [Member]
Series E Preferred Stock [Member]
Series F Preferred Stock [Member]
Total
Beginning balance, value at Sep. 30, 2021 $ 561,494 $ 15,228,254 $ 499,500 $ (17,016,966) $ 510 $ 1,000 $ 387 $ (725,821)
Shares, Outstanding, Beginning Balance at Sep. 30, 2021 561,495,726       509,988 1,000,000 386,975  
Common stock issued for conversion of convertible note payable and accrued interest $ 25,798 (25,540) $ (258)
Stock Issued During Period, Shares, Conversion of Convertible Securities 25,798,400           (257,984)  
Common stock subscribed for cash proceeds 5,000 5,000
Common stock issued for stock payable $ 19,980 479,520 (499,500)
Stock Issued During Period, Shares, New Issues 19,980,000              
Common stock issued for settlement liability $ 6,000 155,460 161,460
Settlement of Accounts Payable with Related Party Shares 6,000,000              
Stock-based compensation 322,266 322,266
Stock-based compensation, related parties 186,926 186,926
Conversion of Series G Preferred Stock to common $ 109,053 234,366 343,419
Conversion of Series G Preferred Stock to Common Shares 109,052,543              
Net loss (1,487,810) (1,487,810)
Ending balance, value at Sep. 30, 2022 $ 722,325 16,581,252 5,000 (18,504,776) $ 510 $ 1,000 $ 129 (1,194,560)
Shares, Outstanding, Ending Balance at Sep. 30, 2022 722,326,669       509,988 1,000,000 128,991  
Common stock subscribed for cash proceeds $ 51,883 25,617   77,500
Stock Issued During Period, Shares, Other 51,882,319              
Common stock issued for stock payable $ 1,515 3,485 (5,000)
Stock Issued During Period, Shares, New Issues 1,515,152              
Stock-based compensation $ 50,000 414,878   464,878
Stock Issued During Period, Shares, Employee Benefit Plan 50,000,000              
Stock-based compensation, related parties 805,098   805,098
Conversion of Series G Preferred Stock to common $ 100,713 136,380 237,093
Conversion of Series G Preferred Stock to Common Shares 100,712,968              
Net loss (1,949,249) (1,949,249)
Conversion of Series D Preferred Stock to common $ 50,999 (50,489) $ (510)
Conversion of Series D Preferred Stock to Common Shares 50,998,800       (509,988)      
Common stock issued for the conversion of debt $ 2,000 18,000   20,000
Common Stock Issued for The Conversion of Debt Shares 2,000,000              
Common stock issued for settlement of liability, related party $ 16,684 88,694   105,378
Common Stock Issued for Settlement of Liability Related Party in Shares 16,683,622              
Ending balance, value at Sep. 30, 2023 $ 996,119 $ 18,022,916 $ 5,000 $ (20,454,025) $ 1,000 $ 129 $ (1,433,861)
Shares, Outstanding, Ending Balance at Sep. 30, 2023 996,119,530       1,000,000 128,991  
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.23.4
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
CASH FLOW FROM OPERATING ACTIVITIES:    
Net loss $ (1,949,249) $ (1,487,810)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock compensation 464,878 322,266
Stock compensation, related parties 805,098 186,926
Amortization of discount on convertible note payable 33,391 54,664
(Gain) loss on settlement of liabilities, related party (6,724) 146,460
Loss on conversion of preferred stock liability 5,939
Changes in operating assets and liabilities    
Prepaid expenses 3,550 (3,550)
Accounts payable and accrued liabilities 247,444 172,957
Accounts payable and accrued liabilities to related party 187,641 259,471
Accrued interest payable 8,211 15,682
NET CASH USED IN OPERATING ACTIVITIES (205,760) (326,995)
CASH FLOWS FROM FINANCING ACTIVITIES    
Proceeds from convertible notes payable 55,000
Proceeds from sale of share-settled Series G preferred stock 73,000 310,000
Proceeds from related party advances 4,395 28,900
Repayment of related party advances (5,500) (16,500)
Proceeds from sale of common stock 72,500 5,000
NET CASH PROVIDED BY FINANCING ACTIVITIES 199,395 327,400
NET INCREASE (DECREASE) IN CASH (6,365) 405
Cash at beginning of period 6,365 5,960
Cash at end of period 6,365
Cash paid during the period for:    
Interest
Taxes
Noncash investing and financing transactions:    
Conversion of Series D preferred stock 50,999
Conversion of Series F preferred stock 25,798
Conversion of Series G preferred stock 227,975 324,500
Common stock issued for stock payable 5,000 499,500
Common stock issued for settlement of liabilities 15,000
Common stock issued for the conversion of debt 20,000
Note payable issued for settlement of accounts payable $ 300,000
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.23.4
General Organization and Business
 12 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
General Organization and Business

Note 1. General Organization and Business

 

GlobeStar Therapeutics Corporation (the “Company”) was incorporated on April 29, 2016. The Company’s year-end is September 30. On October 4, 2019, the Company filed Articles of Continuance with the Secretary of State of Wyoming to continue its business in the state of Wyoming. As part of these Articles of Continuance, effective October 4, 2019, the Company has no limit on the authorized shares of common stock that can be issued. The Company filed its Certificate of Dissolution with the Secretary of State of Nevada on October 21, 2019 because it is no longer a Nevada corporation.

 

The Company is developing an expanded platform of products that include addition of treatment for Multiple Sclerosis and other neurodegenerative diseases. The potential pharmaceutical products related to treatment for multiple sclerosis are licensed to the Company through the worldwide licensing agreement described in Note 8.
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.23.4
Summary of Significant Accounting Policies
 12 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The consolidated financial statements of the Company include the accounts of the Company and its wholly owned subsidiaries, SomaCeuticals, Inc., First Titan Energy, LLC and First Titan Technical, LLC from the date of their formations or acquisition. Significant intercompany transactions have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

Fair Value of Financial Instruments

 

The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization. 

 

FASB Accounting Standards Codification (ASC) 820 Fair Value Measurements and Disclosures (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
   
Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
   
Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2023. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accounts payable and accrued expenses.

 

Effective June 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to each performance obligation in the contract; and (5) recognizing revenue when each performance obligation is satisfied.

 

Advertising and Marketing Costs

 

We expense advertising and marketing costs as incurred. Advertising and marketing costs were $3,900 and $43,031 for the years ended September 30, 2023 and 2022, respectively.

 

Research and Development Costs

 

Research and development costs are expensed as incurred. The Company incurred no research and development costs during the years ended September 30, 2023 and 2022.

 

Cash and Cash Equivalents

 

All cash is maintained with a major financial institution in the United States. Deposits with this bank may occasionally exceed the amount of insurance provided on such deposits. For the purpose of the financial statements, cash includes cash in banks. Cash was $0 and $6,365 as of September 30, 2023 and 2022, respectively. There were no cash equivalents as of September 30, 2023 and 2022.

 

Income Taxes

 

The Company accounts for income taxes under ASC 740 Income Taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized as of September 30, 2023 and 2022.

 

Commitments and Contingencies

 

The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. There are no known commitments or contingencies as of September 30, 2023 or 2022.

 

Recently Issued Accounting Pronouncements

 

Accounting standards promulgated by the Financial Accounting Standards Board (the “FASB”) are subject to change. Changes in such standards may have an impact on our future financial statements. The following are a summary of recent accounting developments.

 

In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification; and (3) revises the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The Company adopted this guidance early on October 1, 2023 with no impact to the consolidated financial statements or results of operations of the Company.

 

There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on our consolidated financial position, results of operations or cash flows.

 
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.23.4
Going Concern
 12 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern

Note 3. Going Concern

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. For the year ended September 30, 2023, the Company had a net loss of $1,949,249. As of September 30, 2023, the Company had a working capital deficit of $1,433,861 and an accumulated deficit of $20,454,025. The Company has no revenue. Without additional capital, the Company will not be able to remain in business.

 

These factors raise a substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

 

Management has plans to address the Company’s financial situation as follows:

 

In the near term, management plans to continue to focus on raising the funds necessary to implement the Company’s business plan. Management will continue to seek out debt financing to obtain the capital required to meet the Company’s financial obligations. There is no assurance, however, that lenders will advance capital to the Company or that the new business operations will be profitable. The possibility of failure in obtaining additional funding and the potential inability to achieve profitability raise doubts about the Company’s ability to continue as a going concern.

 

In the long term, management believes that the Company’s projects and initiatives will be successful and will provide cash flow to the Company, which will be used to finance the Company’s future growth. However, there can be no assurances that the Company’s planned activities will be successful, or that the Company will ultimately attain profitability. The Company’s long-term viability depends on its ability to obtain adequate sources of debt or equity funding to meet current commitments and fund the continuation of its business operations, and the ability of the Company to achieve adequate profitability and cash flows from operations to sustain its operations.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.23.4
Related Party Transactions
 12 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
Related Party Transactions

Note 4. Related Party Transactions

 

For the year ended September 30, 2023

 

As of September 30, 2023 and September 30, 2022, the Company owed $454,665 and $379,126 to officers of the Company for compensation which are recorded as accounts payable related party. Additionally, during the years ended September 30, 2023 and 2022 the Company received short term, unsecured, non-interest bearing advances from the Company’s CEO totaling $21,200 and $2,500, respectively. As of September 30, 2023 and 2022, the Company owed $6,295 and $12,400 on these related party advances, respectively.

 

In February 2022, the Company entered into an amended and restatement employment agreement with Jim Katzaroff, the CEO. Mr. Katzaroff is entitled to an annual salary of $180,000 and a bonus as determined by the Board of Directors. Mr. Katzaroff may elect to receive payment in shares of stock based on the average of the three lowest trading prices for the 15 days prior to election of payment in stock. Further, in the event of a change of control of the Company, Mr. Katzaroff is entitled to a payment equal to 2.99 multiplied by the larger of the total compensation paid to Mr. Katzaroff over the prior 12-month period or the average compensation paid or payable to the Consultant over the prior three years.

 

The Company awarded Mr. Katzaroff a total of 35,000,000 common stock options with an exercise price of $0.009 per share, an exercise term of five years. The options vest 50% immediately, and the remainder on monthly basis over two years. Mr. Katzaroff is also entitled to additional options in the event of the Company issuing equity or equity equivalents in the future, with him receiving an amount of options equal to 3% of future options or warrants issued, excluding grants to officers. The exercise price of these additional options will be 110% of the price per equity equivalent. To date, a total of 11,632,356 additional options were issued to Mr. Katzaroff pursuant to the agreement terms. The total fair value of these option grants at issuance was $53,117. During the years ended September 30, 2023 and 2022, the Company recognized $108,802 and $186,926 of stock-based compensation, related to outstanding stock options under this agreement, respectively. At September 30, 2023, the Company had $42,228 of unrecognized expense related to options.

 

Additionally, Mr. Katzaroff will earn a fee related to any strategic transaction, as defined in the agreement, including but not limited to acquisitions, divestitures, partnerships or joint ventures, of at least 2% for any transactions not introduced by Mr. Katzaroff, or 4% for any introduced by Mr. Katzaroff of up to $20,000,000, and an additional 0.75% - 3.5% for amounts above that threshold. As of June 30, 2023, no amounts have been earned or paid.

 

Mr. Katzaroff will also receive an activity fee of 3% of gross revenues related to activities including securing a variety of vendor, sales or advertising relationships, or any new revenue generating activity. If such activity is a cost saving initiative instead of revenue generating, Mr. Katzaroff will receive 10% of the cost savings. As of September 30, 2023, no amounts have been earned or paid.

 

On April 4, 2023, the Company issued 7,422,535 shares to James Katzaroff to settle $50,000 of accrued compensation. The Company recognized a loss of $3,442 on this issuance based on the fair value of the shares issued.

 

On August 4, 2023, the Company issued 2,000,000 shares to its CFO Robert Chicoski to settle $12,000 of accrued compensation. The shares had a fair value of $3,600. No gain was recognized due to the related party nature of the transaction, with the Company recognizing the settlement in additional paid in capital.

 

On September 26, 2023, the Company entered into an agreement with SMI HealthCare LLC (“SMIHC”) to manage an initial clinical trial, regulatory filings, intellectual property rights filings, manufacturing, sales and distribution in India, Southeast Asia, Africa, and the Middle East, excluding Israel and Iraq, and for government and private aid organizations, for the Company's patented Multiple Sclerosis treatment. The agreement with SMIHC was approved by the parties’ respective boards of directors. Implementation of the first phase is subject to the Company arranging financing. The first phase includes formation of the Company and SMIHC subsidiaries in India, the clinical trial, regulatory and intellectual property rights filings in India, identifying manufacturers, and planning for the commercial launch in India and countries in the region that accept Drug Controller General of India (“DCGI”) approvals. Implementation of the second phase is expected to commence approximately nine months later, and is subject to receipt of DCGI marketing approval and the Company arranging financing. The second phase may continue for the duration of patent validity, and consists initially of sales, marketing and distribution in India and thereafter, countries in SMIHC’s territory that will permit sales and distribution based upon DCGI approval. After proof of market in those countries, the intention is to seek regulatory approvals elsewhere in SMIHC’s territory in order to expand the sales and distribution of the Company’s MS products. Pursuant to with SMIHC, the Company will receive a 5% royalty on any sales under the agreement by the company formed in India under this agreement, and 50% of any sublicense revenue from the India company formed under the agreement. The Company will pay the following (i) initial fees of between $15,000 - $22,500, and monthly fees of between $5,000 and $12,500 per month for Phase A (ii) monthly fees of $12,500, increase after six months to $17,500 per month, and to $25,000 per month after one year. The fee will increase by 5% per year thereafter for Phase B (iii) an initial management fee of $15,000 upon certain milestones and monthly management fee of $5,000 per month thereafter.

 

SMIHC is an affiliate of SMI Group LLC, a privately-held Los Angeles-based company. Kevin Spivak, a shareholder of the Company and consultant is the chairman of SMI Group though he did not advise the Company on this transaction and has waived fees payable to an SMI company for introducing SMIHC to the Company.

 

On September 19, 2023, the Company entered into a supplement to employment agreement with Jim Katzaroff, the CEO. For Mr. Katzaroff’s contribution to the SMIHC transaction, he will be paid the following (i) during the term of the agreement with SMIHC, a fee of 3% of any SMIHC generated revenue and (ii) not less than ¼ of the participation in Pro Forma Profits Before Tax to be payable to the Company at its senior executive pursuant to the SMIHC translation. Additionally, for Mr. Katzaroff’s contribution to the AIP transaction, he will be paid the following (i) if the Company invests in AIP, or merges with AIP, Mr. Katzaroff will receive a fee ranging from 1.5% - 4% during on the aggregate consideration of the AIP transaction and (ii) if AIP generated any revenue for the Company by reason of introductions, sales agency, distribution or other similar activities, he will receive a 3% fee for the term of the AIP transaction.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.23.4
Convertible Notes Payable and Advances
 12 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Convertible Notes Payable and Advances

Note 5. Convertible Notes Payable and Advances

 

Convertible notes payable consisted of the following at September 30, 2023 and 2022:

                 
    September 30,
2023		     September 30,
2022		  
Convertible note dated April 13, 2017 in the original principal amount of $20,000, no stated maturity date, bearing interest at 3% per year, convertible into common stock at a rate of $0.01 per share.   $ —     $ 20,000  
Convertible note dated May 10, 2023 in the original principal amount of $21,300 maturing May 10, 2024, bearing interest at 12%, convertible beginning six months from issuance into common stock at a rate of 61% of the lowest trading price during the 20 days prior to conversion.     21,300       —  
Convertible note dated July 3, 2023 in the original principal amount of $47,250 maturing April 15, 2024, bearing interest at 12%, convertible beginning six months from issuance into common stock at a rate of 61% of the lowest trading price during the 20 days prior to conversion.     47,250       —  
Total convertible notes payable     68,550       20,000  
Unamortized discount     (8,840 )     —  
                 
Total current convertible notes payable, net of discount   $ 59,710     $ 20,000  

 

All principal along with accrued interest is payable on the maturity date. The notes are convertible into common stock at the option of the holder. The holder of the notes cannot convert the notes into shares of common stock if that conversion would result in the holder owning more than 4.9% of the outstanding stock of the Company.

 

On May 10, 2023, the Company entered into a Securities Purchase Agreement (the “May 2023 Securities Purchase Agreement”) with 1800 Diagonal Lending LLC (“1800 Diagonal”). Pursuant to the terms of the May 2023 Securities Purchase Agreement, the Company issued a convertible promissory note (the “May 2023 Note”) to 1800 Diagonal in the aggregate principal amount of $21,300 with the Company receiving $15,000 in cash proceeds. Effective May 10, 2023, the Company issued the May 2023 Note to 1800 Diagonal consistent with the terms of the May 2023 Securities Purchase Agreement. The May 2023 Note bears interest at 12%, with a 22% rate in the event of default, with an Original Issue Discount of $1,050 and matures on May 10, 2024. Pursuant to the terms of the May 2023 Note, the outstanding principal and accrued interest on the note shall be convertible beginning six months from issuance into shares of the Company’s common stock at 61% of the lowest trading price of the Company’s common stock during the 20 days prior to conversion. The Company recognized $6,300 of discount and deferred finance costs and amortized $2,462 during the six months ended June 30, 2023. The conversion option on the note payable was not bifurcated as a derivative under ASC 815 due to sufficient authorized shares being available to settle the conversion feature.

 

On July 3, 2023, the Company entered into a Securities Purchase Agreement (the “July 2023 Securities Purchase Agreement”) with 1800 Diagonal Lending LLC (“1800 Diagonal”). Pursuant to the terms of the July 2023 Securities Purchase Agreement, the Company issued a convertible promissory note (the “May 2023 Note”) to 1800 Diagonal in the aggregate principal amount of $47,250 with the Company receiving $40,000 in cash proceeds. Effective July 3, 2023, the Company issued the July 2023 Note to 1800 Diagonal consistent with the terms of the July 2023 Securities Purchase Agreement. The July 2023 Note bears interest at 12%, with a 22% rate in the event of default, with an Original Issue Discount of $2,250 and matures on April. 15, 2024. Pursuant to the terms of the July 2023 Note, the outstanding principal and accrued interest on the note shall be convertible beginning six months from issuance into shares of the Company’s common stock at 61% of the lowest trading price of the Company’s common stock during the 20 days prior to conversion. The Company recognized $7,250 of discount and deferred finance costs and amortized $2,248 during the year ended September 30, 2023. The conversion option on the note payable was not bifurcated as a derivative under ASC 815 due to sufficient authorized shares being available to settle the conversion feature.

 

As of September 30, 2023 and September 30, 2022, accrued interest on convertible notes payable was $225,363 and $225,953, respectively.

 

Conversions to Common Stock

 

During the year ended September 30, 2023, the holders of the April 2017 convertible note payable elected to convert principal of $20,000 into 2,000,000 shares of common stock. The conversion was in accordance with the terms of the agreement and no gain or loss was recognized.

 

Advances

 

As of September 30, 2023 and 2022, the Company had non-interest bearing advances payable to third parties of $59,650. These advances are payable on demand.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.23.4
Stockholders’ deficit
 12 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Stockholders’ deficit

Note 6. Stockholders’ deficit

 

Preferred Stock

 

Our authorized preferred stock consists of 20,000,000 shares of $0.001 par value preferred stock.

 

Series A Preferred Stock – Our board of directors has designated up to 6,000,000 shares of Series A Preferred Stock. The Series A Preferred Stock has a liquidation value of $2.00 per share. The initial number issued is 5,000,000 with additional shares to be issued as a dividend not to exceed a total of 6,000,000 shares. The rank of the Series A is prior to all common and preferred shares. In addition, the Series A Preferred Stock retains protective provisions to maintain their seniority with respect to liquidation or dissolution. The Series A Preferred Stock holds no voting rights and earns an 8% per annum dividend, payable in additional shares of Series A Preferred Stock. At September 30, 2023 and 2022, there were no shares of our Series A Preferred Stock outstanding, respectively.

 

Series B Preferred Stock – Our board of directors has designated up to 1,000,000 shares of Series B Preferred Stock. The Series B Preferred Stock has a liquidation value of $1.00 per share. The holders of the Series B Preferred Stock are entitled to dividends of 8% per year payable quarterly in cash or in shares of common stock at the option of the Company. The holders of the Series B Preferred Stock have no voting rights. The Series B Preferred Stock is redeemable at the option of the Company at a price of $1.00 per share. At September 30, 2023 and 2022, there were no shares of our Series B Preferred Stock outstanding.

 

Series C Preferred Stock – On September 12, 2017, our board of directors designated up to 1,200,000 shares of Series C Preferred Stock with a liquidation value of $0.50 per share. The holders of the Series C Preferred Stock have no voting rights. The Series C Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of one share of common stock for each share of Series C Preferred Stock. The Series C Preferred Stock is redeemable at the option of the Company at a price of $0.50 per share. The Series C Preferred Stock has been canceled, and there are no shares of Series C Preferred Stock outstanding as of September 30, 2023 and 2022.

 

Series D Preferred Stock – On September 21, 2017, our board of directors designated up to 539,988 shares of Series D Preferred Stock with a liquidation value of $1.00 per share. The holders of the Series D Preferred Stock have no voting rights. The Series D Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock. The Series D Preferred Stock is not redeemable. In July 2023, the Company issued 50,998,800 shares to the holder of the Series D Preferred Stock for Full conversion of 509,988 shares outstanding. At September 30, 2023 and 2022, there were 0 and 509,988 shares of Series D Preferred Stock outstanding, respectively.

 

Series E Preferred Stock – On August 3, 2015, our board of directors designated 1,000,000 shares of Series E Preferred stock. The Series E Preferred stock is subordinate to our common stock. It does not receive dividends and does not participate in equity distributions. The Series E Preferred stock retained 2/3 of the voting rights in the Company.

 

At September 30, 2023 and 2022, there were 1,000,000 shares of Series E Preferred stock outstanding. Dividends, when, as and if declared by the Board of Directors, shall be paid out of funds at the time legally available for such purposes.

 

Series F Preferred Stock – On September 21, 2017, our board of directors designated up to 501,975 shares of Series F Preferred Stock with a liquidation value of $1.00 per share. The holders of the Series F Preferred Stock have no voting rights. The Series F Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock. The Series F Preferred Stock is not redeemable. At September 30, 2021, 386,975 shares of the Series F Preferred Stock were issued and outstanding. During the year ended September 30, 2022, 257,984 shares of Series F Preferred Stock was converted into 25,798,400 shares of common stock. At September 30, 2023 and 2022, 128,991 shares of the Series F Preferred Stock were issued and outstanding.

 

Conversions to Common Stock of Convertible Notes Payable

 

During the year ended September 30, 2023, the holders of the April 2017 convertible note payable elected to convert principal of $20,000 into 2,000,000 shares of common stock. The conversion was in accordance with the terms of the agreement and no gain or loss was recognized.

 

Common stock issued for Services

 

On April 6, 2023, the Company issued 50,000,000 shares to a consultant for services rendered to the Company. The shares had a fair value of $360,000. 

 

Common stock issued for settlement of liabilities

 

During the year ended September 30, 2022, the Company issued 6,000,000 shares of common stock and 900,000 warrants for the settlement of liabilities totaling $15,000. The Company recorded a $146,460 loss on settlement of liabilities related to this transaction.

 

On April 4, 2023, the Company issued 7,422,535 shares to James Katzaroff to settle $50,000 of accrued compensation. The Company recognized a loss of $3,442 on this issuance based on the fair value of the shares issued.

 

On April 25, 2023, the Company issued 7,261,087 shares of common stock to 7 to Stand to settle the outstanding royalty balance of $50,102 under the License Agreement. The Company recognized a gain of $10,166 on the issuance related to the fair value of the shares. See Note 7.

 

Common stock issued for stock payable

 

In July 2023, the Company also issued a total of 1,512,152 shares to settle subscription payables of $5,000.

 

In December 2021, the Company issued 19,980,000 shares of common stock as part of the common stock unit sales that occurred during the year ended September 30, 2021. As of September 30, 2022, no shares are remaining to be issued for these unit sales.

 

In September 2022, the Company received two subscriptions of $5,000 in cash for 1,515,152 shares of common stock and an equal number of warrants to purchase common stock at an exercise price of $0.01 for one year. In December 2022, the Company received $5,000 of cash as a subscription for an additional 1,515,152 shares of common stock and an equal number of warrants to purchase common stock at an exercise price of $0.01 for one year. The warrants had a fair value of $4,067 based on a Black-Scholes pricing model using the following assumptions: 1) volatility of 176.37%; 2) risk free rate of 4.74%; 3) dividend yield of 0% and 4) expected term of 1 year. In February 2023, the Company received $8,000 of cash and $7,000 of expenses paid on the Company’s behalf as a subscription for 7,500,000 shares of common stock. The common shares were issued in May 2023.

 

Common Stock Warrants

 

During the year ended September 30, 2023, the Company amended the exercise price of the common stock warrants issued to investors in its 2021 private placement to reduce the price from $0.03 per share to $0.01 per share. In accordance with ASC 718, the Company estimated the incremental value of the warrants based on terms immediately preceding the amendment, and immediately after the amendment, using the follow range of assumptions in a Black-Scholes option price model: 1) volatility of 203%; 2) expected term of approximately one year; 3) risk-free rate of 5.05%; 5) a common stock price at the date of grant of $0.086 and 6) a dividend yield of 0%. The Company recognized stock-based compensation expense of $51,761 related to the repricing.

 

In February 2022, the Company entered into a consulting agreement with Spivak Management, Inc. (the “Consultant”). Under the agreement, the Consultant will provide business strategy advice and introductions to the Company for a period of five years unless mutually terminated sooner. The Consultant is also entitled to additional warrants in the event of the Company issuing equity or equity equivalents in the future, with him receiving an number of warrants equal to 3% of future warrants issued, excluding grants to officers. The exercise price of these additional warrants will be 110% of the price per equity equivalent. The total fair value of these option grants at issuance was $53,117 using the follow range of assumptions in a Black-Scholes option price model volatility of 215.45 % - 253.78% ; 2) risk free rate of 2.37% - 4.46%; 3) dividend yield of 0% and 4) expected term of 5.0 years. During the years ended September 30, 2023 the Company recognized $53,117, related to this agreement, respectively.

 

The Company recognized $322,266 of expense related to these warrants during the year ended September 30, 2022. The Company estimated the fair value of the warrants based on a Black-Scholes pricing model using the following assumptions: 1) volatility of 254.43%; 2) risk free rate of 1.76%; 3) dividend yield of 0% and 4) expected term of 5 years.

 

The following table summarizes the stock warrant activity for the years ended September 30, 2023 and 2022:

 

    Warrants     Weighted-Average
Exercise Price
Per Share		  
Outstanding, September 30, 2021     29,970,000     $ 0.03  
Granted     41,415,152       0.01  
Exercised     —       —  
Forfeited     —       —  
Expired     —       —  
Outstanding, September 30, 2022     71,385,152     $ 0.02  
Granted     90,181,342       0.002  
Exercised     —       —  
Forfeited     —       —  
Expired     (3,030,304 )     0.01  
Outstanding, September 30, 2023     158,536,190     $ 0.01  

 

As of September 30, 2023, the outstanding warrants had an expected remaining life of 1.60 years and have an intrinsic value of $69,300.

 

Common Stock Options

 

As discussed in Note 4, The Company awarded common stock options to Mr. Katzaroff in connection with his amended and restated employment agreement. During the year ended September 30, 2023, the Company estimated the fair value of the options to be $53,117, using the following assumptions range: 1) volatility of 215.45 % - 253.78% ; 2) risk free rate of 2.37% - 4.46%; 3) dividend yield of 0% and 4) expected term of 5.0 years. The Company recognized $108,802 of expense related to the fair value of options vesting during the year ended September 30, 2023. The Company recognized $186,926 of expense related to the fair value of options vesting during the year ended September 30, 2022. The Company expects to recognize an additional $42,229 of expense related to these options assuming all vest.

 

The Company also recognized $696,294 of expense related to the estimated fair value of stock options awarded to officers of the Company. The Company awarded 50,000,000 options with a $0.01 exercise price to the Company’s CFO Robert Chicoski that expire in May 2026, and awarded 20,000,000 options with an exercise price of $0.01 each to Mr. Farley and Mr. Penderghast which expire in April 2026. The fair value was estimated using a Black-Scholes option pricing model and the following assumptions: 1) volatility of 184%; 2) expected term of approximately three years; 3) risk-free rate of 4.52%; 5) a common stock price at the date of grant of $0.086 and 6) a dividend yield of 0%. The option wards vested immediately.

 

At September 30, 2023, the Company had $42,229 of unrecognized expenses related to options.

 

The following table summarizes the stock option activity for the years ended September 30, 2023 and 2022:

 

    Options     Weighted-Average
Exercise Price
Per Share		  
Outstanding, September 30, 2021     70,000,000     $ 0.03  
Granted     35,000,000       0.01  
Exercised     —       —  
Forfeited     —       —  
Expired     —       —  
Outstanding, September 30, 2022     105,000,000       0.02  
Granted     101,632,356       0.01  
Exercised     —       —  
Forfeited     —       —  
Expired     (70,000,000 )     0.03  
Outstanding, September 30, 2023     136,632,356     $ 0.01  

 

As of September 30, 2023, the aggregate intrinsic value of options vested and outstanding were $0. As of September 30, 2023, the outstanding options had a weighted average remaining term of 2.94 years.
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.23.4
Series G Preferred Stock
 12 Months Ended
Sep. 30, 2023
Series G Preferred Stock  
Series G Preferred Stock

Note 7. Series G Preferred Stock

 

On August 11, 2021, our board of directors designated up to 1,000,000 shares of Series G Preferred Stock with a liquidation value of $1.00 per share. The holders of the Series G Preferred Stock have no voting rights except on matters related specifically to the Series G Preferred Stock. The Series G Preferred Stock carries a dividend of 8% of the stated value per share, which is cumulative and payable upon redemption, liquidation or conversion, and increases to 22% in case of default. The Series G Preferred Stock and accrued dividends are convertible beginning 180 days from issuance at the option of the holder into shares of common stock at a rate of a conversion price of 75% of the average three lowest trading prices during the 15 days prior to conversion. The Company will be required to redeem the Series G Preferred Stock upon the earlier of 15 months from issuance date or upon on event of default as defined in the agreement.

 

Based on the economic characteristics of the Series G Preferred Stock, the Company determined that the Series G should be accounted for as a liability under ASC 480-10, based on the discounted conversion price providing an effectively fixed monetary amount that the preferred stock is convertible into.

 

During the year ended September 30, 2023, the Company sold an aggregate of 89,100 shares of Series G Preferred Stock for net cash proceeds of $73,000. The Company recorded a debt discount of $16,100 for the difference between the cash proceeds and the total amount to be redeemed by the holder of $89,100. The Company amortized $28,681 of discount related to Series G Preferred Stock for the year ended September 30, 2023. The dividends on the Series G Preferred Stock are accrued as interest. The Company recognized $5,039 of interest on the Series G Preferred Stock and had an accrued interest balance of $3,556 and $3,983 as of September 30, 2023 and September 30, 2022, respectively. During the year ended September 30, 2023, the holder of the Series G converted 227,975 shares of Series G and $9,119 of dividends into 100,712,968 shares of common stock. The conversions were in accordance with the terms of the agreement and no gain or loss was recognized.

 

During the year ended September 30, 2022, the Company sold an aggregate of 369,875 shares of Series G Preferred Stock for net cash proceeds of $310,000. The Company recorded a debt discount of $59,875 for the difference between the cash proceeds and the total amount to be redeemed by the holder of $369,875. The Company amortized $54,664 of discount related to Series G Preferred Stock for the year months ended September 30, 2022. The dividends on the Series G Preferred Stock are accrued as interest. The Company recognized $15,852 of interest on the Series G Preferred Stock and had an accrued interest balance of $3,983 and $1,281 as of September 30, 2022 and September 30, 2021, respectively. During the year ended September 30, 2022, the holder of the Series G converted 324,500 shares of Series G and $12,980 of dividends into 109,052,543 shares of common stock, and the Company recognized a loss of $5,939.

 

As of September 30, 2023 and September 30, 2022, 0 and 138,875 shares of the Series G Preferred Stock were issued and outstanding, respectively. The balance of the Series G Preferred stock liability was $0 and $126,294, respectively, net of unamortized discount of $0 and $12,581, respectively.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.23.4
Commitments and Contingent Liabilities
 12 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingent Liabilities

Note 8. Commitments and Contingent Liabilities

 

In February 2022, the Company entered into a consulting agreement with Spivak Management, Inc. (the “Consultant”). Under the agreement, the Consultant will provide business strategy advice and introductions to the Company for a period of five years unless mutually terminated sooner. Concurrently, Kenin Spivak, who controls Spivak Management, Inc., entered into a stock purchase agreement with the Company to purchase 6,000,000 shares of common stock for $25,000 cash. The purchase and issuance of the shares was to be completed by June 30, 2022.

 

The Consultant will be paid a signing bonus of $25,000 upon receipt by the Company of the $25,000 cash under the stock purchase agreement described above. The Consultant will also receive the larger of $12,500 per month, or 50% of the CEO’s fixed cash compensation under the amended employment agreement described in Note 4. The Consultant may elect to receive this payment in stock.

 

In July 2022, the consultant agreement and the stock purchase agreement were amended to reduce the subscription amount to $17,500. In August 2022, $17,500 was placed in escrow by Mr. Spivak for the Company’s Benefit, and the Company paid $17,500 to the Consultant from the escrow account. The 6,000,000 shares owed to Mr. Spivak were not issued by June 30, 2023, and were issued in August 2023.

 

The Consultant may also receive a bonus in each calendar year of the agreement equal to the larger of any bonus awarded by the Board of Directors to the Consultant or 50% of the largest bonus payable by the Company to anyone other than the Consultant. If the agreement is terminated with one year of a change of control of the Company, the Consultant will be entitled to receive a payment equal to 2.99 times the larger of the total compensation paid to the Consultant over the prior 12 month period or the average compensation paid or payable to the Consultant over the prior three years. On September 19, 2023, the Company entered into a second supplement to consulting agreement. Pursuant to the agreement, in In lieu of Base Fees accrued through September 2023 and interest on late payment thereof, the Company shall pay to the Consultant, the sum of $300,000 in installments on and from the first to occur of the following until the full $300,000 is paid in full. The Company will continue to pay the Consultant a fee of $12,500 per month. The Company reclassified $250,000 of fee accrued in accounts payable owed to the Consultant and interest expense of $50,000 to a note payable. As of September 30, 2023 and September 30, 2022, the Company owed the consultant $337,500 and $100,000, which included accounts payable and accrued liabilities of $37,500 and $100,000 and notes payable of $300,000 and $0, respectively.

 

On August 10, 2023, the Company entered into a consulting agreement with Valerian Capital, LLC ( “Valerian”). Under the agreement, Valerian will provide management consulting, business advisory, shareholder information and public relations to the Company for a period of six months unless mutually terminated sooner. Upon execution of the agreement, Valerian will purchase 33,333,333 shares of the Company’s stock for a total purchase price of $25,000 and have the option to purchase an additional 33,333,333 shares for $25,000 during the first 45 days of the agreement. Lastly, Valerian will have the right to purchase 66,000,000 warrants with an exercise price of $0.00075 for up to one year following the agreement. As of September 30, 2023, the Company received $25,000 and issued 33,333,333 shares of common stock to Valerian.

 

Litigation

 

From time to time, the Company may be subject to routine litigation, claims, or disputes in the ordinary course of business. In the opinion of management, no pending or known threatened claims, actions or proceedings against the Company are expected to have a material adverse effect on the Company’s financial position, results of operations or cash flows. The Company cannot predict with certainty, however, the outcome or effect of any of the litigation or investigatory matters specifically described above or any other pending litigation or claims. There can be no assurance as to the ultimate outcome of any lawsuits and investigations.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.23.4
License Agreement
 12 Months Ended
Sep. 30, 2023
License Agreement  
License Agreement

Note 9. License Agreement

 

Effective August 23, 2020 the Company’s wholly-owned subsidiary, SomaCeuticals, Inc. entered into an exclusive global license agreement with 7 to Stand, Inc. for the rights to U.S. patent 10,610,592 issued to Fabrizio de Silvestri, Terni, Italy, as inventor, April 7, 2020 for treatment of Multiple Sclerosis. In consideration for the license agreement, SomaCeuticals agreed to pay 7 to Stand a royalty of 7.1% of the net sales of any product developed under the patent on a worldwide basis. Additionally, the Company will issue shares of common stock to 7 to Stand upon completion of the following milestones:

 

● Common shares representing 5% of total number of outstanding common shares of the Company immediately following any change of control of the Company; the Company issued 29,130,167 shares of common stock as a result of the change of control discussed in Note 5. These shares were issued in July 2021.
   
● 29,130,167 Common shares immediately following the first round of funding under a private offer of equity or debt securities; These shares were issued in July 2021.
   
● 29,130,167 Common shares immediately following the commencement of clinical trials for Federal Drug Administration clearance of the product; and
   
● Common shares representing an adjustment to increase 7 to Stand’s total ownership to 19.99% of total number of outstanding common shares of the Company immediately following FDA clearance of the product for sale. The Company expects to issue 29,130,166 shares of common stock related to this provision if met.
   
● $40,000 of royalties to be paid to 7 to Stand annually, on a quarterly basis. The license agreement may be terminated by 7 to Stand if 1) SomaCeuticals does not begin clinical trials within one year of the agreement; 2) if SomaCeuticals terminates the continuation of the clinical trials; or 3) shall not commence marketing the product within reasonable time after obtaining FDA approval.

 

The Company paid no royalties and accrued $43,851 of royalties and late fees during the year ended September 30, 2023. During the year ended September 30, 2023, the Company and 7 to Stand agreed to settle a total of $50,102 by issuance of 7,261,087 shares of common stock. The Company recognized a gain of $10,166 based on the fair value of the shares issued.

 

The Company owed $20,000 of royalties and late fees under this agreement as of September 30, 2023 and $26,250 as of September 30, 2022.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.23.4
Income Taxes
 12 Months Ended
Sep. 30, 2023
Income Tax Disclosure [Abstract]  
Income Taxes

Note 10. Income Taxes

 

There is no current or deferred income tax expense or benefit for the period ended September 30, 2023 and 2021. The Company currently has net operating loss carryforwards aggregating approximately $5,217,000 which expire beginning in 2033. The deferred tax asset related to the net operating loss carryforwards has been fully reserved.

 

The provision for income taxes is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes. The items causing this difference for the period from April 29, 2016 (date of inception) through September 30, 2023 and 2022 is the valuation allowance as follows.

 

    September 30, 2023   September 30, 2022  
Net operating loss carryforward at statutory tax rate   $ 1,096,000   $ 962,000  
Valuation allowance     (1,096,000 )   (962,000 )
Deferred tax benefit, net   $ —   $ —  

 

The Company has not recognized an income tax benefit for the period based on uncertainties concerning its ability to generate taxable income in future periods. The tax benefit for the current period presented is offset by a valuation allowance (100%) established against deferred tax assets arising from operating losses and other temporary differences, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not.

 

The tax returns for fiscal year 2017 and forward are still open for review by the Internal Revenue Service.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.23.4
Subsequent Events
 12 Months Ended
Sep. 30, 2023
Subsequent Events [Abstract]  
Subsequent Events

Note 11. Subsequent Events

 

On November 2, 2023, the Company entered into a consulting agreement with Advanced Innovate Partners (“AIP”) under which AIP will provide advice to GlobeStar and SMIHC on the global design, strategy and execution of clinical trials. Pursuant to the agreement, the Company will pay the following (i) AIP $5,000 per month during Phase A period, if the Company receives regulatory approval to manufacture, sell and distribute products in India or the United States within 60 days of the agreement (ii) AIP $6,000 per month during Phase B period (iii) AIP a sales commission of between 10% and 15% related to any customers, distributors or sales agents introduced to the Company by AIP and (iv) a commission of 4% of any proceeds from equity investments to the Company introduced by AIP, or 2% of any loan proceeds from lenders introduced by AIP.

 

Subsequent to September 30, 2023, the holder of the May 10, 2023 convertible note was issued 30,297,790 shares of common stock upon conversion of all $21,300 of principal and $1,278 of accrued interest.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.23.4
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The consolidated financial statements of the Company include the accounts of the Company and its wholly owned subsidiaries, SomaCeuticals, Inc., First Titan Energy, LLC and First Titan Technical, LLC from the date of their formations or acquisition. Significant intercompany transactions have been eliminated in consolidation.
Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization. 

 

FASB Accounting Standards Codification (ASC) 820 Fair Value Measurements and Disclosures (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
   
Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
   
Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2023. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accounts payable and accrued expenses.

 

Effective June 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to each performance obligation in the contract; and (5) recognizing revenue when each performance obligation is satisfied.
Advertising and Marketing Costs

Advertising and Marketing Costs

 

We expense advertising and marketing costs as incurred. Advertising and marketing costs were $3,900 and $43,031 for the years ended September 30, 2023 and 2022, respectively.
Research and Development Costs

Research and Development Costs

 

Research and development costs are expensed as incurred. The Company incurred no research and development costs during the years ended September 30, 2023 and 2022.
Cash and Cash Equivalents

Cash and Cash Equivalents

 

All cash is maintained with a major financial institution in the United States. Deposits with this bank may occasionally exceed the amount of insurance provided on such deposits. For the purpose of the financial statements, cash includes cash in banks. Cash was $0 and $6,365 as of September 30, 2023 and 2022, respectively. There were no cash equivalents as of September 30, 2023 and 2022.
Income Taxes

Income Taxes

 

The Company accounts for income taxes under ASC 740 Income Taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized as of September 30, 2023 and 2022.
Commitments and Contingencies

Commitments and Contingencies

 

The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. There are no known commitments or contingencies as of September 30, 2023 or 2022.
Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

 

Accounting standards promulgated by the Financial Accounting Standards Board (the “FASB”) are subject to change. Changes in such standards may have an impact on our future financial statements. The following are a summary of recent accounting developments.

 

In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification; and (3) revises the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The Company adopted this guidance early on October 1, 2023 with no impact to the consolidated financial statements or results of operations of the Company.

 

There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on our consolidated financial position, results of operations or cash flows.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.23.4
Convertible Notes Payable and Advances (Tables)
 12 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Convertible notes payable consisted of the following at September 30, 2023 and 2022:

Convertible notes payable consisted of the following at September 30, 2023 and 2022:

                 
    September 30,
2023		     September 30,
2022		  
Convertible note dated April 13, 2017 in the original principal amount of $20,000, no stated maturity date, bearing interest at 3% per year, convertible into common stock at a rate of $0.01 per share.   $ —     $ 20,000  
Convertible note dated May 10, 2023 in the original principal amount of $21,300 maturing May 10, 2024, bearing interest at 12%, convertible beginning six months from issuance into common stock at a rate of 61% of the lowest trading price during the 20 days prior to conversion.     21,300       —  
Convertible note dated July 3, 2023 in the original principal amount of $47,250 maturing April 15, 2024, bearing interest at 12%, convertible beginning six months from issuance into common stock at a rate of 61% of the lowest trading price during the 20 days prior to conversion.     47,250       —  
Total convertible notes payable     68,550       20,000  
Unamortized discount     (8,840 )     —  
                 
Total current convertible notes payable, net of discount   $ 59,710     $ 20,000  
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.23.4
Stockholders’ deficit (Tables)
 12 Months Ended
Sep. 30, 2023
Equity [Abstract]  
The following table summarizes the stock warrant activity for the years ended September 30, 2023 and 2022:

The following table summarizes the stock warrant activity for the years ended September 30, 2023 and 2022:

 

    Warrants     Weighted-Average
Exercise Price
Per Share		  
Outstanding, September 30, 2021     29,970,000     $ 0.03  
Granted     41,415,152       0.01  
Exercised     —       —  
Forfeited     —       —  
Expired     —       —  
Outstanding, September 30, 2022     71,385,152     $ 0.02  
Granted     90,181,342       0.002  
Exercised     —       —  
Forfeited     —       —  
Expired     (3,030,304 )     0.01  
Outstanding, September 30, 2023     158,536,190     $ 0.01  
The following table summarizes the stock option activity for the years ended September 30, 2023 and 2022:

The following table summarizes the stock option activity for the years ended September 30, 2023 and 2022:

 

    Options     Weighted-Average
Exercise Price
Per Share		  
Outstanding, September 30, 2021     70,000,000     $ 0.03  
Granted     35,000,000       0.01  
Exercised     —       —  
Forfeited     —       —  
Expired     —       —  
Outstanding, September 30, 2022     105,000,000       0.02  
Granted     101,632,356       0.01  
Exercised     —       —  
Forfeited     —       —  
Expired     (70,000,000 )     0.03  
Outstanding, September 30, 2023     136,632,356     $ 0.01  
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.23.4
Income Taxes (Tables)
 12 Months Ended
Sep. 30, 2023
Income Tax Disclosure [Abstract]  
Schedule of provision for income taxes

The provision for income taxes is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes. The items causing this difference for the period from April 29, 2016 (date of inception) through September 30, 2023 and 2022 is the valuation allowance as follows.

 

    September 30, 2023   September 30, 2022  
Net operating loss carryforward at statutory tax rate   $ 1,096,000   $ 962,000  
Valuation allowance     (1,096,000 )   (962,000 )
Deferred tax benefit, net   $ —   $ —  
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.23.4
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Accounting Policies [Abstract]    
Advertising and marketing costs $ 3,900 $ 43,031
Research and development 0 0
Cash 0 6,365
Cash equivalents $ 0 $ 0
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.23.4
Going Concern (Details Narrative) - USD ($)
 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Net loss $ 1,949,249 $ 1,487,810
Working capital deficit 1,433,861  
Accumulated deficit 20,454,025 18,504,776
Revenue
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.23.4
Related Party Transactions (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Sep. 26, 2023
Sep. 19, 2023
Sep. 19, 2023
Apr. 04, 2023
Feb. 28, 2022
Sep. 30, 2023
Sep. 30, 2022
Aug. 04, 2023
Apr. 06, 2023
Dec. 31, 2021
Related Party Transaction [Line Items]                    
Compensation           $ 187,641 $ 259,471      
Related party advances           $ 6,295 $ 12,400      
Annual fees   $ 12,500                
Common stock, shares outstanding           996,119,530 722,326,669      
Issuance of common stock           996,119,530 722,326,669   50,000,000 19,980,000
Fair value           $ 0        
Mr Katzaroff [Member]                    
Related Party Transaction [Line Items]                    
Description of additional options           Additionally, Mr. Katzaroff will earn a fee related to any strategic transaction, as defined in the agreement, including but not limited to acquisitions, divestitures, partnerships or joint ventures, of at least 2% for any transactions not introduced by Mr. Katzaroff, or 4% for any introduced by Mr. Katzaroff of up to $20,000,000, and an additional 0.75% - 3.5% for amounts above that threshold. As of June 30, 2023, no amounts have been earned or paid.        
Issuance of common stock       7,422,535            
Settelment amount       $ 50,000            
Recognized loss       $ 3,442            
Officer [Member]                    
Related Party Transaction [Line Items]                    
Compensation           $ 454,665 $ 379,126      
Chief Executive Officer [Member]                    
Related Party Transaction [Line Items]                    
Compensation           $ 21,200 $ 2,500      
Chief Executive Officer [Member] | Mr Katzaroff [Member]                    
Related Party Transaction [Line Items]                    
Description of options     (i) during the term of the agreement with SMIHC, a fee of 3% of any SMIHC generated revenue and (ii) not less than ¼ of the participation in Pro Forma Profits Before Tax to be payable to the Company at its senior executive pursuant to the SMIHC translation. Additionally, for Mr. Katzaroff’s contribution to the AIP transaction, he will be paid the following (i) if the Company invests in AIP, or merges with AIP, Mr. Katzaroff will receive a fee ranging from 1.5% - 4% during on the aggregate consideration of the AIP transaction and (ii) if AIP generated any revenue for the Company by reason of introductions, sales agency, distribution or other similar activities, he will receive a 3% fee for the term of the AIP transaction.              
Board of Directors Chairman [Member]                    
Related Party Transaction [Line Items]                    
Royalty on any sales under the agreement Pursuant to with SMIHC, the Company will receive a 5% royalty on any sales under the agreement by the company formed in India under this agreement, and 50% of any sublicense revenue from the India company formed under the agreement. The Company will pay the following (i) initial fees of between $15,000 - $22,500, and monthly fees of between $5,000 and $12,500 per month for Phase A (ii) monthly fees of $12,500, increase after six months to $17,500 per month, and to $25,000 per month after one year. The fee will increase by 5% per year thereafter for Phase B (iii) an initial management fee of $15,000 upon certain milestones and monthly management fee of $5,000 per month thereafter.                  
Board of Directors Chairman [Member] | Mr Katzaroff [Member]                    
Related Party Transaction [Line Items]                    
Annual fees         $ 180,000          
Payable to consultant term         3 years          
Common stock, shares outstanding           35,000,000        
Exercise price, per shares           $ 0.009        
Exercise term           5 years        
Description of options           The options vest 50% immediately, and the remainder on monthly basis over two years. Mr. Katzaroff is also entitled to additional options in the event of the Company issuing equity or equity equivalents in the future, with him receiving an amount of options equal to 3% of future options or warrants issued, excluding grants to officers. The exercise price of these additional options will be 110% of the price per equity equivalent. To date, a total of 11,632,356 additional options were issued to Mr. Katzaroff pursuant to the agreement terms. The total fair value of these option grants at issuance was $53,117. During the years ended September 30, 2023 and 2022, the Company recognized $108,802 and $186,926 of stock-based compensation, related to outstanding stock options under this agreement, respectively. At September 30, 2023, the Company had $42,228 of unrecognized expense related to options.        
Chief Financial Officer [Member] | Robert Chicoski [Member]                    
Related Party Transaction [Line Items]                    
Compensation               $ 12,000    
Issuance of common stock               2,000,000    
Fair value               $ 3,600    
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.23.4
Convertible notes payable consisted of the following at September 30, 2023 and 2022: (Details) - USD ($)
 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Short-Term Debt [Line Items]    
Total current convertible notes payable, net of discount $ 59,710 $ 20,000
Total convertible notes payable 68,550 20,000
Unamortized discount $ (8,840)
Convertible Note Date April 13 2017 [Member]    
Short-Term Debt [Line Items]    
Dated Apr. 13, 2017  
Amount $ 20,000  
Interest 3.00%  
Conversion price $ 0.01  
Total current convertible notes payable, net of discount 20,000
Convertible Note Date May 10 2023 [Member]    
Short-Term Debt [Line Items]    
Dated May 10, 2023  
Amount $ 21,300  
Interest 12.00%  
Total current convertible notes payable, net of discount $ 21,300
Maturity date May 10, 2024  
Convertible Note Date July 3, 2023 [Member]    
Short-Term Debt [Line Items]    
Dated Jul. 03, 2023  
Amount $ 47,250  
Interest 12.00%  
Total current convertible notes payable, net of discount $ 47,250
Maturity date Apr. 15, 2024  
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.23.4
Convertible Notes Payable and Advances (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Jul. 03, 2023
May 10, 2023
Feb. 28, 2022
Sep. 30, 2023
Jun. 30, 2023
Sep. 30, 2022
Short-Term Debt [Line Items]            
Common stock issued for stock payable     $ 25,000      
Debt discount       $ 8,840  
Conversion of stock description Pursuant to the terms of the July 2023 Note, the outstanding principal and accrued interest on the note shall be convertible beginning six months from issuance into shares of the Company’s common stock at 61% of the lowest trading price of the Company’s common stock during the 20 days prior to conversion. Pursuant to the terms of the May 2023 Note, the outstanding principal and accrued interest on the note shall be convertible beginning six months from issuance into shares of the Company’s common stock at 61% of the lowest trading price of the Company’s common stock during the 20 days prior to conversion.        
Recognized of discount       7,250 $ 6,300  
Deferred finance costs       2,248 $ 2,462  
Accounts payable and accrued liabilities       225,363   225,953
Principal amount       $ 68,550   20,000
May 2023 Securities Purchase Agreement [Member]            
Short-Term Debt [Line Items]            
Common stock issued for stock payable   $ 21,300        
Cash proceeds   $ 15,000        
Interest rate   12.00%        
Debt discount   $ 1,050        
Maturity date   May 10, 2024        
July 2023 Securities Purchase Agreement [Member]            
Short-Term Debt [Line Items]            
Common stock issued for stock payable $ 47,250          
Cash proceeds $ 40,000          
Interest rate 12.00%          
Debt discount $ 2,250          
Maturity date Apr. 15, 2024          
Convertible Debt [Member]            
Short-Term Debt [Line Items]            
Beneficial conversion discount on convertible note payable       The notes are convertible into common stock at the option of the holder. The holder of the notes cannot convert the notes into shares of common stock if that conversion would result in the holder owning more than 4.9% of the outstanding stock of the Company.    
Convertible Debt One [Member]            
Short-Term Debt [Line Items]            
Principal amount       $ 20,000    
Conversion of shares       2,000,000    
Advance [Member]            
Short-Term Debt [Line Items]            
Accounts payable and accrued liabilities       $ 59,650   $ 59,650
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.23.4
The following table summarizes the stock warrant activity for the years ended September 30, 2023 and 2022: (Details) - $ / shares
 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Equity [Abstract]    
Warrants outstanding, beginning 71,385,152 29,970,000
Warrants outstanding, beginning (in per shares) $ 0.02 $ 0.03
Granted 90,181,342 41,415,152
Granted (in per shares) $ 0.002 $ 0.01
Expired (3,030,304)  
Expired (in per shares) $ 0.01  
Warrants outstanding, ending 158,536,190 71,385,152
Warrants outstanding, ending (in per shares) $ 0.01 $ 0.02
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.23.4
The following table summarizes the stock option activity for the years ended September 30, 2023 and 2022: (Details) - $ / shares
 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Equity [Abstract]    
Option outstanding, beginning 105,000,000 70,000,000
Option outstanding, beginning (in per shares) $ 0.02 $ 0.03
Granted 101,632,356 35,000,000
Granted (in per shares) $ 0.01 $ 0.01
Exercised
Exercised (in per shares)
Forfeited
Forfeited (in per shares)
Expired (70,000,000)
Expired (in per shares) $ 0.03
Option outstanding, ending 136,632,356 105,000,000
Option outstanding, ending (in per shares) $ 0.01 $ 0.02
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.23.4
Stockholders’ deficit (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Apr. 25, 2023
Apr. 06, 2023
Sep. 21, 2017
Aug. 03, 2015
Jul. 31, 2023
Feb. 28, 2023
Dec. 31, 2022
Sep. 30, 2022
Feb. 28, 2022
Sep. 30, 2023
Sep. 30, 2022
Apr. 04, 2023
Dec. 31, 2021
Sep. 30, 2021
Sep. 12, 2017
Class of Stock [Line Items]                              
Preferred stock authorized               20,000,000   20,000,000 20,000,000        
Preferred stock, par value (in dollars per share)               $ 0.001   $ 0.001 $ 0.001        
Common stock issued   50,000,000           722,326,669   996,119,530 722,326,669   19,980,000    
Fair value of shares issued   $ 360,000                          
Settlement of liabilities               $ 15,000     $ 15,000        
Gain (loss) related to settlement of liabilities                     146,460        
Shares issued to settle subscription payables         1,512,152   1,515,152 1,515,152              
Subscription payables settle         $ 5,000   $ 5,000 $ 5,000          
Exercise price to purchase common stock             $ 0.01 $ 0.01              
Volatility rate                     254.43%        
Risk free rate                     1.76%        
Dividend yield                     0.00%        
Expected term                     5 years        
Cash received           $ 8,000                  
Expenses paid           $ 7,000                  
Amended the exercise price               0.02   $ 0.01 $ 0.02     $ 0.03  
Expected remaining life                   2 years 11 months 8 days          
Expenses related to the fair value                   $ 108,802 $ 186,926        
Additional expenses                   $ 42,229          
Other description                   The fair value was estimated using a Black-Scholes option pricing model and the following assumptions: 1) volatility of 184%; 2) expected term of approximately three years; 3) risk-free rate of 4.52%; 5) a common stock price at the date of grant of $0.086 and 6) a dividend yield of 0%. The option wards vested immediately.          
Unrecognized expenses related to options                   $ 42,229          
Aggregate intrinsic value                   $ 0          
Private Placement [Member] | Maximum [Member]                              
Class of Stock [Line Items]                              
Amended the exercise price                   $ 0.03          
Private Placement [Member] | Minimum [Member]                              
Class of Stock [Line Items]                              
Amended the exercise price                   $ 0.01          
License Agreement Terms [Member]                              
Class of Stock [Line Items]                              
Common stock issued 7,261,087                            
Royalty expense $ 50,102                            
Recognized gain $ 10,166                            
Mr Katzaroff [Member]                              
Class of Stock [Line Items]                              
Common stock issued                       7,422,535      
Settelment amount                       $ 50,000      
Dividend yield                   0.00%          
Expected term                   5 years          
Fair value of option grants                   $ 53,117          
Mr Katzaroff [Member] | Maximum [Member]                              
Class of Stock [Line Items]                              
Volatility rate                   253.78%          
Risk free rate                   446.00%          
Mr Katzaroff [Member] | Minimum [Member]                              
Class of Stock [Line Items]                              
Volatility rate                   215.45%          
Risk free rate                   237.00%          
Spivak Management Inc [Member]                              
Class of Stock [Line Items]                              
Dividend yield                 0.00%            
Expected term                 5 years            
Fair value of option grants                   $ 53,117          
Spivak Management Inc [Member] | Maximum [Member]                              
Class of Stock [Line Items]                              
Volatility rate                 253.78%            
Risk free rate                 4.46%            
Spivak Management Inc [Member] | Minimum [Member]                              
Class of Stock [Line Items]                              
Volatility rate                 215.45%            
Risk free rate                 2.37%            
Common Stock [Member]                              
Class of Stock [Line Items]                              
Stock issued during period, shares, conversion of convertible securities                     6,000,000        
Stock issued during period, shares, conversion of convertible securities                     25,798,400        
Subscription payables settle                   $ 1,515 $ 19,980        
Number of shares subscribe           7,500,000                  
Warrant [Member]                              
Class of Stock [Line Items]                              
Stock issued during period, shares, conversion of convertible securities                     900,000        
Fair value of warrants             $ 4,067                
Volatility rate             176.37%                
Risk free rate             4.74%                
Dividend yield             0.00%                
Expected term             1 year                
Expected remaining life                   1 year 7 months 6 days          
Aggregate intrinsic value                   $ 69,300          
Warrant [Member] | Private Placement [Member]                              
Class of Stock [Line Items]                              
Volatility rate                   203.00%          
Risk free rate                   5.05%          
Dividend yield                   0.00%          
Expected term                   1 year          
Grant stock price, per share                   $ 0.086          
Convertible Notes Payable [Member]                              
Class of Stock [Line Items]                              
Principal amount                   $ 20,000          
Shares converted                   2,000,000          
Common stock issued                   30,297,790          
Chief Financial Officer [Member]                              
Class of Stock [Line Items]                              
Expenses related to the fair value                   $ 696,294          
Robert Chicoski [Member]                              
Class of Stock [Line Items]                              
Shares issued to settle subscription payables                   50,000,000          
Exercise price                   $ 0.01          
Mr Farley [Member]                              
Class of Stock [Line Items]                              
Shares issued to settle subscription payables                   20,000,000          
Exercise price                   $ 0.01          
Mr Penderghast [Member]                              
Class of Stock [Line Items]                              
Shares issued to settle subscription payables                   20,000,000          
Exercise price                   $ 0.01          
Series A Preferred Stock [Member]                              
Class of Stock [Line Items]                              
Preferred stock, par value (in dollars per share)               $ 0.001   $ 0.001 $ 0.001        
Preferred stock shares designated                   6,000,000          
Preferred stock liquidation preference                   $ 2.00          
Additional share to be issued                   5,000,000          
Preferred stock dividends                   6,000,000          
Preferred stock dividend rate                   8.00%          
Preferred stock, shares outstanding               0   0 0        
Preferred stock, shares issued               0   0 0        
Series B Preferred Stock [Member]                              
Class of Stock [Line Items]                              
Preferred stock authorized                   1,000,000          
Preferred stock, par value (in dollars per share)               $ 0.001   $ 0.001 $ 0.001        
Preferred stock liquidation preference                   $ 1.00          
Preferred stock dividend rate                   8.00%          
Preferred stock, shares outstanding               0   0 0        
Preferred stock, shares issued               0   0 0        
Series C Preferred Stock [Member]                              
Class of Stock [Line Items]                              
Preferred stock, par value (in dollars per share)               $ 0.001   $ 0.001 $ 0.001        
Preferred stock shares designated                             1,200,000
Preferred stock liquidation preference                             $ 0.50
Preferred stock, shares outstanding               0   0 0        
Preferred stock redemption price per share                             $ 0.50
Preferred stock, shares issued               0   0 0        
Series D Preferred Stock [Member]                              
Class of Stock [Line Items]                              
Preferred stock, par value (in dollars per share)               $ 0.001   $ 0.001 $ 0.001        
Preferred stock shares designated     539,988                        
Preferred stock liquidation preference     $ 1.00                        
Preferred stock, shares outstanding         509,988     509,988   0 509,988        
Preferred stock, conversion basis     The Series D Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock.                        
Preferred stock, shares issued         50,998,800     509,988   0 509,988        
Subscription payables settle                          
Series E Preferred Stock [Member]                              
Class of Stock [Line Items]                              
Preferred stock, par value (in dollars per share)               $ 0.001   $ 0.001 $ 0.001        
Preferred stock, shares outstanding       1,000,000       1,000,000   1,000,000 1,000,000        
Preferred stock, shares issued               1,000,000   1,000,000 1,000,000        
Description of voting rights       The Series E Preferred stock retained 2/3 of the voting rights in the Company.                      
Subscription payables settle                          
Series E Preferred Stock [Member] | Director [Member]                              
Class of Stock [Line Items]                              
Preferred stock authorized               1,000,000     1,000,000        
Series F Preferred Stock [Member]                              
Class of Stock [Line Items]                              
Preferred stock, par value (in dollars per share)               $ 0.001   $ 0.001 $ 0.001        
Preferred stock shares designated     501,975                        
Preferred stock liquidation preference     $ 1.00                        
Preferred stock, shares outstanding               128,991   128,991 128,991     386,975  
Preferred stock, conversion basis     The Series F Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock.                        
Preferred stock, shares issued               128,991   128,991 128,991     386,975  
Convertible preferred stock shares               257,984     257,984        
Conversion of shares                     25,798,400        
Stock issued during period, shares, conversion of convertible securities                     (257,984)        
Subscription payables settle                          
Common Stock Warrants [Member]                              
Class of Stock [Line Items]                              
Stock based compensation related to repricing                   51,761          
Expenses related to warrants                   $ 322,266          
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.23.4
Series G Preferred Stock (Details Narrative) - USD ($)
 12 Months Ended
Aug. 11, 2021
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2021
Net cash proceeds   $ 89,100 $ 369,875  
Debt discount   8,840  
Amortization of debt discount   28,681 54,664  
Common Stock [Member]        
Recognized loss   $ 0 $ 5,939  
Series G Preferred Stock [Member]        
Preferred stock, shares designated 1,000,000      
Preferred stock liquidation preference $ 1.00      
Description of voting rights The holders of the Series G Preferred Stock have no voting rights except on matters related specifically to the Series G Preferred Stock.      
Preferred stock, conversion basis The Series G Preferred Stock carries a dividend of 8% of the stated value per share, which is cumulative and payable upon redemption, liquidation or conversion, and increases to 22% in case of default.      
Number of share sold   89,100 369,875  
Net cash proceeds   $ 73,000 $ 310,000  
Debt discount   16,100 59,875  
Interest recognized   5,039 15,852  
Accrued interest   $ 3,556 $ 3,983 $ 1,281
Conversion of stock shares converted   227,975 324,500  
Preferred stock, shares issued   0 138,875  
Preferred stock, shares outstanding   0 138,875  
Liabilities related to stock   $ 0 $ 126,294  
Unamortized discount   $ 0 $ 12,581  
Series G Preferred Stock [Member] | Common Stock [Member]        
Conversion of stock shares converted   100,712,968 109,052,543  
Dividend value   $ 9,119 $ 12,980  
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.23.4
Commitments and Contingent Liabilities (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Sep. 19, 2023
Aug. 10, 2023
Aug. 31, 2022
Jul. 31, 2022
Feb. 28, 2022
Sep. 30, 2023
Sep. 30, 2022
Apr. 06, 2023
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Shares issue         6,000,000        
Value of share issue         $ 25,000        
Description of commitment         The Consultant will be paid a signing bonus of $25,000 upon receipt by the Company of the $25,000 cash under the stock purchase agreement described above. The Consultant will also receive the larger of $12,500 per month, or 50% of the CEO’s fixed cash compensation under the amended employment agreement described in Note 4. The Consultant may elect to receive this payment in stock.        
Common stock, shares issued           996,119,530 722,326,669 50,000,000 19,980,000
Accrued fees $ 300,000                
Consultant fees 12,500                
Interest expense to a note payable           $ 91,603 $ 70,346    
Accounts payable and accrued liabilities           37,500 100,000    
Notes payable           300,000    
Common stock, value           $ 996,119 $ 722,325    
Common Stock [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Shares issue           1,515,152 19,980,000    
Notes Payable, Other Payables [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Interest expense to a note payable 50,000                
Accrued Liabilities [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Fee accrued in accounts payable $ 250,000                
Subscription Arrangement [Member] | Mr Spivak [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Obligation benefits paid     $ 17,500            
Common stock, shares issued     6,000,000            
Consultant Agreement [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Consultant fees           $ 337,500 $ 100,000    
Purchase Commitment, Description   Upon execution of the agreement, Valerian will purchase 33,333,333 shares of the Company’s stock for a total purchase price of $25,000 and have the option to purchase an additional 33,333,333 shares for $25,000 during the first 45 days of the agreement. Lastly, Valerian will have the right to purchase 66,000,000 warrants with an exercise price of $0.00075 for up to one year following the agreement. As of September 30, 2023, the Company received $25,000 and issued 33,333,333 shares of common stock to Valerian.              
Consultant Agreement [Member] | Common Stock [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Common stock, shares issued           33,333,333      
Common stock, value           $ 25,000      
Subscription Arrangement [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Description of purchase agreement       In July 2022, the consultant agreement and the stock purchase agreement were amended to reduce the subscription amount to $17,500.          
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.23.4
License Agreement (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Aug. 23, 2020
Feb. 28, 2022
Sep. 30, 2023
Sep. 30, 2022
Apr. 06, 2023
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Rights to issued   6,000,000        
Description of milestone Common shares representing 5% of total number of outstanding common shares of the Company immediately following any change of control of the Company; the Company issued 29,130,167 shares of common stock as a result of the change of control discussed in Note 5. These shares were issued in July 2021.          
Description of milestone one 29,130,167 Common shares immediately following the first round of funding under a private offer of equity or debt securities; These shares were issued in July 2021.          
Description of milestone two 29,130,167 Common shares immediately following the commencement of clinical trials for Federal Drug Administration clearance of the product; and          
Description of milestone three Common shares representing an adjustment to increase 7 to Stand’s total ownership to 19.99% of total number of outstanding common shares of the Company immediately following FDA clearance of the product for sale. The Company expects to issue 29,130,166 shares of common stock related to this provision if met.          
Description of milestone four $40,000 of royalties to be paid to 7 to Stand annually, on a quarterly basis. The license agreement may be terminated by 7 to Stand if 1) SomaCeuticals does not begin clinical trials within one year of the agreement; 2) if SomaCeuticals terminates the continuation of the clinical trials; or 3) shall not commence marketing the product within reasonable time after obtaining FDA approval.          
Paid for royalties     $ 20,000      
Royalties and late fess       $ 26,250    
Agreed to settle     $ 996,119 $ 722,325    
Common stock, shares issued     996,119,530 722,326,669 50,000,000 19,980,000
Royalty Arrangement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Paid for royalties     $ 0      
Royalties and late fess     43,851      
Agreed to settle     $ 50,102      
Common stock, shares issued     7,261,087      
Recognized gain     $ 10,166      
License Agreement [Member] | Patents [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Royalty of net sales 7.10%          
License Agreement [Member] | Patents [Member] | Fabrizio De Silvestri [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Rights to issued 10,610,592          
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.23.4
Schedule of provision for income taxes (Details) - USD ($)
 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Income Tax Disclosure [Abstract]    
Net operating loss carryforward at statutory tax rate $ 1,096,000 $ 962,000
Valuation allowance (1,096,000) (962,000)
Deferred tax benefit, net
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.23.4
Income Taxes (Details Narrative)
Sep. 30, 2023
USD ($)
Income Tax Disclosure [Abstract]  
Operating loss carryforwards $ 5,217,000
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.23.4
Subsequent Events (Details Narrative) - USD ($)
 12 Months Ended
Nov. 02, 2023
Sep. 30, 2023
Apr. 06, 2023
Sep. 30, 2022
Dec. 31, 2021
Subsequent Event [Line Items]          
Common stock, shares issued   996,119,530 50,000,000 722,326,669 19,980,000
Accrued interest   $ 225,363   $ 226,270  
Convertible Notes Payable [Member]          
Subsequent Event [Line Items]          
Common stock, shares issued   30,297,790      
Conversion of all of principal   $ 21,300      
Accrued interest   $ 1,278      
Subsequent Event [Member]          
Subsequent Event [Line Items]          
Consulting agreement (i) AIP $5,000 per month during Phase A period, if the Company receives regulatory approval to manufacture, sell and distribute products in India or the United States within 60 days of the agreement (ii) AIP $6,000 per month during Phase B period (iii) AIP a sales commission of between 10% and 15% related to any customers, distributors or sales agents introduced to the Company by AIP and (iv) a commission of 4% of any proceeds from equity investments to the Company introduced by AIP, or 2% of any loan proceeds from lenders introduced by AIP.        
XML 50 form_10-k_htm.xml IDEA: XBRL DOCUMENT 0001502152 2022-10-01 2023-09-30 0001502152 2023-03-31 0001502152 2024-01-16 0001502152 2023-09-30 0001502152 2022-09-30 0001502152 us-gaap:SeriesAPreferredStockMember 2023-09-30 0001502152 us-gaap:SeriesAPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesBPreferredStockMember 2023-09-30 0001502152 us-gaap:SeriesBPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesCPreferredStockMember 2023-09-30 0001502152 us-gaap:SeriesCPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesDPreferredStockMember 2023-09-30 0001502152 us-gaap:SeriesDPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesEPreferredStockMember 2023-09-30 0001502152 us-gaap:SeriesEPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesFPreferredStockMember 2023-09-30 0001502152 us-gaap:SeriesFPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesGPreferredStockMember 2023-09-30 0001502152 us-gaap:SeriesGPreferredStockMember 2022-09-30 0001502152 2021-10-01 2022-09-30 0001502152 us-gaap:CommonStockMember 2021-09-30 0001502152 us-gaap:SeriesDPreferredStockMember 2021-09-30 0001502152 us-gaap:SeriesEPreferredStockMember 2021-09-30 0001502152 us-gaap:SeriesFPreferredStockMember 2021-09-30 0001502152 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001502152 gstc:StockPayableMember 2021-09-30 0001502152 us-gaap:RetainedEarningsMember 2021-09-30 0001502152 2021-09-30 0001502152 us-gaap:CommonStockMember 2022-09-30 0001502152 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001502152 gstc:StockPayableMember 2022-09-30 0001502152 us-gaap:RetainedEarningsMember 2022-09-30 0001502152 us-gaap:CommonStockMember 2021-10-01 2022-09-30 0001502152 us-gaap:SeriesDPreferredStockMember 2021-10-01 2022-09-30 0001502152 us-gaap:SeriesEPreferredStockMember 2021-10-01 2022-09-30 0001502152 us-gaap:SeriesFPreferredStockMember 2021-10-01 2022-09-30 0001502152 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2022-09-30 0001502152 gstc:StockPayableMember 2021-10-01 2022-09-30 0001502152 us-gaap:RetainedEarningsMember 2021-10-01 2022-09-30 0001502152 us-gaap:CommonStockMember 2022-10-01 2023-09-30 0001502152 us-gaap:SeriesDPreferredStockMember 2022-10-01 2023-09-30 0001502152 us-gaap:SeriesEPreferredStockMember 2022-10-01 2023-09-30 0001502152 us-gaap:SeriesFPreferredStockMember 2022-10-01 2023-09-30 0001502152 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2023-09-30 0001502152 gstc:StockPayableMember 2022-10-01 2023-09-30 0001502152 us-gaap:RetainedEarningsMember 2022-10-01 2023-09-30 0001502152 us-gaap:CommonStockMember 2023-09-30 0001502152 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001502152 gstc:StockPayableMember 2023-09-30 0001502152 us-gaap:RetainedEarningsMember 2023-09-30 0001502152 srt:OfficerMember 2022-10-01 2023-09-30 0001502152 srt:OfficerMember 2021-10-01 2022-09-30 0001502152 srt:ChiefExecutiveOfficerMember 2023-09-30 0001502152 srt:ChiefExecutiveOfficerMember 2022-09-30 0001502152 srt:BoardOfDirectorsChairmanMember gstc:MrKatzaroffMember 2022-02-01 2022-02-28 0001502152 srt:BoardOfDirectorsChairmanMember gstc:MrKatzaroffMember 2023-09-30 0001502152 srt:BoardOfDirectorsChairmanMember gstc:MrKatzaroffMember 2022-10-01 2023-09-30 0001502152 gstc:MrKatzaroffMember 2022-10-01 2023-09-30 0001502152 gstc:MrKatzaroffMember 2023-04-04 0001502152 gstc:MrKatzaroffMember 2023-04-02 2023-04-04 0001502152 srt:ChiefFinancialOfficerMember gstc:RobertChicoskiMember 2023-08-04 0001502152 srt:BoardOfDirectorsChairmanMember 2023-09-24 2023-09-26 0001502152 srt:ChiefExecutiveOfficerMember gstc:MrKatzaroffMember 2023-09-18 2023-09-19 0001502152 gstc:ConvertibleNoteDateApril132017Member 2022-10-01 2023-09-30 0001502152 gstc:ConvertibleNoteDateApril132017Member 2023-09-30 0001502152 gstc:ConvertibleNoteDateApril132017Member 2022-09-30 0001502152 gstc:ConvertibleNoteDateMay102023Member 2022-10-01 2023-09-30 0001502152 gstc:ConvertibleNoteDateMay102023Member 2023-09-30 0001502152 gstc:ConvertibleNoteDateMay102023Member 2022-09-30 0001502152 gstc:ConvertibleNoteDateJuly32023Member 2022-10-01 2023-09-30 0001502152 gstc:ConvertibleNoteDateJuly32023Member 2023-09-30 0001502152 gstc:ConvertibleNoteDateJuly32023Member 2022-09-30 0001502152 us-gaap:ConvertibleDebtMember 2022-10-01 2023-09-30 0001502152 gstc:May2023SecuritiesPurchaseAgreementMember 2023-05-08 2023-05-10 0001502152 gstc:May2023SecuritiesPurchaseAgreementMember 2023-05-10 0001502152 2023-05-08 2023-05-10 0001502152 2023-06-30 0001502152 gstc:July2023SecuritiesPurchaseAgreementMember 2023-07-02 2023-07-03 0001502152 gstc:July2023SecuritiesPurchaseAgreementMember 2023-07-03 0001502152 2023-07-02 2023-07-03 0001502152 gstc:ConvertibleDebtOneMember 2023-09-30 0001502152 gstc:ConvertibleDebtOneMember 2022-10-01 2023-09-30 0001502152 gstc:AdvanceMember 2023-09-30 0001502152 gstc:AdvanceMember 2022-09-30 0001502152 us-gaap:SeriesAPreferredStockMember 2022-10-01 2023-09-30 0001502152 us-gaap:SeriesBPreferredStockMember 2022-10-01 2023-09-30 0001502152 us-gaap:SeriesCPreferredStockMember 2017-09-12 0001502152 us-gaap:SeriesDPreferredStockMember 2017-09-21 0001502152 us-gaap:SeriesDPreferredStockMember 2017-09-20 2017-09-21 0001502152 us-gaap:SeriesDPreferredStockMember 2023-07-31 0001502152 us-gaap:SeriesEPreferredStockMember 2015-08-03 0001502152 us-gaap:SeriesEPreferredStockMember 2015-08-02 2015-08-03 0001502152 srt:DirectorMember us-gaap:SeriesEPreferredStockMember 2022-09-30 0001502152 us-gaap:SeriesFPreferredStockMember 2017-09-21 0001502152 us-gaap:SeriesFPreferredStockMember 2017-09-20 2017-09-21 0001502152 us-gaap:ConvertibleNotesPayableMember 2022-10-01 2023-09-30 0001502152 2023-04-06 0001502152 2023-04-03 2023-04-06 0001502152 us-gaap:WarrantMember 2021-10-01 2022-09-30 0001502152 us-gaap:LicenseAgreementTermsMember 2023-04-25 0001502152 us-gaap:LicenseAgreementTermsMember 2023-04-23 2023-04-25 0001502152 2023-07-01 2023-07-31 0001502152 2021-12-31 0001502152 2022-09-01 2022-09-30 0001502152 2022-12-01 2022-12-31 0001502152 us-gaap:WarrantMember 2022-12-01 2022-12-31 0001502152 2023-02-01 2023-02-28 0001502152 us-gaap:CommonStockMember 2023-02-28 0001502152 srt:MaximumMember us-gaap:PrivatePlacementMember 2023-09-30 0001502152 srt:MinimumMember us-gaap:PrivatePlacementMember 2023-09-30 0001502152 us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2022-10-01 2023-09-30 0001502152 us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2023-09-30 0001502152 gstc:CommonStockWarrantsMember 2022-10-01 2023-09-30 0001502152 gstc:SpivakManagementIncMember 2023-09-30 0001502152 srt:MinimumMember gstc:SpivakManagementIncMember 2022-02-01 2022-02-28 0001502152 srt:MaximumMember gstc:SpivakManagementIncMember 2022-02-01 2022-02-28 0001502152 gstc:SpivakManagementIncMember 2022-02-01 2022-02-28 0001502152 us-gaap:WarrantMember 2022-10-01 2023-09-30 0001502152 us-gaap:WarrantMember 2023-09-30 0001502152 gstc:MrKatzaroffMember 2023-09-30 0001502152 srt:MinimumMember gstc:MrKatzaroffMember 2022-10-01 2023-09-30 0001502152 srt:MaximumMember gstc:MrKatzaroffMember 2022-10-01 2023-09-30 0001502152 srt:ChiefFinancialOfficerMember 2022-10-01 2023-09-30 0001502152 gstc:RobertChicoskiMember 2022-10-01 2023-09-30 0001502152 gstc:MrFarleyMember 2022-10-01 2023-09-30 0001502152 gstc:MrPenderghastMember 2022-10-01 2023-09-30 0001502152 us-gaap:SeriesGPreferredStockMember 2021-08-11 0001502152 us-gaap:SeriesGPreferredStockMember 2021-08-09 2021-08-11 0001502152 us-gaap:SeriesGPreferredStockMember 2022-10-01 2023-09-30 0001502152 us-gaap:SeriesGPreferredStockMember us-gaap:CommonStockMember 2022-10-01 2023-09-30 0001502152 us-gaap:SeriesGPreferredStockMember 2021-10-01 2022-09-30 0001502152 us-gaap:SeriesGPreferredStockMember 2021-09-30 0001502152 us-gaap:SeriesGPreferredStockMember us-gaap:CommonStockMember 2021-10-01 2022-09-30 0001502152 2022-02-01 2022-02-28 0001502152 us-gaap:SubscriptionArrangementMember 2022-07-01 2022-07-31 0001502152 us-gaap:SubscriptionArrangementMember gstc:MrSpivakMember 2022-08-01 2022-08-31 0001502152 us-gaap:SubscriptionArrangementMember gstc:MrSpivakMember 2022-08-31 0001502152 2023-09-19 0001502152 2023-09-17 2023-09-19 0001502152 us-gaap:AccruedLiabilitiesMember 2023-09-17 2023-09-19 0001502152 us-gaap:NotesPayableOtherPayablesMember 2023-09-17 2023-09-19 0001502152 gstc:ConsultantAgreementMember 2022-10-01 2023-09-30 0001502152 gstc:ConsultantAgreementMember 2021-10-01 2022-09-30 0001502152 gstc:ConsultantAgreementMember 2023-08-08 2023-08-10 0001502152 gstc:ConsultantAgreementMember us-gaap:CommonStockMember 2023-09-30 0001502152 us-gaap:PatentsMember gstc:FabrizioDeSilvestriMember gstc:LicenseAgreementMember 2020-08-22 2020-08-23 0001502152 us-gaap:PatentsMember gstc:LicenseAgreementMember 2020-08-22 2020-08-23 0001502152 2020-08-22 2020-08-23 0001502152 us-gaap:RoyaltyArrangementMember 2022-10-01 2023-09-30 0001502152 us-gaap:RoyaltyArrangementMember 2023-09-30 0001502152 us-gaap:SubsequentEventMember 2023-11-01 2023-11-02 0001502152 us-gaap:ConvertibleNotesPayableMember 2023-09-30 iso4217:USD shares iso4217:USD shares pure false FY --09-30 2023 false 0001502152 Unlimited Unlimited P3Y P5Y P1Y P1Y P5Y P5Y P1Y7M6D P5Y P2Y11M8D 10-K true 2023-09-30 false 333-170315 GlobeStar Therapeutics Corporation WY 27-3480481 719 Jadwin Avenue Richland WA 99352 206 451-1970 Common stock, $0.001 par value No No Yes Yes Non-accelerated Filer true true false false 4851851 1026417320 Fruci & Associates, II, PLLC 5525 Spokane, Washington 6365 3550 9915 9915 328178 380735 454665 379126 6295 12400 59650 59650 300000 59710 20000 0 12581 126294 225363 226270 1433861 1204475 1433861 1204475 0.001 0.001 996119530 996119530 722326669 722326669 996119 722325 20000000 20000000 0.001 0.001 0 0 0 0 0 0 0.001 0.001 0 0 0 0 0 0 0.001 0.001 0 0 0 0 0 0 0.001 0.001 0 0 509988 509988 0 510 0.001 0.001 1000000 1000000 1000000 1000000 1000 1000 0.001 0.001 128991 128991 128991 128991 129 129 18022916 16581252 0 1515152 5000 -20454025 -18504776 -1433861 -1194560 9915 1864370 1265065 1864370 1265065 -1864370 -1265065 6724 -146460 -5939 91603 70346 -84879 -222745 -1949249 -1487810 -0.00 -0.00 827324789 628539782 561495726 561494 509988 510 1000000 1000 386975 387 15228254 499500 -17016966 -725821 25798400 25798 -257984 -258 -25540 5000 5000 19980000 19980 479520 -499500 6000000 6000 155460 161460 322266 322266 186926 186926 109052543 109053 234366 343419 -1487810 -1487810 722326669 722325 509988 510 1000000 1000 128991 129 16581252 5000 -18504776 -1194560 100712968 100713 136380 237093 1515152 1515 3485 -5000 51882319 51883 25617 77500 50998800 50999 -509988 -510 -50489 2000000 2000 18000 20000 16683622 16684 88694 105378 50000000 50000 414878 464878 805098 805098 -1949249 -1949249 996119530 996119 1000000 1000 128991 129 18022916 5000 -20454025 -1433861 -1949249 -1487810 464878 322266 805098 186926 33391 54664 6724 -146460 -5939 -3550 3550 247444 172957 187641 259471 8211 15682 -205760 -326995 55000 73000 310000 4395 28900 5500 16500 72500 5000 199395 327400 -6365 405 6365 5960 6365 50999 25798 227975 324500 5000 499500 15000 20000 300000 <p id="xdx_80A_eus-gaap--NatureOfOperations_zWiqci1pXAYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1. <span id="xdx_829_ztFt8JJKIdub">General Organization and Business</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">GlobeStar Therapeutics Corporation (the “Company”) was incorporated on April 29, 2016. The Company’s year-end is September 30. On October 4, 2019, the Company filed Articles of Continuance with the Secretary of State of Wyoming to continue its business in the state of Wyoming. As part of these Articles of Continuance, effective October 4, 2019, the Company has no limit on the authorized shares of common stock that can be issued. The Company filed its Certificate of Dissolution with the Secretary of State of Nevada on October 21, 2019 because it is no longer a Nevada corporation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is developing an expanded platform of products that include addition of treatment for Multiple Sclerosis and other neurodegenerative diseases. The potential pharmaceutical products related to treatment for multiple sclerosis are licensed to the Company through the worldwide licensing agreement described in Note 8.</p> <p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_z3lE9ChgEqka" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2. <span id="xdx_82B_zj4TmfDVJOC4">Summary of Significant Accounting Policies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zs1lGdQDf3gb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86E_zy2DQo05Ia9f">Basis of Presentation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements of the Company include the accounts of the Company and its wholly owned subsidiaries, SomaCeuticals, Inc., First Titan Energy, LLC and First Titan Technical, LLC from the date of their formations or acquisition. Significant intercompany transactions have been eliminated in consolidation.</p> <p id="xdx_850_znktHbWnQD6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--UseOfEstimates_zsaakHxJ2Uok" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_868_zyjSvTJ2QIJd">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> <p id="xdx_85C_z0u3SBERuHu7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z3uZTF3qOoqk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_865_zEclgBBM2rQg">Fair Value of Financial Instruments</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FASB Accounting Standards Codification (ASC) 820 <i>Fair Value Measurements and Disclosures</i> (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in"> <tr style="vertical-align: top"> <td style="width: 7%"><span style="font-size: 10pt">Level 1 -</span></td> <td style="width: 93%; text-align: justify"><span style="font-size: 10pt">Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td style="text-align: justify"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">Level 2 -</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td style="text-align: justify"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">Level 3 -</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Inputs that are both significant to the fair value measurement and unobservable.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2023. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accounts payable and accrued expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective June 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to each performance obligation in the contract; and (5) recognizing revenue when each performance obligation is satisfied.</p> <p id="xdx_851_zJDUeZzzTBN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--AdvertisingCostsPolicyTextBlock_zFfVu5d4KfT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_867_z5cr6Cd0cech">Advertising and Marketing Costs</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expense advertising and marketing costs as incurred. Advertising and marketing costs were $<span id="xdx_90C_eus-gaap--MarketingAndAdvertisingExpense_c20221001__20230930_zBrNHhU7iYXb" title="Advertising and marketing costs">3,900</span> and $<span id="xdx_90F_eus-gaap--MarketingAndAdvertisingExpense_c20211001__20220930_zMezUWXIDDH5" title="Advertising and marketing costs">43,031</span> for the years ended September 30, 2023 and 2022, respectively.</p> <p id="xdx_858_zt3VUgryYJUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zUTABxpo7J2i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_867_zJBLj7BgNizh">Research and Development Costs</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are expensed as incurred. The Company incurred <span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_do_c20221001__20230930_z5btU3XZvTbe" title="Research and development"><span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_do_c20211001__20220930_zsYJFilEeVwe" title="Research and development">no</span></span> research and development costs during the years ended September 30, 2023 and 2022.</p> <p id="xdx_85C_z3ngyISq0K3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zaSYkLeaW1fd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_862_z2XVtV5WKMei">Cash and Cash Equivalents</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All cash is maintained with a major financial institution in the United States. Deposits with this bank may occasionally exceed the amount of insurance provided on such deposits. For the purpose of the financial statements, cash includes cash in banks. Cash was $<span id="xdx_903_eus-gaap--Cash_iI_c20230930_zl0GKYAdBzze" title="Cash">0</span> and $<span id="xdx_90E_eus-gaap--Cash_iI_c20220930_zEE2E4dft2Zg" title="Cash">6,365</span> as of September 30, 2023 and 2022, respectively. There were <span id="xdx_901_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20230930_zMLchy2bL5Me" title="Cash equivalents"><span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20220930_zOXS1BPgPxa" title="Cash equivalents">no</span></span> cash equivalents as of September 30, 2023 and 2022.</p> <p id="xdx_856_z9oBZ7TmOeh2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_zAYeiOVKFJA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86F_zKo2JtcsS507">Income Taxes</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes under ASC 740 <i>Income Taxes</i>. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized as of September 30, 2023 and 2022.</p> <p id="xdx_854_zyZJuueRmzYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zIICr45uw9L6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_860_zIMXO4cc28q3">Commitments and Contingencies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. There are no known commitments or contingencies as of September 30, 2023 or 2022.</p> <p id="xdx_85E_zStlRUvEcnta" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zznJ6oaltEqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_861_zxrXrpaErFY">Recently Issued Accounting Pronouncements</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounting standards promulgated by the Financial Accounting Standards Board (the “FASB”) are subject to change. Changes in such standards may have an impact on our future financial statements. The following are a summary of recent accounting developments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification; and (3) revises the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The Company adopted this guidance early on October 1, 2023 with no impact to the consolidated financial statements or results of operations of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on our consolidated financial position, results of operations or cash flows.</p> <p id="xdx_850_zFbkcSlg3F6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zs1lGdQDf3gb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86E_zy2DQo05Ia9f">Basis of Presentation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements of the Company include the accounts of the Company and its wholly owned subsidiaries, SomaCeuticals, Inc., First Titan Energy, LLC and First Titan Technical, LLC from the date of their formations or acquisition. Significant intercompany transactions have been eliminated in consolidation.</p> <p id="xdx_842_eus-gaap--UseOfEstimates_zsaakHxJ2Uok" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_868_zyjSvTJ2QIJd">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> <p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z3uZTF3qOoqk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_865_zEclgBBM2rQg">Fair Value of Financial Instruments</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FASB Accounting Standards Codification (ASC) 820 <i>Fair Value Measurements and Disclosures</i> (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in"> <tr style="vertical-align: top"> <td style="width: 7%"><span style="font-size: 10pt">Level 1 -</span></td> <td style="width: 93%; text-align: justify"><span style="font-size: 10pt">Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td style="text-align: justify"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">Level 2 -</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td style="text-align: justify"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">Level 3 -</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Inputs that are both significant to the fair value measurement and unobservable.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2023. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accounts payable and accrued expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective June 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to each performance obligation in the contract; and (5) recognizing revenue when each performance obligation is satisfied.</p> <p id="xdx_84A_eus-gaap--AdvertisingCostsPolicyTextBlock_zFfVu5d4KfT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_867_z5cr6Cd0cech">Advertising and Marketing Costs</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expense advertising and marketing costs as incurred. Advertising and marketing costs were $<span id="xdx_90C_eus-gaap--MarketingAndAdvertisingExpense_c20221001__20230930_zBrNHhU7iYXb" title="Advertising and marketing costs">3,900</span> and $<span id="xdx_90F_eus-gaap--MarketingAndAdvertisingExpense_c20211001__20220930_zMezUWXIDDH5" title="Advertising and marketing costs">43,031</span> for the years ended September 30, 2023 and 2022, respectively.</p> 3900 43031 <p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zUTABxpo7J2i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_867_zJBLj7BgNizh">Research and Development Costs</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are expensed as incurred. The Company incurred <span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_do_c20221001__20230930_z5btU3XZvTbe" title="Research and development"><span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_do_c20211001__20220930_zsYJFilEeVwe" title="Research and development">no</span></span> research and development costs during the years ended September 30, 2023 and 2022.</p> 0 0 <p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zaSYkLeaW1fd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_862_z2XVtV5WKMei">Cash and Cash Equivalents</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All cash is maintained with a major financial institution in the United States. Deposits with this bank may occasionally exceed the amount of insurance provided on such deposits. For the purpose of the financial statements, cash includes cash in banks. Cash was $<span id="xdx_903_eus-gaap--Cash_iI_c20230930_zl0GKYAdBzze" title="Cash">0</span> and $<span id="xdx_90E_eus-gaap--Cash_iI_c20220930_zEE2E4dft2Zg" title="Cash">6,365</span> as of September 30, 2023 and 2022, respectively. There were <span id="xdx_901_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20230930_zMLchy2bL5Me" title="Cash equivalents"><span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20220930_zOXS1BPgPxa" title="Cash equivalents">no</span></span> cash equivalents as of September 30, 2023 and 2022.</p> 0 6365 0 0 <p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_zAYeiOVKFJA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86F_zKo2JtcsS507">Income Taxes</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes under ASC 740 <i>Income Taxes</i>. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized as of September 30, 2023 and 2022.</p> <p id="xdx_847_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zIICr45uw9L6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_860_zIMXO4cc28q3">Commitments and Contingencies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. There are no known commitments or contingencies as of September 30, 2023 or 2022.</p> <p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zznJ6oaltEqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_861_zxrXrpaErFY">Recently Issued Accounting Pronouncements</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounting standards promulgated by the Financial Accounting Standards Board (the “FASB”) are subject to change. Changes in such standards may have an impact on our future financial statements. The following are a summary of recent accounting developments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification; and (3) revises the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The Company adopted this guidance early on October 1, 2023 with no impact to the consolidated financial statements or results of operations of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on our consolidated financial position, results of operations or cash flows.</p> <p id="xdx_801_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zm4c92dbwnU" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 3. <span id="xdx_821_zXeJUdU7WdXb">Going Concern</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. For the year ended September 30, 2023, the Company had a net loss of $<span id="xdx_905_eus-gaap--NetIncomeLoss_iN_di_c20221001__20230930_z9CStqJvZMN" title="Net loss">1,949,249</span>. As of September 30, 2023, the Company had a working capital deficit of $<span id="xdx_902_ecustom--WorkingCapital_c20221001__20230930_zF9ogbUuim43" title="Working capital deficit">1,433,861</span> and an accumulated deficit of $<span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20230930_znA1YrYKCQcc" title="Accumulated deficit">20,454,025</span>. The Company has <span id="xdx_90D_eus-gaap--Revenues_dxL_c20221001__20230930_zcGD6hHzOKUa" title="Revenue::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0605">no</span></span> revenue. Without additional capital, the Company will not be able to remain in business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These factors raise a substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has plans to address the Company’s financial situation as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the near term, management plans to continue to focus on raising the funds necessary to implement the Company’s business plan. Management will continue to seek out debt financing to obtain the capital required to meet the Company’s financial obligations. There is no assurance, however, that lenders will advance capital to the Company or that the new business operations will be profitable. The possibility of failure in obtaining additional funding and the potential inability to achieve profitability raise doubts about the Company’s ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the long term, management believes that the Company’s projects and initiatives will be successful and will provide cash flow to the Company, which will be used to finance the Company’s future growth. However, there can be no assurances that the Company’s planned activities will be successful, or that the Company will ultimately attain profitability. The Company’s long-term viability depends on its ability to obtain adequate sources of debt or equity funding to meet current commitments and fund the continuation of its business operations, and the ability of the Company to achieve adequate profitability and cash flows from operations to sustain its operations.</p> -1949249 1433861 -20454025 <p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z7wiw0WdVIGi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 4. <span id="xdx_822_z90dyAcH7Ntf">Related Party Transactions</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">For the year ended September 30, 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2023 and September 30, 2022, the Company owed $<span id="xdx_900_eus-gaap--IncreaseDecreaseInAccountsPayableRelatedParties_c20221001__20230930__srt--TitleOfIndividualAxis__srt--OfficerMember_z4PBvVTLZ7Og" title="Accounts payable related party">454,665</span> and $<span id="xdx_904_eus-gaap--IncreaseDecreaseInAccountsPayableRelatedParties_c20211001__20220930__srt--TitleOfIndividualAxis__srt--OfficerMember_zlTUDUtsnK6l" title="Compensation">379,126</span> to officers of the Company for compensation which are recorded as accounts payable related party. Additionally, during the years ended September 30, 2023 and 2022 the Company received short term, unsecured, non-interest bearing advances from the Company’s CEO totaling $<span id="xdx_90D_eus-gaap--AccruedSalariesCurrent_iI_c20230930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zdts8aRxtmWb" title="Compensation">21,200</span> and $<span id="xdx_903_eus-gaap--AccruedSalariesCurrent_iI_c20220930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zSzgclVSmNEl" title="Compensation">2,500</span>, respectively. As of September 30, 2023 and 2022, the Company owed $<span id="xdx_90C_eus-gaap--IncreaseDecreaseInDueToOtherRelatedPartiesCurrent_c20221001__20230930_zLmUMsE5Rls3" title="Related party advances">6,295</span> and $<span id="xdx_908_eus-gaap--IncreaseDecreaseInDueToOtherRelatedPartiesCurrent_c20211001__20220930_zyu86fIaxyAh" title="Related party advances">12,400</span> on these related party advances, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2022, the Company entered into an amended and restatement employment agreement with Jim Katzaroff, the CEO. Mr. Katzaroff is entitled to an annual salary of $<span id="xdx_902_eus-gaap--ProfessionalFees_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zeNP9rw5Erxc" title="Annual fees">180,000</span> and a bonus as determined by the Board of Directors. Mr. Katzaroff may elect to receive payment in shares of stock based on the average of the three lowest trading prices for the 15 days prior to election of payment in stock. Further, in the event of a change of control of the Company, Mr. Katzaroff is entitled to a payment equal to 2.99 multiplied by the larger of the total compensation paid to Mr. Katzaroff over the prior 12-month period or the average compensation paid or payable to the Consultant over the prior <span id="xdx_90C_ecustom--PayableToConsultantTerm_dxL_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z5HVqaChjJ15" title="Payable to consultant term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0623">three</span></span> years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company awarded Mr. Katzaroff a total of <span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pid_uShares_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zvFozS8VdCPe" title="Common stock, shares outstanding">35,000,000</span> common stock options with an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z5q3lcCeTzT1" title="Exercise price, per shares">0.009</span> per share, an exercise term of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dxL_c20221001__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zJ4w7Y6iH3A" title="Exercise term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0629">five</span></span> years. <span id="xdx_90F_ecustom--DescriptionOfOptions_c20221001__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z9VEcwTPcdNk" title="Description of options">The options vest 50% immediately, and the remainder on monthly basis over two years. Mr. Katzaroff is also entitled to additional options in the event of the Company issuing equity or equity equivalents in the future, with him receiving an amount of options equal to 3% of future options or warrants issued, excluding grants to officers. The exercise price of these additional options will be 110% of the price per equity equivalent. To date, a total of 11,632,356 additional options were issued to Mr. Katzaroff pursuant to the agreement terms. The total fair value of these option grants at issuance was $53,117. During the years ended September 30, 2023 and 2022, the Company recognized $108,802 and $186,926 of stock-based compensation, related to outstanding stock options under this agreement, respectively. At September 30, 2023, the Company had $42,228 of unrecognized expense related to options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_900_ecustom--DescriptionOfAdditionalOptions_c20221001__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember_zGhV0Y25lZ2a" title="Description of additional options">Additionally, Mr. Katzaroff will earn a fee related to any strategic transaction, as defined in the agreement, including but not limited to acquisitions, divestitures, partnerships or joint ventures, of at least 2% for any transactions not introduced by Mr. Katzaroff, or 4% for any introduced by Mr. Katzaroff of up to $20,000,000, and an additional 0.75% - 3.5% for amounts above that threshold. As of June 30, 2023, no amounts have been earned or paid.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mr. Katzaroff will also receive an activity fee of 3% of gross revenues related to activities including securing a variety of vendor, sales or advertising relationships, or any new revenue generating activity. If such activity is a cost saving initiative instead of revenue generating, Mr. Katzaroff will receive 10% of the cost savings. As of September 30, 2023, no amounts have been earned or paid.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 4, 2023, the Company issued <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20230404__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember_zmFItknyzTKl" title="Common stock, shares issued">7,422,535</span> shares to James Katzaroff to settle $<span id="xdx_90E_eus-gaap--CompensatingBalanceAmount_iI_c20230404__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember_zfewKm32r0P7" title="Settelment amount">50,000</span> of accrued compensation. The Company recognized a loss of $<span id="xdx_90F_eus-gaap--LossOnFairValueHedgeIneffectiveness_c20230402__20230404__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember_zyP6CMRCKYH" title="Recognized loss">3,442</span> on this issuance based on the fair value of the shares issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 4, 2023, the Company issued <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20230804__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertChicoskiMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zscb06nF1Cnf" title="Issuance of common stock">2,000,000</span> shares to its CFO Robert Chicoski to settle $<span id="xdx_90A_eus-gaap--AccruedSalariesCurrent_iI_c20230804__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertChicoskiMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zvKUlSNATOF7" title="Compensation">12,000</span> of accrued compensation. The shares had a fair value of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20230804__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertChicoskiMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zkCt2e2oWE9k" title="Fair value">3,600</span>. No gain was recognized due to the related party nature of the transaction, with the Company recognizing the settlement in additional paid in capital.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 26, 2023, the Company entered into an agreement with SMI HealthCare LLC (“SMIHC”) to manage an initial clinical trial, regulatory filings, intellectual property rights filings, manufacturing, sales and distribution in India, Southeast Asia, Africa, and the Middle East, excluding Israel and Iraq, and for government and private aid organizations, for the Company's patented Multiple Sclerosis treatment. The agreement with SMIHC was approved by the parties’ respective boards of directors. Implementation of the first phase is subject to the Company arranging financing. The first phase includes formation of the Company and SMIHC subsidiaries in India, the clinical trial, regulatory and intellectual property rights filings in India, identifying manufacturers, and planning for the commercial launch in India and countries in the region that accept Drug Controller General of India (“DCGI”) approvals. Implementation of the second phase is expected to commence approximately nine months later, and is subject to receipt of DCGI marketing approval and the Company arranging financing. The second phase may continue for the duration of patent validity, and consists initially of sales, marketing and distribution in India and thereafter, countries in SMIHC’s territory that will permit sales and distribution based upon DCGI approval. After proof of market in those countries, the intention is to seek regulatory approvals elsewhere in SMIHC’s territory in order to expand the sales and distribution of the Company’s MS products. <span id="xdx_903_ecustom--DescriptionIndefiniteLivedLicenseAgreements_c20230924__20230926__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zRRshNVML1ia" title="Royalty on any sales under the agreement">Pursuant to with SMIHC, the Company will receive a 5% royalty on any sales under the agreement by the company formed in India under this agreement, and 50% of any sublicense revenue from the India company formed under the agreement. The Company will pay the following (i) initial fees of between $15,000 - $22,500, and monthly fees of between $5,000 and $12,500 per month for Phase A (ii) monthly fees of $12,500, increase after six months to $17,500 per month, and to $25,000 per month after one year. The fee will increase by 5% per year thereafter for Phase B (iii) an initial management fee of $15,000 upon certain milestones and monthly management fee of $5,000 per month thereafter.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">SMIHC is an affiliate of SMI Group LLC, a privately-held Los Angeles-based company. Kevin Spivak, a shareholder of the Company and consultant is the chairman of SMI Group though he did not advise the Company on this transaction and has waived fees payable to an SMI company for introducing SMIHC to the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 19, 2023, the Company entered into a supplement to employment agreement with Jim Katzaroff, the CEO. For Mr. Katzaroff’s contribution to the SMIHC transaction, he will be paid the following <span id="xdx_90A_ecustom--DescriptionOfOptions_c20230918__20230919__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_za5dcmGe2IY9" title="Description of options">(i) during the term of the agreement with SMIHC, a fee of 3% of any SMIHC generated revenue and (ii) not less than ¼ of the participation in Pro Forma Profits Before Tax to be payable to the Company at its senior executive pursuant to the SMIHC translation. Additionally, for Mr. Katzaroff’s contribution to the AIP transaction, he will be paid the following (i) if the Company invests in AIP, or merges with AIP, Mr. Katzaroff will receive a fee ranging from 1.5% - 4% during on the aggregate consideration of the AIP transaction and (ii) if AIP generated any revenue for the Company by reason of introductions, sales agency, distribution or other similar activities, he will receive a 3% fee for the term of the AIP transaction.</span></p> 454665 379126 21200 2500 6295 12400 180000 35000000 0.009 The options vest 50% immediately, and the remainder on monthly basis over two years. Mr. Katzaroff is also entitled to additional options in the event of the Company issuing equity or equity equivalents in the future, with him receiving an amount of options equal to 3% of future options or warrants issued, excluding grants to officers. The exercise price of these additional options will be 110% of the price per equity equivalent. To date, a total of 11,632,356 additional options were issued to Mr. Katzaroff pursuant to the agreement terms. The total fair value of these option grants at issuance was $53,117. During the years ended September 30, 2023 and 2022, the Company recognized $108,802 and $186,926 of stock-based compensation, related to outstanding stock options under this agreement, respectively. At September 30, 2023, the Company had $42,228 of unrecognized expense related to options. Additionally, Mr. Katzaroff will earn a fee related to any strategic transaction, as defined in the agreement, including but not limited to acquisitions, divestitures, partnerships or joint ventures, of at least 2% for any transactions not introduced by Mr. Katzaroff, or 4% for any introduced by Mr. Katzaroff of up to $20,000,000, and an additional 0.75% - 3.5% for amounts above that threshold. As of June 30, 2023, no amounts have been earned or paid. 7422535 50000 3442 2000000 12000 3600 Pursuant to with SMIHC, the Company will receive a 5% royalty on any sales under the agreement by the company formed in India under this agreement, and 50% of any sublicense revenue from the India company formed under the agreement. The Company will pay the following (i) initial fees of between $15,000 - $22,500, and monthly fees of between $5,000 and $12,500 per month for Phase A (ii) monthly fees of $12,500, increase after six months to $17,500 per month, and to $25,000 per month after one year. The fee will increase by 5% per year thereafter for Phase B (iii) an initial management fee of $15,000 upon certain milestones and monthly management fee of $5,000 per month thereafter. (i) during the term of the agreement with SMIHC, a fee of 3% of any SMIHC generated revenue and (ii) not less than ¼ of the participation in Pro Forma Profits Before Tax to be payable to the Company at its senior executive pursuant to the SMIHC translation. Additionally, for Mr. Katzaroff’s contribution to the AIP transaction, he will be paid the following (i) if the Company invests in AIP, or merges with AIP, Mr. Katzaroff will receive a fee ranging from 1.5% - 4% during on the aggregate consideration of the AIP transaction and (ii) if AIP generated any revenue for the Company by reason of introductions, sales agency, distribution or other similar activities, he will receive a 3% fee for the term of the AIP transaction. <p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_zb8gtzBhNy1d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span>Note 5. <span id="xdx_82D_zzjxMlq1OLSd">Convertible Notes Payable and Advances</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_890_eus-gaap--ConvertibleDebtTableTextBlock_zOsXUUi0Pbs3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BA_zD1RkvSNq5pf">Convertible notes payable consisted of the following at September 30, 2023 and 2022:</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 70%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30,<br/> 2023</b></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30,<br/> 2022</b></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Convertible note dated <span id="xdx_90F_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20221001__20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_z9nMOUe09IZ7" title="Dated">April 13, 2017</span> in the original principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_zYYw0wr1AT4d" title="Amount">20,000</span>, no stated maturity date, bearing interest at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_zhRk5tY4Oczi" title="Interest">3</span>% per year, convertible into common stock at a rate of $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_uUSDPShares_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_zOzkWqQvhOi2" title="Conversion price">0.01</span> per share.</td> <td> </td> <td>$</td> <td id="xdx_981_eus-gaap--ConvertibleDebt_iI_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_zZogwH5ytNV8" style="text-align: right" title="Convertible note"><span style="-sec-ix-hidden: xdx2ixbrl0665">—</span></td> <td> </td> <td> </td> <td>$</td> <td id="xdx_988_eus-gaap--ConvertibleDebt_iI_c20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_zzGyuPsZHcY6" style="text-align: right" title="Convertible note">20,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Convertible note dated <span id="xdx_906_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20221001__20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateMay102023Member_zWXDv2tsCoTb" title="Dated">May 10, 2023</span> in the original principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateMay102023Member_zNTLLzPjgXF7" title="Amount">21,300</span> maturing <span id="xdx_90E_eus-gaap--LongTermDebtMaturityDate_iI_dd_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateMay102023Member_ziuBRTX07dHa" title="Maturity date">May 10, 2024</span>, bearing interest at <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateMay102023Member_zctM1qz2ymCi" title="Interest">12</span>%, convertible beginning six months from issuance into common stock at a rate of 61% of the lowest trading price during the 20 days prior to conversion.</td> <td> </td> <td> </td> <td id="xdx_98D_eus-gaap--ConvertibleDebt_iI_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateMay102023Member_ztWH9vH2bGR3" style="text-align: right" title="Convertible note">21,300</td> <td> </td> <td> </td> <td> </td> <td id="xdx_988_eus-gaap--ConvertibleDebt_iI_c20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateMay102023Member_zcDOwJs2N2Bc" style="text-align: right" title="Convertible note"><span style="-sec-ix-hidden: xdx2ixbrl0679">—</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Convertible note dated <span id="xdx_902_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20221001__20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateJuly32023Member_zJmJOfGXVwVc" title="Dated">July 3, 2023</span> in the original principal amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateJuly32023Member_zHnOVaw0YWa2" title="Amount">47,250</span> maturing <span id="xdx_904_eus-gaap--LongTermDebtMaturityDate_iI_dd_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateJuly32023Member_z5eBR8cpL1hf" title="Maturity date">April 15, 2024</span>, bearing interest at <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateJuly32023Member_zCVdtlVOi9X3" title="Interest">12</span>%, convertible beginning six months from issuance into common stock at a rate of 61% of the lowest trading price during the 20 days prior to conversion.</td> <td> </td> <td style="border-bottom: Black 1pt solid"> </td> <td id="xdx_984_eus-gaap--ConvertibleDebt_iI_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateJuly32023Member_zAhK1XvZklx3" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible note">47,250</td> <td> </td> <td> </td> <td style="border-bottom: Black 1pt solid"> </td> <td id="xdx_985_eus-gaap--ConvertibleDebt_iI_c20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateJuly32023Member_zQAsxuW559w9" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible note"><span style="-sec-ix-hidden: xdx2ixbrl0691">—</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Total convertible notes payable </td> <td> </td> <td> </td> <td id="xdx_980_eus-gaap--ConvertibleNotesPayable_iI_c20230930_zHoDUVF4Nsk4" style="text-align: right" title="Total convertible notes payable">68,550</td> <td> </td> <td> </td> <td> </td> <td id="xdx_985_eus-gaap--ConvertibleNotesPayable_iI_c20220930_zVJXVhv9lc07" style="text-align: right" title="Total convertible notes payable">20,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Unamortized discount</td> <td> </td> <td style="border-bottom: Black 1pt solid"> </td> <td id="xdx_981_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_c20230930_zudxhN8WrZp5" style="border-bottom: Black 1pt solid; text-align: right" title="Unamortized discount">(8,840</td> <td>)</td> <td> </td> <td style="border-bottom: Black 1pt solid"> </td> <td id="xdx_989_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_c20220930_zGeGvxvvZD63" style="border-bottom: Black 1pt solid; text-align: right" title="Unamortized discount"><span style="-sec-ix-hidden: xdx2ixbrl0699">—</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total current convertible notes payable, net of discount</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_982_eus-gaap--ConvertibleDebt_iI_c20230930_zQIwsgwFwiT7" style="border-bottom: black 2.25pt double; text-align: right" title="Total current convertible notes payable, net of discount">59,710</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_98B_eus-gaap--ConvertibleDebt_iI_c20220930_zJ8MVlkGtD1i" style="border-bottom: black 2.25pt double; text-align: right" title="Total current convertible notes payable, net of discount">20,000</td> <td> </td></tr> </table> <p id="xdx_8A8_zB6Qghu6X3rj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All principal along with accrued interest is payable on the maturity date. <span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleTermsOfConversionFeature_c20221001__20230930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zFQYMZijcJ29" title="Beneficial conversion discount on convertible note payable">The notes are convertible into common stock at the option of the holder. The holder of the notes cannot convert the notes into shares of common stock if that conversion would result in the holder owning more than 4.9% of the outstanding stock of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 10, 2023, the Company entered into a Securities Purchase Agreement (the “May 2023 Securities Purchase Agreement”) with 1800 Diagonal Lending LLC (“1800 Diagonal”). Pursuant to the terms of the May 2023 Securities Purchase Agreement, the Company issued a convertible promissory note (the “May 2023 Note”) to 1800 Diagonal in the aggregate principal amount of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230508__20230510__us-gaap--TypeOfArrangementAxis__custom--May2023SecuritiesPurchaseAgreementMember_ztfR34XMzAng" title="Common stock issued for stock payable">21,300</span> with the Company receiving $<span id="xdx_90C_ecustom--CashProceeds_c20230508__20230510__us-gaap--TypeOfArrangementAxis__custom--May2023SecuritiesPurchaseAgreementMember_zmOBA6GCwUyh" title="Cash proceeds">15,000</span> in cash proceeds. Effective May 10, 2023, the Company issued the May 2023 Note to 1800 Diagonal consistent with the terms of the May 2023 Securities Purchase Agreement. The May 2023 Note bears interest at <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230510__us-gaap--TypeOfArrangementAxis__custom--May2023SecuritiesPurchaseAgreementMember_zZTfw76SRcne" title="Interest rate">12</span>%, with a 22% rate in the event of default, with an Original Issue Discount of $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20230510__us-gaap--TypeOfArrangementAxis__custom--May2023SecuritiesPurchaseAgreementMember_z0Np2oNUD4x8" title="Debt discount">1,050</span> and matures on <span id="xdx_90D_eus-gaap--LongTermDebtMaturityDate_iI_dd_c20230510__us-gaap--TypeOfArrangementAxis__custom--May2023SecuritiesPurchaseAgreementMember_zRyNaC2f4YMk" title="Maturity date">May 10, 2024</span>. <span id="xdx_905_eus-gaap--ConversionOfStockDescription_pid_c20230508__20230510_ztplf4GoTbj6" title="Conversion of stock description">Pursuant to the terms of the May 2023 Note, the outstanding principal and accrued interest on the note shall be convertible beginning six months from issuance into shares of the Company’s common stock at 61% of the lowest trading price of the Company’s common stock during the 20 days prior to conversion.</span> The Company recognized $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20230630_zH7NNAUjSzol" title="Recognized of discount">6,300</span> of discount and deferred finance costs and amortized $<span id="xdx_909_eus-gaap--OtherDeferredCostsGross_iI_c20230630_zlRlzFIL1w7h" title="Deferred finance costs">2,462</span> during the six months ended June 30, 2023. The conversion option on the note payable was not bifurcated as a derivative under ASC 815 due to sufficient authorized shares being available to settle the conversion feature.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 3, 2023, the Company entered into a Securities Purchase Agreement (the “July 2023 Securities Purchase Agreement”) with 1800 Diagonal Lending LLC (“1800 Diagonal”). Pursuant to the terms of the July 2023 Securities Purchase Agreement, the Company issued a convertible promissory note (the “May 2023 Note”) to 1800 Diagonal in the aggregate principal amount of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230702__20230703__us-gaap--TypeOfArrangementAxis__custom--July2023SecuritiesPurchaseAgreementMember_z1d7n1FVf7wd" title="Common stock issued for stock payable">47,250</span> with the Company receiving $<span id="xdx_90A_ecustom--CashProceeds_c20230702__20230703__us-gaap--TypeOfArrangementAxis__custom--July2023SecuritiesPurchaseAgreementMember_z6FpOVOZfcj4" title="Cash proceeds">40,000</span> in cash proceeds. Effective July 3, 2023, the Company issued the July 2023 Note to 1800 Diagonal consistent with the terms of the July 2023 Securities Purchase Agreement. The July 2023 Note bears interest at <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230703__us-gaap--TypeOfArrangementAxis__custom--July2023SecuritiesPurchaseAgreementMember_zsWZieHL85y3" title="Interest rate">12</span>%, with a 22% rate in the event of default, with an Original Issue Discount of $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20230703__us-gaap--TypeOfArrangementAxis__custom--July2023SecuritiesPurchaseAgreementMember_zvHobJTypmpf" title="Debt discount">2,250</span> and matures on <span id="xdx_905_eus-gaap--LongTermDebtMaturityDate_iI_dd_c20230703__us-gaap--TypeOfArrangementAxis__custom--July2023SecuritiesPurchaseAgreementMember_zLmT6L8Gxzll" title="Maturity date">April. 15, 2024</span>. <span id="xdx_90C_eus-gaap--ConversionOfStockDescription_pid_c20230702__20230703_zZYPQp6SGMde" title="Conversion of stock description">Pursuant to the terms of the July 2023 Note, the outstanding principal and accrued interest on the note shall be convertible beginning six months from issuance into shares of the Company’s common stock at 61% of the lowest trading price of the Company’s common stock during the 20 days prior to conversion.</span> The Company recognized $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20230930_zcC6CYWZjvwc" title="Recognized of discount">7,250</span> of discount and deferred finance costs and amortized $<span id="xdx_90D_eus-gaap--OtherDeferredCostsGross_iI_c20230930_zrGbVoEyJja2" title="Deferred finance costs">2,248</span> during the year ended September 30, 2023. The conversion option on the note payable was not bifurcated as a derivative under ASC 815 due to sufficient authorized shares being available to settle the conversion feature.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2023 and September 30, 2022, accrued interest on convertible notes payable was $<span id="xdx_90B_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iI_c20230930_zTkDhSqcrPM" title="Accrued interest on convertible notes payable">225,363</span> and $<span id="xdx_90A_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iI_c20220930_zjRphFLsvb85" title="Accrued interest on convertible notes payable">225,953</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Conversions to Common Stock</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2023, the holders of the April 2017 convertible note payable elected to convert principal of $<span id="xdx_905_eus-gaap--ConvertibleNotesPayable_iI_c20230930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtOneMember_zn5HLkeFe4Ma" title="Principal amount">20,000</span> into <span id="xdx_90A_eus-gaap--ConversionOfStockSharesConverted1_pid_uShares_c20221001__20230930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtOneMember_zTMudDpm6al2" title="Conversion of shares">2,000,000</span> shares of common stock. The conversion was in accordance with the terms of the agreement and no gain or loss was recognized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Advances</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2023 and 2022, the Company had non-interest bearing advances payable to third parties of $<span id="xdx_90D_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iI_c20230930__us-gaap--ShortTermDebtTypeAxis__custom--AdvanceMember_zGdC7akD2W6c" title="Accounts payable and accrued liabilities"><span id="xdx_903_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iI_c20220930__us-gaap--ShortTermDebtTypeAxis__custom--AdvanceMember_zd64JXPh6HNh" title="Accounts payable and accrued liabilities">59,650</span></span>. These advances are payable on demand.</p> <p id="xdx_890_eus-gaap--ConvertibleDebtTableTextBlock_zOsXUUi0Pbs3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BA_zD1RkvSNq5pf">Convertible notes payable consisted of the following at September 30, 2023 and 2022:</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 70%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30,<br/> 2023</b></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30,<br/> 2022</b></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Convertible note dated <span id="xdx_90F_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20221001__20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_z9nMOUe09IZ7" title="Dated">April 13, 2017</span> in the original principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_zYYw0wr1AT4d" title="Amount">20,000</span>, no stated maturity date, bearing interest at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_zhRk5tY4Oczi" title="Interest">3</span>% per year, convertible into common stock at a rate of $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_uUSDPShares_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_zOzkWqQvhOi2" title="Conversion price">0.01</span> per share.</td> <td> </td> <td>$</td> <td id="xdx_981_eus-gaap--ConvertibleDebt_iI_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_zZogwH5ytNV8" style="text-align: right" title="Convertible note"><span style="-sec-ix-hidden: xdx2ixbrl0665">—</span></td> <td> </td> <td> </td> <td>$</td> <td id="xdx_988_eus-gaap--ConvertibleDebt_iI_c20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateApril132017Member_zzGyuPsZHcY6" style="text-align: right" title="Convertible note">20,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Convertible note dated <span id="xdx_906_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20221001__20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateMay102023Member_zWXDv2tsCoTb" title="Dated">May 10, 2023</span> in the original principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateMay102023Member_zNTLLzPjgXF7" title="Amount">21,300</span> maturing <span id="xdx_90E_eus-gaap--LongTermDebtMaturityDate_iI_dd_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateMay102023Member_ziuBRTX07dHa" title="Maturity date">May 10, 2024</span>, bearing interest at <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateMay102023Member_zctM1qz2ymCi" title="Interest">12</span>%, convertible beginning six months from issuance into common stock at a rate of 61% of the lowest trading price during the 20 days prior to conversion.</td> <td> </td> <td> </td> <td id="xdx_98D_eus-gaap--ConvertibleDebt_iI_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateMay102023Member_ztWH9vH2bGR3" style="text-align: right" title="Convertible note">21,300</td> <td> </td> <td> </td> <td> </td> <td id="xdx_988_eus-gaap--ConvertibleDebt_iI_c20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateMay102023Member_zcDOwJs2N2Bc" style="text-align: right" title="Convertible note"><span style="-sec-ix-hidden: xdx2ixbrl0679">—</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Convertible note dated <span id="xdx_902_eus-gaap--DebtInstrumentIssuanceDate1_dd_c20221001__20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateJuly32023Member_zJmJOfGXVwVc" title="Dated">July 3, 2023</span> in the original principal amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateJuly32023Member_zHnOVaw0YWa2" title="Amount">47,250</span> maturing <span id="xdx_904_eus-gaap--LongTermDebtMaturityDate_iI_dd_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateJuly32023Member_z5eBR8cpL1hf" title="Maturity date">April 15, 2024</span>, bearing interest at <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateJuly32023Member_zCVdtlVOi9X3" title="Interest">12</span>%, convertible beginning six months from issuance into common stock at a rate of 61% of the lowest trading price during the 20 days prior to conversion.</td> <td> </td> <td style="border-bottom: Black 1pt solid"> </td> <td id="xdx_984_eus-gaap--ConvertibleDebt_iI_c20230930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateJuly32023Member_zAhK1XvZklx3" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible note">47,250</td> <td> </td> <td> </td> <td style="border-bottom: Black 1pt solid"> </td> <td id="xdx_985_eus-gaap--ConvertibleDebt_iI_c20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteDateJuly32023Member_zQAsxuW559w9" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible note"><span style="-sec-ix-hidden: xdx2ixbrl0691">—</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Total convertible notes payable </td> <td> </td> <td> </td> <td id="xdx_980_eus-gaap--ConvertibleNotesPayable_iI_c20230930_zHoDUVF4Nsk4" style="text-align: right" title="Total convertible notes payable">68,550</td> <td> </td> <td> </td> <td> </td> <td id="xdx_985_eus-gaap--ConvertibleNotesPayable_iI_c20220930_zVJXVhv9lc07" style="text-align: right" title="Total convertible notes payable">20,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Unamortized discount</td> <td> </td> <td style="border-bottom: Black 1pt solid"> </td> <td id="xdx_981_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_c20230930_zudxhN8WrZp5" style="border-bottom: Black 1pt solid; text-align: right" title="Unamortized discount">(8,840</td> <td>)</td> <td> </td> <td style="border-bottom: Black 1pt solid"> </td> <td id="xdx_989_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_c20220930_zGeGvxvvZD63" style="border-bottom: Black 1pt solid; text-align: right" title="Unamortized discount"><span style="-sec-ix-hidden: xdx2ixbrl0699">—</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total current convertible notes payable, net of discount</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_982_eus-gaap--ConvertibleDebt_iI_c20230930_zQIwsgwFwiT7" style="border-bottom: black 2.25pt double; text-align: right" title="Total current convertible notes payable, net of discount">59,710</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_98B_eus-gaap--ConvertibleDebt_iI_c20220930_zJ8MVlkGtD1i" style="border-bottom: black 2.25pt double; text-align: right" title="Total current convertible notes payable, net of discount">20,000</td> <td> </td></tr> </table> 2017-04-13 20000 0.03 0.01 20000 2023-05-10 21300 2024-05-10 0.12 21300 2023-07-03 47250 2024-04-15 0.12 47250 68550 20000 8840 59710 20000 The notes are convertible into common stock at the option of the holder. The holder of the notes cannot convert the notes into shares of common stock if that conversion would result in the holder owning more than 4.9% of the outstanding stock of the Company. 21300 15000 0.12 1050 2024-05-10 Pursuant to the terms of the May 2023 Note, the outstanding principal and accrued interest on the note shall be convertible beginning six months from issuance into shares of the Company’s common stock at 61% of the lowest trading price of the Company’s common stock during the 20 days prior to conversion. 6300 2462 47250 40000 0.12 2250 2024-04-15 Pursuant to the terms of the July 2023 Note, the outstanding principal and accrued interest on the note shall be convertible beginning six months from issuance into shares of the Company’s common stock at 61% of the lowest trading price of the Company’s common stock during the 20 days prior to conversion. 7250 2248 225363 225953 20000 2000000 59650 59650 <p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zj6nokwbnfMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 6. <span id="xdx_82F_zXN7x33otKid">Stockholders’ deficit</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Preferred Stock</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our authorized preferred stock consists of <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20230930_zNZLCYOeISM" title="Preferred stock, shares authorized"><span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20220930_zsYSAFQBvXL1" title="Preferred stock, shares authorized">20,000,000</span></span> shares of $<span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20230930_zcj9Ltb5NNI6" title="Preferred stock, par value (in dollars per share)"><span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20220930_zdZkRIcbe0oi" title="Preferred stock, par value (in dollars per share)">0.001</span></span> par value preferred stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Series A Preferred Stock</span></i> – Our board of directors has designated up to <span id="xdx_904_ecustom--PreferredStockSharesDesignated_iI_pid_uShares_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zKXFuRmDfbfc" title="Preferred stock, shares designated">6,000,000</span> shares of Series A Preferred Stock. The Series A Preferred Stock has a liquidation value of $<span id="xdx_904_eus-gaap--PreferredStockLiquidationPreference_iI_pid_uUSDPShares_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zZM5B0RAjmGd" title="Preferred stock liquidation preference">2.00</span> per share. The initial number issued is <span id="xdx_90F_ecustom--AdditionalShareToBeIssued_iI_pid_uShares_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zrgxkkLkotjf" title="Additional share to be issued">5,000,000</span> with additional shares to be issued as a dividend not to exceed a total of <span id="xdx_900_eus-gaap--PreferredStockDividendsShares_pid_uShares_c20221001__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zukkLaSAU335" title="Preferred stock dividends">6,000,000</span> shares. The rank of the Series A is prior to all common and preferred shares. In addition, the Series A Preferred Stock retains protective provisions to maintain their seniority with respect to liquidation or dissolution. The Series A Preferred Stock holds no voting rights and earns an <span id="xdx_907_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20221001__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zntOxl3vmwH8" title="Preferred stock dividend rate">8</span>% per annum dividend, payable in additional shares of Series A Preferred Stock. At September 30, 2023 and 2022, there were <span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_uShares_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zIkl9zDDOUKa" title="Preferred stock, shares outstanding"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_uShares_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z4ADtdHakNr5" title="Preferred stock, shares outstanding">no</span></span> shares of our Series A Preferred Stock outstanding, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Series B Preferred Stock</span></i> – Our board of directors has designated up to <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zQoc9asosVjd" title="Preferred stock authorized">1,000,000</span> shares of Series B Preferred Stock. The Series B Preferred Stock has a liquidation value of $<span id="xdx_900_eus-gaap--PreferredStockLiquidationPreference_iI_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z0c8elFEMaC8" title="Preferred stock liquidation preference">1.00 </span>per share. The holders of the Series B Preferred Stock are entitled to dividends of <span id="xdx_909_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20221001__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zVgfVdKEHnel" title="Preferred stock dividend rate">8</span>% per year payable quarterly in cash or in shares of common stock at the option of the Company. The holders of the Series B Preferred Stock have no voting rights. The Series B Preferred Stock is redeemable at the option of the Company at a price of $1.00 per share. At September 30, 2023 and 2022, there were <span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_uShares_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUzQ3vmumL46" title="Preferred stock, shares outstanding"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_uShares_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zFWHAX0Ohj29" title="Preferred stock, shares outstanding">no</span></span> shares of our Series B Preferred Stock outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Series C Preferred Stock</span></i> – On September 12, 2017, our board of directors designated up to <span id="xdx_900_ecustom--PreferredStockSharesDesignated_iI_pid_uShares_c20170912__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zW80q0bbGdz7" title="Preferred stock, shares designated">1,200,000</span> shares of Series C Preferred Stock with a liquidation value of $<span id="xdx_90F_eus-gaap--PreferredStockLiquidationPreference_iI_pid_uUSDPShares_c20170912__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zwqijr9RvMqi" title="Preferred stock liquidation preference">0.50</span> per share. The holders of the Series C Preferred Stock have no voting rights. The Series C Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of one share of common stock for each share of Series C Preferred Stock. The Series C Preferred Stock is redeemable at the option of the Company at a price of $<span id="xdx_90E_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_uUSDPShares_c20170912__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zoPh1AFMOjl3" title="Preferred stock redemption price per share">0.50</span> per share. The Series C Preferred Stock has been canceled, and there are <span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_uShares_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zqjnI6Lbkza8" title="Preferred stock, shares outstanding"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_uShares_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zYahE27G74aa" title="Preferred stock, shares outstanding">no</span></span> shares of Series C Preferred Stock outstanding as of September 30, 2023 and 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Series D Preferred Stock</span></i> – On September 21, 2017, our board of directors designated up to <span id="xdx_90A_ecustom--PreferredStockSharesDesignated_iI_pid_uShares_c20170921__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zyeNW4QhKsme" title="Preferred stock, shares designated">539,988</span> shares of Series D Preferred Stock with a liquidation value of $<span id="xdx_901_eus-gaap--PreferredStockLiquidationPreference_iI_pid_uUSDPShares_c20170921__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zKDE8CFMP2ec" title="Preferred stock liquidation preference">1.00</span> per share. The holders of the Series D Preferred Stock have no voting rights. <span id="xdx_90D_eus-gaap--PreferredStockConversionBasis_c20170920__20170921__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zIlzsnTrDR9g" title="Preferred stock, conversion basis">The Series D Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock. </span>The Series D Preferred Stock is not redeemable. In July 2023, the Company issued <span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_pid_uShares_c20230731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zoTXek1Mrbnb" title="Preferred stock, issued">50,998,800</span> shares to the holder of the Series D Preferred Stock for Full conversion of <span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_uShares_c20230731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zKuoM34ajx6k" title="Preferred stock, outstanding">509,988</span> shares outstanding. At September 30, 2023 and 2022, there were <span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_ztrfRi6flYv9" title="Preferred stock, shares issued">0</span> and <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zdXfOyGizr55" title="Preferred stock, shares issued">509,988</span> shares of Series D Preferred Stock outstanding, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Series E Preferred Stock</span></i> – On August 3, 2015, our board of directors designated <span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_c20150803__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zoKuPvEN0Z62" title="Preferred stock, shares outstanding">1,000,000</span> shares of Series E Preferred stock. The Series E Preferred stock is subordinate to our common stock. It does not receive dividends and does not participate in equity distributions. <span id="xdx_90E_eus-gaap--PreferredStockVotingRights_c20150802__20150803__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zQ8St1Yf8K3k" title="Description of voting rights">The Series E Preferred stock retained 2/3 of the voting rights in the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2023 and 2022, there were <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zfq8rPxFBKgj" title="Preferred stock authorized">1,000,000</span> shares of Series E Preferred stock outstanding. Dividends, when, as and if declared by the Board of Directors, shall be paid out of funds at the time legally available for such purposes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Series F Preferred Stock</span></i> – On September 21, 2017, our board of directors designated up to <span id="xdx_908_ecustom--PreferredStockSharesDesignated_iI_c20170921__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_z1MsPtNDzvOi" title="Preferred stock shares designated">501,975</span> shares of Series F Preferred Stock with a liquidation value of $<span id="xdx_909_eus-gaap--PreferredStockLiquidationPreference_iI_pid_uUSDPShares_c20170921__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zAkgLsHI3rl3" title="Preferred stock liquidation preference">1.00</span> per share. The holders of the Series F Preferred Stock have no voting rights. <span id="xdx_90A_eus-gaap--PreferredStockConversionBasis_c20170920__20170921__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_z0KXhxW0rxqg" title="Preferred stock, conversion basis">The Series F Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock.</span> The Series F Preferred Stock is not redeemable. At September 30, 2021, <span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zddjhxDwZZY1" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zBDB8KHk8Lo6">386,975</span></span> shares of the Series F Preferred Stock were issued and outstanding. During the year ended September 30, 2022, <span id="xdx_908_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_uShares_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zuFrSAz9NKCc" title="Convertible preferred stock shares">257,984</span> shares of Series F Preferred Stock was converted into <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_pid_uShares_c20211001__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zkS87dQMWW67" title="Conversion of shares">25,798,400</span> shares of common stock. At September 30, 2023 and 2022, <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zKtKwdLocMJd" title="Preferred stock, shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zbUlZ3Y5tO89" title="Preferred stock, shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zkDGNwGoY17e"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_z2HhyvQJeRFj">128,991</span></span></span></span> shares of the Series F Preferred Stock were issued and outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Conversions to Common Stock of Convertible Notes Payable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2023, the holders of the April 2017 convertible note payable elected to convert principal of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_c20221001__20230930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zvnG7Bvbf2sd" title="Principal amount">20,000</span> into <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_uShares_c20221001__20230930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zfGdwoEd7ebl" title="Shares converted">2,000,000</span> shares of common stock. The conversion was in accordance with the terms of the agreement and no gain or loss was recognized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common stock issued for Services</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 6, 2023, the Company issued <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20230406_zVzc90wAuoOa" title="Common stock, shares issued">50,000,000</span> shares to a consultant for services rendered to the Company. The shares had a fair value of $<span id="xdx_908_eus-gaap--GainLossOnFairValueHedgeIneffectivenessNet_c20230403__20230406_zzk5odc3LYMe" title="Fair value of shares issued">360,000</span>. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common stock issued for settlement of liabilities</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2022, the Company issued <span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities1_pid_uShares_c20211001__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmwLLKbW5898" title="Stock issued during period, shares, conversion of convertible securities">6,000,000</span> shares of common stock and <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_uShares_c20211001__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zp3nHr1zR26j" title="Stock issued during period, shares, conversion of convertible securities">900,000</span> warrants for the settlement of liabilities totaling $<span id="xdx_908_eus-gaap--SettlementLiabilitiesCurrent_iI_c20220930_zUkqjeLfA3G7" title="Settlement of liabilities">15,000</span>. The Company recorded a $<span id="xdx_905_eus-gaap--GainLossRelatedToLitigationSettlement_c20211001__20220930_zzS9SYMFTc2k" title="Gain (loss) related to settlement of liabilities">146,460</span> loss on settlement of liabilities related to this transaction.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 4, 2023, the Company issued <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20230404__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember_zwZFRWSW2xd8" title="Common stock, shares issued">7,422,535</span> shares to James Katzaroff to settle $<span id="xdx_90D_eus-gaap--CompensatingBalanceAmount_iI_c20230404__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember_z0ddDUrrfWD3" title="Settelment amount">50,000</span> of accrued compensation. The Company recognized a loss of $3,442 on this issuance based on the fair value of the shares issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 25, 2023, the Company issued <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20230425__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--LicenseAgreementTermsMember_zNIDs1XJjdH6" title="Common stock, shares issued">7,261,087</span> shares of common stock to 7 to Stand to settle the outstanding royalty balance of $<span id="xdx_906_eus-gaap--RoyaltyExpense_c20230423__20230425__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--LicenseAgreementTermsMember_zNdKD7nn0vH6" title="Royalty expense">50,102</span> under the License Agreement. The Company recognized a gain of $<span id="xdx_900_eus-gaap--GainOnFairValueHedgeIneffectiveness_c20230423__20230425__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__us-gaap--LicenseAgreementTermsMember_zeHi5IpO6sxa" title="Recognized gain">10,166</span> on the issuance related to the fair value of the shares. See Note 7.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common stock issued for stock payable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2023, the Company also issued a total of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_uShares_c20230701__20230731_zumJHGQCi5E8" title="Shares issued to settle subscription payables">1,512,152</span> shares to settle subscription payables of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230701__20230731_zuPF7MZ9MXT6" title="Subscription payables settle">5,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2021, the Company issued<span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20211231_zHwl0SMpxHSh" title="Common stock issued"> 19,980,000</span> shares of common stock as part of the common stock unit sales that occurred during the year ended September 30, 2021. As of September 30, 2022, no shares are remaining to be issued for these unit sales.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2022, the Company received two subscriptions of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220901__20220930_zYfLjvKEyDwe" title="Subscription payables settle">5,000</span> in cash for <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_uShares_c20220901__20220930_zIxzojC9CZpg" title="Shares issued to settle subscription payables">1,515,152</span> shares of common stock and an equal number of warrants to purchase common stock at an exercise price of $<span id="xdx_90B_ecustom--ExercisePrice_pid_uUSDPShares_c20220901__20220930_zXAGowQmO4u4" title="Exercise price to purchase common stock">0.01</span> for one year. In December 2022, the Company received $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20221201__20221231_zZEva2WBh0Kg" title="Subscription payables settle">5,000</span> of cash as a subscription for an additional <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_uShares_c20221201__20221231_zg55N9H4Uj7c" title="Shares issued to settle subscription payables">1,515,152</span> shares of common stock and an equal number of warrants to purchase common stock at an exercise price of $<span id="xdx_90E_ecustom--ExercisePrice_pid_uUSDPShares_c20221201__20221231_zvs9nhOi7qG9" title="Exercise price to purchase common stock">0.01</span> for one year. The warrants had a fair value of $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20221201__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRmmClC4wExg" title="Fair value of warrants">4,067</span> based on a Black-Scholes pricing model using the following assumptions: 1) volatility of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221201__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zX36DMsKDE9a" title="Volatility rate">176.37</span>%; 2) risk free rate of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20221201__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaH3RoZvFZJf" title="Risk free rate">4.74</span>%; 3) dividend yield of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20221201__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBfWyU56winl" title="Dividend yield">0</span>% and 4) expected term of <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20221201__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIN9lAIbzmOb" title="Expected term::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl0888">1</span></span> year. In February 2023, the Company received $<span id="xdx_909_ecustom--CashReceiveOnSubscription_c20230201__20230228_zXC95eAmmZJ8" title="Cash received">8,000</span> of cash and $<span id="xdx_901_eus-gaap--OtherExpenses_c20230201__20230228_zOMULleiEyD7" title="Expenses paid">7,000</span> of expenses paid on the Company’s behalf as a subscription for <span id="xdx_906_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20230228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuqIYzWr0qPa" title="Number of shares subscribe">7,500,000</span> shares of common stock. The common shares were issued in May 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common Stock Warrants</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2023, the Company amended the exercise price of the common stock warrants issued to investors in its 2021 private placement to reduce the price from $<span id="xdx_90B_ecustom--ShareBasedCompensationArrangementWarrantOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20230930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--RangeAxis__srt--MaximumMember_zbz0pkBGmVFc" title="Amended the exercise price">0.03</span> per share to $<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementWarrantOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20230930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--RangeAxis__srt--MinimumMember_zmHR8SVXsO91" title="Amended the exercise price">0.01</span> per share. In accordance with ASC 718, the Company estimated the incremental value of the warrants based on terms immediately preceding the amendment, and immediately after the amendment, using the follow range of assumptions in a Black-Scholes option price model: 1) volatility of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221001__20230930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z87oLmzdTSpc" title="Volatility rate">203</span>%; 2) expected term of approximately <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20221001__20230930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zU5nvM2QvOXc" title="Expected term::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl0902">one</span></span> year; 3) risk-free rate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20221001__20230930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4Iy6EQsXMha" title="Risk free rate">5.05</span>%; 5) a common stock price at the date of grant of $<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_uUSDPShares_c20230930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zD2KHdHBJeUl" title="Grant stock price, per share">0.086</span> and 6) a dividend yield of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20221001__20230930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zX2iGLTAsqf8" title="Dividend yield">0</span>%. The Company recognized stock-based compensation expense of $<span id="xdx_900_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20221001__20230930__us-gaap--StatementClassOfStockAxis__custom--CommonStockWarrantsMember_zJbHin8wM4th" title="Stock based compensation related to repricing">51,761</span> related to the repricing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In February 2022, the Company entered into a consulting agreement with Spivak Management, Inc. (the “Consultant”). Under the agreement, the Consultant will provide business strategy advice and introductions to the Company for a period of five years unless mutually terminated sooner. </span>The Consultant is also entitled to additional warrants in the event of the Company issuing equity or equity equivalents in the future, with him receiving an number of warrants equal to 3% of future warrants issued, excluding grants to officers. The exercise price of these additional warrants will be 110% of the price per equity equivalent. The total fair value of these option grants at issuance was $<span id="xdx_906_ecustom--OptiongGrantsValue_iI_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SpivakManagementIncMember_zbqubm37wONh" title="Fair value of option grants">53,117</span> using the follow range of assumptions in a Black-Scholes option price model volatility of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SpivakManagementIncMember__srt--RangeAxis__srt--MinimumMember_zs41nTR2eoZj" title="Volatility rate">215.45</span> % - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SpivakManagementIncMember__srt--RangeAxis__srt--MaximumMember_zO8AqcJNoNIa" title="Volatility rate">253.78</span>% ; 2) risk free rate of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SpivakManagementIncMember__srt--RangeAxis__srt--MinimumMember_zCaw30Vrofzh">2.37</span>% - <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SpivakManagementIncMember__srt--RangeAxis__srt--MaximumMember_zSCqgYJgvMGa">4.46</span>%; 3) dividend yield of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SpivakManagementIncMember_zDDEiqa6wIIb" title="Dividend yield">0</span>% and 4) expected term of <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SpivakManagementIncMember_zRC5z00tCdSc" title="Expected term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0922">5</span></span>.0 years. During the years ended September 30, 2023 the Company recognized $53,117, related to this agreement, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized $<span id="xdx_906_eus-gaap--OtherGeneralExpense_c20221001__20230930__us-gaap--StatementClassOfStockAxis__custom--CommonStockWarrantsMember_zD0NoZ95kYWa" title="Expenses related to warrants">322,266</span> of expense related to these warrants during the year ended September 30, 2022. The Company estimated the fair value of the warrants based on a Black-Scholes pricing model using the following assumptions: 1) volatility of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20211001__20220930_zijuNisjZSb" title="Volatility rate">254.43</span>%; 2) risk free rate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20211001__20220930_zYz4C3iaJkxf">1.76</span>%; 3) dividend yield of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20211001__20220930_ztSkXDACsSr1" title="Dividend yield">0</span>% and 4) expected term of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20211001__20220930_z8KWBFKn676c" title="Expected term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0931">5</span></span> years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_89A_ecustom--ScheduleOfShareBasedCompensationStockWarrantsActivityTableTextBlock_z3JZL5sXAOv" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B8_zFM8QkVH1GR1">The following table summarizes the stock warrant activity for the years ended September 30, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Warrants</b></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted-Average<br/> Exercise Price<br/> Per Share</b></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%">Outstanding, September 30, 2021</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementWarrantOutstandingNumberOne_iS_pid_uShares_c20211001__20220930_z062JTjLZGkd" style="width: 13%; text-align: right" title="Warrants outstanding, beginning">29,970,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_986_ecustom--ShareBasedCompensationArrangementWarrantOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20211001__20220930_zghcaMVCG3ja" style="width: 13%; text-align: right">0.03</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Granted</td> <td> </td> <td> </td> <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementWarrantGrantedNumberone_pid_uShares_c20211001__20220930_zPCQYFjLXQtf" style="text-align: right" title="Granted">41,415,152</td> <td> </td> <td> </td> <td> </td> <td id="xdx_985_ecustom--ShareBasedCompensationArrangementWarrantExercisedWeightedAverageTwoExercisePrice_pid_uUSDPShares_c20211001__20220930_zX0LJFE3i2Gd" style="text-align: right">0.01</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expired</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Outstanding, September 30, 2022</td> <td> </td> <td> </td> <td id="xdx_981_ecustom--ShareBasedCompensationArrangementWarrantOutstandingNumberOne_iS_pid_uShares_c20221001__20230930_z0eaq2Ki1N1i" style="text-align: right" title="Warrants outstanding, beginning">71,385,152</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_981_ecustom--ShareBasedCompensationArrangementWarrantOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20221001__20230930_zj1eTaNIKHXb" style="text-align: right" title="Warrants outstanding, beginning (in per shares)">0.02</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Granted</td> <td> </td> <td> </td> <td id="xdx_982_ecustom--ShareBasedCompensationArrangementWarrantGrantedNumberone_pid_uShares_c20221001__20230930_zvQE75HR9CCd" style="text-align: right" title="Granted">90,181,342</td> <td> </td> <td> </td> <td> </td> <td id="xdx_986_ecustom--ShareBasedCompensationArrangementWarrantExercisedWeightedAverageTwoExercisePrice_pid_uUSDPShares_c20221001__20230930_zvHWeEYH4k1d" style="text-align: right" title="Granted (in per shares)">0.002</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Expired</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_uShares_c20221001__20230930_zIY9jny6tkgc" style="border-bottom: black 1pt solid; text-align: right" title="Expired">(3,030,304</td> <td>)</td> <td> </td> <td> </td> <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementWarrantExpirationWeightedAverageTwoExercisePrice_pid_uUSDPShares_c20221001__20230930_zXozFhfhvSa2" style="text-align: right" title="Expired (in per shares)">0.01</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding, September 30, 2023</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_982_ecustom--ShareBasedCompensationArrangementWarrantOutstandingNumberOne_iE_pid_uShares_c20221001__20230930_z4G9JS1zZso1" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants outstanding, ending">158,536,190</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementWarrantOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20221001__20230930_zulhXR2iUPq3" style="text-align: right" title="Warrants outstanding, ending (in per shares)">0.01</td> <td> </td></tr> </table> <p id="xdx_8AA_zwxpVHFJV6m5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2023, the outstanding warrants had an expected remaining life of <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20221001__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6or26Gg86h" title="Expected life::XDX::P1Y7M6D"><span style="-sec-ix-hidden: xdx2ixbrl0958">1.60 </span></span>years and have an intrinsic value of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMpBSMhjfPOj" title="Aggregate intrinsic value">69,300</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common Stock Options</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As discussed in Note 4, The Company awarded common stock options to Mr. Katzaroff in connection with his amended and restated employment agreement. During the year ended September 30, 2023, the Company estimated the fair value of the options to be $<span id="xdx_905_ecustom--OptiongGrantsValue_iI_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember_zkiXUePsAHBj" title="Fair value of option grants">53,117</span>, using the following assumptions range: 1) volatility of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221001__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember__srt--RangeAxis__srt--MinimumMember_zlZKoeJRIDD3" title="Volatility rate">215.45</span> % - <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221001__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember__srt--RangeAxis__srt--MaximumMember_zxbLc1QiSAk5" title="Volatility rate">253.78</span>% ; 2) risk free rate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20221001__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember__srt--RangeAxis__srt--MinimumMember_zan4hHoXr1M5" title="Risk free rate">2.37</span>% -<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20221001__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember__srt--RangeAxis__srt--MaximumMember_zBmZq7KXZ7o5" title="Risk free rate"> 4.46</span>%; 3) dividend yield of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20221001__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember_zk1DMsoCHTzb">0</span>% and 4) expected term of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxL_c20221001__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrKatzaroffMember_zynY7EvA2aa7" title="Expected term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0973">5.0</span></span> years. The Company recognized $<span id="xdx_908_ecustom--FairValueExpenses_c20221001__20230930_zJfIncNLpAG1">108,802</span> of expense related to the fair value of options vesting during the year ended September 30, 2023. The Company recognized $<span id="xdx_90A_ecustom--FairValueExpenses_c20211001__20220930_zxlCQStSMoCe">186,926</span> of expense related to the fair value of options vesting during the year ended September 30, 2022. The Company expects to recognize an additional $<span id="xdx_901_eus-gaap--CostsAndExpenses_c20221001__20230930_zD7HunrE9Luk" title="Additional expenses">42,229</span> of expense related to these options assuming all vest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company also recognized $<span id="xdx_901_ecustom--FairValueExpenses_c20221001__20230930__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zAHbxsj8V7y1" title="Expenses related to the fair value">696,294</span> of expense related to the estimated fair value of stock options awarded to officers of the Company. The Company awarded <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_uShares_c20221001__20230930__srt--TitleOfIndividualAxis__custom--RobertChicoskiMember_zHqThf8b0qCb">50,000,000</span> options with a $<span id="xdx_904_ecustom--ExercisePrice1_pid_uUSDPShares_c20221001__20230930__srt--TitleOfIndividualAxis__custom--RobertChicoskiMember_zlppNvVqpTrf" title="Exercise price">0.01</span> exercise price to the Company’s CFO Robert Chicoski that expire in May 2026, and awarded <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_uShares_c20221001__20230930__srt--TitleOfIndividualAxis__custom--MrFarleyMember_zglebpQE3CK6"><span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_uShares_c20221001__20230930__srt--TitleOfIndividualAxis__custom--MrPenderghastMember_zGbndCYmshNg">20,000,000</span></span> options with an exercise price of $<span id="xdx_90A_ecustom--ExercisePrice1_pid_uUSDPShares_c20221001__20230930__srt--TitleOfIndividualAxis__custom--MrFarleyMember_zQ2x02VZ8en1" title="Exercise price"><span id="xdx_90E_ecustom--ExercisePrice1_pid_uUSDPShares_c20221001__20230930__srt--TitleOfIndividualAxis__custom--MrPenderghastMember_zzxsaQU3cR22" title="Exercise price">0.01</span></span> each to Mr. Farley and Mr. Penderghast which expire in April 2026. <span id="xdx_906_ecustom--ConversionOfStockDescriptionOther_c20221001__20230930_zinICPPqmJxj" title="Other description">The fair value was estimated using a Black-Scholes option pricing model and the following assumptions: 1) volatility of 184%; 2) expected term of approximately three years; 3) risk-free rate of 4.52%; 5) a common stock price at the date of grant of $0.086 and 6) a dividend yield of 0%. The option wards vested immediately.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2023, the Company had $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_c20221001__20230930_zhmqQLqZN147" title="Unrecognized expenses related to options">42,229</span> of unrecognized expenses related to options.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zUpnvXU3Zj62" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B6_zTNn3XNa6ir1">The following table summarizes the stock option activity for the years ended September 30, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 0.6pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Options</b></td> <td style="padding-bottom: 0.6pt"> </td> <td style="padding-bottom: 0.6pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted-Average<br/> Exercise Price<br/> Per Share</b></td> <td style="padding-bottom: 0.6pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%">Outstanding, September 30, 2021</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20211001__20220930_zS5mpZtqqq8" style="width: 13%; text-align: right" title="Option outstanding, beginning">70,000,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20211001__20220930_zcPdHhq35h9k" style="width: 13%; text-align: right" title="Option outstanding, beginning (in per shares)">0.03</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Granted</td> <td> </td> <td> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20211001__20220930_zPiBfH3VHE67" style="text-align: right" title="Granted">35,000,000</td> <td> </td> <td> </td> <td> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20211001__20220930_zlrcZsRaifHc" style="text-align: right" title="Granted (in per shares)">0.01</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20211001__20220930_zO0ba1Ev3nBj" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1004">—</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20211001__20220930_zd69wGL7qA2j" style="text-align: right" title="Exercised (in per shares)"><span style="-sec-ix-hidden: xdx2ixbrl1006">—</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Forfeited</td> <td> </td> <td> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20211001__20220930_znRAwKSQfQ8f" style="text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1008">—</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20211001__20220930_zwwCvP5e9mk7" style="text-align: right" title="Forfeited (in per shares)"><span style="-sec-ix-hidden: xdx2ixbrl1010">—</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expired</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_uShares_c20211001__20220930_z33ZcXqfYrs4" style="border-bottom: black 1pt solid; text-align: right" title="Expired"><span style="-sec-ix-hidden: xdx2ixbrl1012">—</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20211001__20220930_zzhVpXm8OvN9" style="text-align: right" title="Expired (in per shares)"><span style="-sec-ix-hidden: xdx2ixbrl1014">—</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Outstanding, September 30, 2022</td> <td> </td> <td> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20221001__20230930_zoHsDF43yicc" style="text-align: right" title="Option outstanding, beginning">105,000,000</td> <td> </td> <td> </td> <td> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20221001__20230930_zt3PGXztQSc1" style="text-align: right">0.02</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Granted</td> <td> </td> <td> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20221001__20230930_zzs0GBLC8Dx7" style="text-align: right" title="Granted">101,632,356</td> <td> </td> <td> </td> <td> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20221001__20230930_zjwRCb4uZ1w2" style="text-align: right">0.01</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Exercised</td> <td> </td> <td> </td> <td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20221001__20230930_zhHOgcE2jtS2" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1022">—</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20221001__20230930_zwUHXAKape53" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1023">—</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Forfeited</td> <td> </td> <td> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20221001__20230930_zyfIhy0WMTMj" style="text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1025">—</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20221001__20230930_zcxp1BTEBSNi" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1026">—</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 0.6pt">Expired</td> <td style="padding-bottom: 0.6pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_uShares_c20221001__20230930_zHNsD96Revx8" style="border-bottom: black 1pt solid; text-align: right" title="Expired">(70,000,000</td> <td style="padding-bottom: 0.6pt">)</td> <td style="padding-bottom: 0.6pt"> </td> <td> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20221001__20230930_zJ2VDG2Zn0Pc" style="text-align: right">0.03</td> <td style="padding-bottom: 0.6pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.8pt">Outstanding, September 30, 2023</td> <td style="padding-bottom: 1.8pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20221001__20230930_z9QIJQsNOTz2" style="border-bottom: black 2.25pt double; text-align: right" title="Option outstanding, ending">136,632,356</td> <td style="padding-bottom: 1.8pt"> </td> <td style="padding-bottom: 1.8pt"> </td> <td>$</td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20221001__20230930_znmZr2FwJzS7" style="text-align: right" title="Option outstanding, ending (in per shares)">0.01</td> <td style="padding-bottom: 1.8pt"> </td></tr> </table> <p id="xdx_8AF_zR3bDoFuJoP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2023, the aggregate intrinsic value of options vested and outstanding were $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20230930_znG5qTA8ZVh7" title="Aggregate intrinsic value">0</span>. As of September 30, 2023, the outstanding options had a weighted average remaining term of<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtxL_c20221001__20230930_zAfBlsSruyW6" title="Expected remaining life::XDX::P2Y11M8D"> <span style="-sec-ix-hidden: xdx2ixbrl1038">2.94</span></span> years.</p> 20000000 20000000 0.001 0.001 6000000 2.00 5000000 6000000 0.08 0 0 1000000 1.00 0.08 0 0 1200000 0.50 0.50 0 0 539988 1.00 The Series D Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock. 50998800 509988 0 509988 1000000 The Series E Preferred stock retained 2/3 of the voting rights in the Company. 1000000 501975 1.00 The Series F Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock. 386975 386975 257984 25798400 128991 128991 128991 128991 20000 2000000 50000000 360000 6000000 900000 15000 146460 7422535 50000 7261087 50102 10166 1512152 5000 19980000 5000 1515152 0.01 5000 1515152 0.01 4067 1.7637 0.0474 0 8000 7000 7500000 0.03 0.01 2.03 0.0505 0.086 0 51761 53117 2.1545 2.5378 0.0237 0.0446 0 322266 2.5443 0.0176 0 <p id="xdx_89A_ecustom--ScheduleOfShareBasedCompensationStockWarrantsActivityTableTextBlock_z3JZL5sXAOv" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B8_zFM8QkVH1GR1">The following table summarizes the stock warrant activity for the years ended September 30, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Warrants</b></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted-Average<br/> Exercise Price<br/> Per Share</b></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%">Outstanding, September 30, 2021</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementWarrantOutstandingNumberOne_iS_pid_uShares_c20211001__20220930_z062JTjLZGkd" style="width: 13%; text-align: right" title="Warrants outstanding, beginning">29,970,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_986_ecustom--ShareBasedCompensationArrangementWarrantOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20211001__20220930_zghcaMVCG3ja" style="width: 13%; text-align: right">0.03</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Granted</td> <td> </td> <td> </td> <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementWarrantGrantedNumberone_pid_uShares_c20211001__20220930_zPCQYFjLXQtf" style="text-align: right" title="Granted">41,415,152</td> <td> </td> <td> </td> <td> </td> <td id="xdx_985_ecustom--ShareBasedCompensationArrangementWarrantExercisedWeightedAverageTwoExercisePrice_pid_uUSDPShares_c20211001__20220930_zX0LJFE3i2Gd" style="text-align: right">0.01</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expired</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Outstanding, September 30, 2022</td> <td> </td> <td> </td> <td id="xdx_981_ecustom--ShareBasedCompensationArrangementWarrantOutstandingNumberOne_iS_pid_uShares_c20221001__20230930_z0eaq2Ki1N1i" style="text-align: right" title="Warrants outstanding, beginning">71,385,152</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_981_ecustom--ShareBasedCompensationArrangementWarrantOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20221001__20230930_zj1eTaNIKHXb" style="text-align: right" title="Warrants outstanding, beginning (in per shares)">0.02</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Granted</td> <td> </td> <td> </td> <td id="xdx_982_ecustom--ShareBasedCompensationArrangementWarrantGrantedNumberone_pid_uShares_c20221001__20230930_zvQE75HR9CCd" style="text-align: right" title="Granted">90,181,342</td> <td> </td> <td> </td> <td> </td> <td id="xdx_986_ecustom--ShareBasedCompensationArrangementWarrantExercisedWeightedAverageTwoExercisePrice_pid_uUSDPShares_c20221001__20230930_zvHWeEYH4k1d" style="text-align: right" title="Granted (in per shares)">0.002</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Expired</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_uShares_c20221001__20230930_zIY9jny6tkgc" style="border-bottom: black 1pt solid; text-align: right" title="Expired">(3,030,304</td> <td>)</td> <td> </td> <td> </td> <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementWarrantExpirationWeightedAverageTwoExercisePrice_pid_uUSDPShares_c20221001__20230930_zXozFhfhvSa2" style="text-align: right" title="Expired (in per shares)">0.01</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding, September 30, 2023</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_982_ecustom--ShareBasedCompensationArrangementWarrantOutstandingNumberOne_iE_pid_uShares_c20221001__20230930_z4G9JS1zZso1" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants outstanding, ending">158,536,190</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementWarrantOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20221001__20230930_zulhXR2iUPq3" style="text-align: right" title="Warrants outstanding, ending (in per shares)">0.01</td> <td> </td></tr> </table> 29970000 0.03 41415152 0.01 71385152 0.02 90181342 0.002 -3030304 0.01 158536190 0.01 69300 53117 2.1545 2.5378 2.37 4.46 0 108802 186926 42229 696294 50000000 0.01 20000000 20000000 0.01 0.01 The fair value was estimated using a Black-Scholes option pricing model and the following assumptions: 1) volatility of 184%; 2) expected term of approximately three years; 3) risk-free rate of 4.52%; 5) a common stock price at the date of grant of $0.086 and 6) a dividend yield of 0%. The option wards vested immediately. 42229 <p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zUpnvXU3Zj62" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B6_zTNn3XNa6ir1">The following table summarizes the stock option activity for the years ended September 30, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 0.6pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Options</b></td> <td style="padding-bottom: 0.6pt"> </td> <td style="padding-bottom: 0.6pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted-Average<br/> Exercise Price<br/> Per Share</b></td> <td style="padding-bottom: 0.6pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%">Outstanding, September 30, 2021</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20211001__20220930_zS5mpZtqqq8" style="width: 13%; text-align: right" title="Option outstanding, beginning">70,000,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20211001__20220930_zcPdHhq35h9k" style="width: 13%; text-align: right" title="Option outstanding, beginning (in per shares)">0.03</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Granted</td> <td> </td> <td> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20211001__20220930_zPiBfH3VHE67" style="text-align: right" title="Granted">35,000,000</td> <td> </td> <td> </td> <td> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20211001__20220930_zlrcZsRaifHc" style="text-align: right" title="Granted (in per shares)">0.01</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20211001__20220930_zO0ba1Ev3nBj" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1004">—</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20211001__20220930_zd69wGL7qA2j" style="text-align: right" title="Exercised (in per shares)"><span style="-sec-ix-hidden: xdx2ixbrl1006">—</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Forfeited</td> <td> </td> <td> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20211001__20220930_znRAwKSQfQ8f" style="text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1008">—</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20211001__20220930_zwwCvP5e9mk7" style="text-align: right" title="Forfeited (in per shares)"><span style="-sec-ix-hidden: xdx2ixbrl1010">—</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expired</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_uShares_c20211001__20220930_z33ZcXqfYrs4" style="border-bottom: black 1pt solid; text-align: right" title="Expired"><span style="-sec-ix-hidden: xdx2ixbrl1012">—</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20211001__20220930_zzhVpXm8OvN9" style="text-align: right" title="Expired (in per shares)"><span style="-sec-ix-hidden: xdx2ixbrl1014">—</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Outstanding, September 30, 2022</td> <td> </td> <td> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20221001__20230930_zoHsDF43yicc" style="text-align: right" title="Option outstanding, beginning">105,000,000</td> <td> </td> <td> </td> <td> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20221001__20230930_zt3PGXztQSc1" style="text-align: right">0.02</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Granted</td> <td> </td> <td> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20221001__20230930_zzs0GBLC8Dx7" style="text-align: right" title="Granted">101,632,356</td> <td> </td> <td> </td> <td> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20221001__20230930_zjwRCb4uZ1w2" style="text-align: right">0.01</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Exercised</td> <td> </td> <td> </td> <td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20221001__20230930_zhHOgcE2jtS2" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1022">—</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20221001__20230930_zwUHXAKape53" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1023">—</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Forfeited</td> <td> </td> <td> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20221001__20230930_zyfIhy0WMTMj" style="text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1025">—</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20221001__20230930_zcxp1BTEBSNi" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1026">—</span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 0.6pt">Expired</td> <td style="padding-bottom: 0.6pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_uShares_c20221001__20230930_zHNsD96Revx8" style="border-bottom: black 1pt solid; text-align: right" title="Expired">(70,000,000</td> <td style="padding-bottom: 0.6pt">)</td> <td style="padding-bottom: 0.6pt"> </td> <td> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20221001__20230930_zJ2VDG2Zn0Pc" style="text-align: right">0.03</td> <td style="padding-bottom: 0.6pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.8pt">Outstanding, September 30, 2023</td> <td style="padding-bottom: 1.8pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20221001__20230930_z9QIJQsNOTz2" style="border-bottom: black 2.25pt double; text-align: right" title="Option outstanding, ending">136,632,356</td> <td style="padding-bottom: 1.8pt"> </td> <td style="padding-bottom: 1.8pt"> </td> <td>$</td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20221001__20230930_znmZr2FwJzS7" style="text-align: right" title="Option outstanding, ending (in per shares)">0.01</td> <td style="padding-bottom: 1.8pt"> </td></tr> </table> 70000000 0.03 35000000 0.01 105000000 0.02 101632356 0.01 70000000 0.03 136632356 0.01 0 <p id="xdx_806_ecustom--SeriesGPreferredStockDisclosureTextBlock_zvYYKdq4gub6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 7. <span id="xdx_826_zVNgcTNK3rW6">Series G Preferred Stock</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 11, 2021, our board of directors designated up to <span id="xdx_90B_ecustom--PreferredStockSharesDesignated_iI_pid_uShares_c20210811__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zhndMxOxfOx8" title="Preferred stock, shares designated">1,000,000</span> shares of Series G Preferred Stock with a liquidation value of $<span id="xdx_90D_eus-gaap--PreferredStockLiquidationPreference_iI_pid_uUSDPShares_c20210811__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_ziXXwZWVp2a" title="Preferred stock liquidation preference">1.00</span> per share. <span id="xdx_903_eus-gaap--PreferredStockVotingRights_c20210809__20210811__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zRkdeUqSBhS4" title="Description of voting rights">The holders of the Series G Preferred Stock have no voting rights except on matters related specifically to the Series G Preferred Stock. </span><span id="xdx_902_eus-gaap--PreferredStockConversionBasis_c20210809__20210811__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zIxrxn80i226" title="Preferred stock, conversion basis">The Series G Preferred Stock carries a dividend of 8% of the stated value per share, which is cumulative and payable upon redemption, liquidation or conversion, and increases to 22% in case of default.</span> The Series G Preferred Stock and accrued dividends are convertible beginning 180 days from issuance at the option of the holder into shares of common stock at a rate of a conversion price of 75% of the average three lowest trading prices during the 15 days prior to conversion. The Company will be required to redeem the Series G Preferred Stock upon the earlier of 15 months from issuance date or upon on event of default as defined in the agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on the economic characteristics of the Series G Preferred Stock, the Company determined that the Series G should be accounted for as a liability under ASC 480-10, based on the discounted conversion price providing an effectively fixed monetary amount that the preferred stock is convertible into.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2023, the Company sold an aggregate of <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_uShares_c20221001__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zPN7z9oHkYxh" title="Number of share sold">89,100</span> shares of Series G Preferred Stock for net cash proceeds of $<span id="xdx_907_ecustom--NetCashProceeds_c20221001__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zOO9nrT5uw6f">73,000</span>. The Company recorded a debt discount of $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_znP59RpYETb" title="Debt discount">16,100</span> for the difference between the cash proceeds and the total amount to be redeemed by the holder of $<span id="xdx_907_ecustom--NetCashProceeds_c20221001__20230930_zUfRzIPnesEa" title="Net cash proceeds">89,100</span>. The Company amortized $<span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_c20221001__20230930_z2JamSYOJn65" title="Amortization of debt discount">28,681</span> of discount related to Series G Preferred Stock for the year ended September 30, 2023. The dividends on the Series G Preferred Stock are accrued as interest. The Company recognized $<span id="xdx_905_ecustom--InterestRecognized_c20221001__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zl1rqQO4c7La" title="Interest recognized">5,039</span> of interest on the Series G Preferred Stock and had an accrued interest balance of $<span id="xdx_90E_eus-gaap--InterestReceivable_iI_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zaUpdUYEdXQ5" title="Accrued interest">3,556</span> and $<span id="xdx_90F_eus-gaap--InterestReceivable_iI_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zOM00Wk6jHHc">3,983</span> as of September 30, 2023 and September 30, 2022, respectively. During the year ended September 30, 2023, the holder of the Series G converted <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_pid_uShares_c20221001__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zoQHt0VOicfk" title="Conversion of stock shares converted">227,975</span> shares of Series G and $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueStockDividend_c20221001__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwB4ctSfUt06" title="Dividend value">9,119</span> of dividends into <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_pid_uShares_c20221001__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhCHC3AfDHu1" title="Conversion of stock shares converted">100,712,968</span> shares of common stock. The conversions were in accordance with the terms of the agreement and <span id="xdx_908_eus-gaap--GainLossOnFairValueHedgesRecognizedInEarnings_do_c20221001__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z59bRZ7XNv13" title="Recognized loss">no</span> gain or loss was recognized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2022, the Company sold an aggregate of <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_uShares_c20211001__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zEVnG3NHD4lg" title="Number of share sold">369,875</span> shares of Series G Preferred Stock for net cash proceeds of $<span id="xdx_90A_ecustom--NetCashProceeds_c20211001__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zrIJvt42YF0g">310,000</span>. The Company recorded a debt discount of $<span id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_z327ciMJb8ii" title="Debt discount">59,875</span> for the difference between the cash proceeds and the total amount to be redeemed by the holder of $<span id="xdx_900_ecustom--NetCashProceeds_c20211001__20220930_zy61iIgISnke" title="Net cash proceeds">369,875</span>. The Company amortized $<span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_c20211001__20220930_zaoUPVk2Yona" title="Amortization of debt discount">54,664</span> of discount related to Series G Preferred Stock for the year months ended September 30, 2022. The dividends on the Series G Preferred Stock are accrued as interest. The Company recognized $<span id="xdx_90A_ecustom--InterestRecognized_c20211001__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zKernZ3Hi5p2" title="Interest recognized">15,852</span> of interest on the Series G Preferred Stock and had an accrued interest balance of $<span id="xdx_901_eus-gaap--InterestReceivable_iI_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zHARrvSeSrEa" title="Accrued interest">3,983</span> and $<span id="xdx_906_eus-gaap--InterestReceivable_iI_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_z1IyLWqVCS4a" title="Accrued interest">1,281</span> as of September 30, 2022 and September 30, 2021, respectively. During the year ended September 30, 2022, the holder of the Series G converted <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_pid_uShares_c20211001__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zycmY3Y0jq1j" title="Conversion of stock shares converted">324,500</span> shares of Series G and $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueStockDividend_c20211001__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFYKQrZKDBX8" title="Dividend value">12,980</span> of dividends into <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_pid_uShares_c20211001__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ4aoB7O6uje" title="Conversion of stock shares converted">109,052,543</span> shares of common stock, and the Company recognized a loss of $<span id="xdx_901_eus-gaap--GainLossOnFairValueHedgesRecognizedInEarnings_c20211001__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyqXHYOhFCNa" title="Recognized loss">5,939</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2023 and September 30, 2022, <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_pid_uShares_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zNkpLjj0d5H1" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_pid_uShares_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_z1zYh3Q8BXdi" title="Preferred stock, shares outstanding">0</span></span> and <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pid_uShares_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_z7sUAEIGljcl"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_uShares_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zLXYvIRgAY95" title="Preferred stock, shares outstanding">138,875</span></span> shares of the Series G Preferred Stock were issued and outstanding, respectively. The balance of the Series G Preferred stock liability was $<span id="xdx_907_eus-gaap--OtherLiabilitiesNoncurrent_iI_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zftGhgMGCYE9" title="Liabilities related to stock">0</span> and $<span id="xdx_90A_eus-gaap--OtherLiabilitiesNoncurrent_iI_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zlFJMoYGfLz9" title="Liabilities related to stock">126,294</span>, respectively, net of unamortized discount of $<span id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iI_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zBGjz3CKYfRj" title="Unamortized discount">0</span> and $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iI_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zteQMTVKm5z4">12,581</span>, respectively.</p> 1000000 1.00 The holders of the Series G Preferred Stock have no voting rights except on matters related specifically to the Series G Preferred Stock. The Series G Preferred Stock carries a dividend of 8% of the stated value per share, which is cumulative and payable upon redemption, liquidation or conversion, and increases to 22% in case of default. 89100 73000 16100 89100 28681 5039 3556 3983 227975 9119 100712968 0 369875 310000 59875 369875 54664 15852 3983 1281 324500 12980 109052543 5939 0 0 138875 138875 0 126294 0 12581 <p id="xdx_80B_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zXRBkNctI0D3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 8. <span id="xdx_820_zq3StFSQm2uf">Commitments and Contingent Liabilities</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In February 2022, the Company entered into a consulting agreement with Spivak Management, Inc. (the “Consultant”). Under the agreement, the Consultant will provide business strategy advice and introductions to the Company for a period of five years unless mutually terminated sooner. Concurrently, Kenin Spivak, who controls Spivak Management, Inc., entered into a stock purchase agreement with the Company to purchase <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20220201__20220228_z9niebblPJZ6" title="Shares issue">6,000,000</span> shares of common stock for $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20220201__20220228_zMJbH3uZuoEg" title="Value of share issue">25,000</span> cash. The purchase and issuance of the shares was to be completed by June 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><span id="xdx_90D_eus-gaap--OtherCommitmentsDescription_c20220201__20220228_zxUARBcVZDr3" title="Description of commitment">The Consultant will be paid a signing bonus of $25,000 upon receipt by the Company of the $25,000 cash under the stock purchase agreement described above. The Consultant will also receive the larger of $12,500 per month, or 50% of the CEO’s fixed cash compensation under the amended employment agreement described in Note 4. The Consultant may elect to receive this payment in stock.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><span id="xdx_90A_eus-gaap--BusinessCombinationBargainPurchaseGainRecognizedDescription_c20220701__20220731__us-gaap--TypeOfArrangementAxis__us-gaap--SubscriptionArrangementMember_zzKjRupeL646" title="Description of purchase agreement">In July 2022, the consultant agreement and the stock purchase agreement were amended to reduce the subscription amount to $17,500.</span> In August 2022, $17,500 was placed in escrow by Mr. Spivak for the Company’s Benefit, and the Company paid $<span id="xdx_90F_eus-gaap--DefinedBenefitPlanBenefitObligationBenefitsPaid_c20220801__20220831__us-gaap--DeferredRevenueArrangementTypeAxis__us-gaap--SubscriptionArrangementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSpivakMember_zNex5k5yMiSa" title="Obligation benefits paid">17,500</span> to the Consultant from the escrow account. The <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20220831__us-gaap--DeferredRevenueArrangementTypeAxis__us-gaap--SubscriptionArrangementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSpivakMember_zEVPoVjsukw6" title="Common stock, shares issued">6,000,000</span> shares owed to Mr. Spivak were not issued by June 30, 2023, and were issued in August 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Consultant may also receive a bonus in each calendar year of the agreement equal to the larger of any bonus awarded by the Board of Directors to the Consultant or 50% of the largest bonus payable by the Company to anyone other than the Consultant. If the agreement is terminated with one year of a change of control of the Company, the Consultant will be entitled to receive a payment equal to 2.99 times the larger of the total compensation paid to the Consultant over the prior 12 month period or the average compensation paid or payable to the Consultant over the prior three years. On September 19, 2023, the Company entered into a second supplement to consulting agreement. Pursuant to the agreement, in In lieu of Base Fees accrued through September 2023 and interest on late payment thereof, the Company shall pay to the Consultant, the sum of $<span id="xdx_90E_eus-gaap--AccruedProfessionalFeesCurrent_iI_c20230919_zaxClBbJZIMi" title="Accrued fees">300,000</span> in installments on and from the first to occur of the following until the full $300,000 is paid in full. The Company will continue to pay the Consultant a fee of $<span id="xdx_906_eus-gaap--ProfessionalFees_c20230917__20230919_zw6TCD5TMOqe" title="Consultant fees">12,500</span> per month. The Company reclassified $<span id="xdx_905_eus-gaap--PaymentsForFees_c20230917__20230919__us-gaap--FinancialInstrumentAxis__us-gaap--AccruedLiabilitiesMember_zilXNCPlKm78" title="Fee accrued in accounts payable">250,000</span> of fee accrued in accounts payable owed to the Consultant and interest expense of $<span id="xdx_902_eus-gaap--InterestExpense_c20230917__20230919__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zU8GH6OmPS2c" title="Interest expense to a note payable">50,000</span> to a note payable. As of September 30, 2023 and September 30, 2022, the Company owed the consultant $<span id="xdx_90B_eus-gaap--ProfessionalFees_c20221001__20230930__us-gaap--DeferredRevenueArrangementTypeAxis__custom--ConsultantAgreementMember_zzd94NIQ0JR5" title="Consultant fees">337,500</span> and $<span id="xdx_908_eus-gaap--ProfessionalFees_c20211001__20220930__us-gaap--DeferredRevenueArrangementTypeAxis__custom--ConsultantAgreementMember_zC2vJeDC1jHb" title="Consultant fees">100,000</span>, which included accounts payable and accrued liabilities of $<span id="xdx_90E_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_c20230930_zMAnhgggbBmk" title="Accounts payable and accrued liabilities">37,500</span> and $<span id="xdx_90B_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_c20220930_z8hVajZ1iMod" title="Accounts payable and accrued liabilities">100,000</span> and notes payable of $<span id="xdx_90B_eus-gaap--NotesPayable_iI_c20230930_zx0ELrWeI4q6" title="Notes payable">300,000</span> and $<span id="xdx_902_eus-gaap--NotesPayable_iI_dxL_c20220930_zAwDSdBj1ky8" title="::XDX::%97"><span style="-sec-ix-hidden: xdx2ixbrl1141">0</span></span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On August 10, 2023, the Company entered into a consulting agreement with Valerian Capital, LLC ( “Valerian”). Under the agreement, Valerian will provide management consulting, business advisory, shareholder information and public relations to the Company for a period of six months unless mutually terminated sooner. <span id="xdx_90F_eus-gaap--SignificantPurchaseCommitmentDescription_c20230808__20230810__us-gaap--DeferredRevenueArrangementTypeAxis__custom--ConsultantAgreementMember_z51B3bktINI4">Upon execution of the agreement, Valerian will purchase 33,333,333 shares of the Company’s stock for a total purchase price of $25,000 and have the option to purchase an additional 33,333,333 shares for $25,000 during the first 45 days of the agreement. Lastly, Valerian will have the right to purchase 66,000,000 warrants with an exercise price of $0.00075 for up to one year following the agreement. As of September 30, 2023, the Company received $<span id="xdx_90F_eus-gaap--CommonStockValue_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DeferredRevenueArrangementTypeAxis__custom--ConsultantAgreementMember_zWN7XYSo6C64" title="Common stock, value">25,000</span> and issued <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DeferredRevenueArrangementTypeAxis__custom--ConsultantAgreementMember_zw8VxLkiaqOk" title="Common stock, share">33,333,333</span> shares of common stock to Valerian.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Litigation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">From time to time, the Company may be subject to routine litigation, claims, or disputes in the ordinary course of business. In the opinion of management, no pending or known threatened claims, actions or proceedings against the Company are expected to have a material adverse effect on the Company’s financial position, results of operations or cash flows. The Company cannot predict with certainty, however, the outcome or effect of any of the litigation or investigatory matters specifically described above or any other pending litigation or claims. There can be no assurance as to the ultimate outcome of any lawsuits and investigations.</span></p> 6000000 25000 The Consultant will be paid a signing bonus of $25,000 upon receipt by the Company of the $25,000 cash under the stock purchase agreement described above. The Consultant will also receive the larger of $12,500 per month, or 50% of the CEO’s fixed cash compensation under the amended employment agreement described in Note 4. The Consultant may elect to receive this payment in stock. In July 2022, the consultant agreement and the stock purchase agreement were amended to reduce the subscription amount to $17,500. 17500 6000000 300000 12500 250000 50000 337500 100000 37500 100000 300000 Upon execution of the agreement, Valerian will purchase 33,333,333 shares of the Company’s stock for a total purchase price of $25,000 and have the option to purchase an additional 33,333,333 shares for $25,000 during the first 45 days of the agreement. Lastly, Valerian will have the right to purchase 66,000,000 warrants with an exercise price of $0.00075 for up to one year following the agreement. As of September 30, 2023, the Company received $25,000 and issued 33,333,333 shares of common stock to Valerian. 25000 33333333 <p id="xdx_80C_ecustom--LicenseAgreementDisclosureTextBlock_zFsdjrFz33E2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 9. <span id="xdx_82D_zFC6NdJmmCsi">License Agreement</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective August 23, 2020 the Company’s wholly-owned subsidiary, SomaCeuticals, Inc. entered into an exclusive global license agreement with 7 to Stand, Inc. for the rights to U.S. patent <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20200822__20200823__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FabrizioDeSilvestriMember_zvLvYkJOnnr4" title="Rights to issued">10,610,592</span> issued to Fabrizio de Silvestri, Terni, Italy, as inventor, April 7, 2020 for treatment of Multiple Sclerosis. In consideration for the license agreement, SomaCeuticals agreed to pay 7 to Stand a royalty of <span id="xdx_908_ecustom--RoyaltyOfNetSalesPercentage_pid_dp_uPure_c20200822__20200823__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z80eDGhsGNre" title="Royalty of net sales">7.1</span>% of the net sales of any product developed under the patent on a worldwide basis. Additionally, the Company will issue shares of common stock to 7 to Stand upon completion of the following milestones:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: center">●</td> <td style="width: 7in; text-align: justify"><span id="xdx_90E_ecustom--DescriptionOfMilestones_c20200822__20200823_zrcLQ0ryawB6" title="Description of milestone">Common shares representing 5% of total number of outstanding common shares of the Company immediately following any change of control of the Company; the Company issued 29,130,167 shares of common stock as a result of the change of control discussed in Note 5. These shares were issued in July 2021.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td style="text-align: center">●</td> <td style="text-align: justify"><span id="xdx_90D_ecustom--DescriptionOfMilestones1_c20200822__20200823_zhNxwmz65mP3" title="Description of milestone one">29,130,167 Common shares immediately following the first round of funding under a private offer of equity or debt securities; These shares were issued in July 2021.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td style="text-align: center">●</td> <td style="text-align: justify"><span id="xdx_902_ecustom--DescriptionOfMilestones2_c20200822__20200823_zRv0HgQkgGi5" title="Description of milestone two">29,130,167 Common shares immediately following the commencement of clinical trials for Federal Drug Administration clearance of the product; and</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td style="text-align: center">●</td> <td style="text-align: justify"><span id="xdx_905_ecustom--DescriptionOfMilestones3_c20200822__20200823_z8JeB7r4pQgi" title="Description of milestone three">Common shares representing an adjustment to increase 7 to Stand’s total ownership to 19.99% of total number of outstanding common shares of the Company immediately following FDA clearance of the product for sale. The Company expects to issue 29,130,166 shares of common stock related to this provision if met.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td style="text-align: center">●</td> <td style="text-align: justify"><span id="xdx_902_ecustom--DescriptionOfMilestones4_c20200822__20200823_zfm6YW4687Vk" title="Description of milestone four">$40,000 of royalties to be paid to 7 to Stand annually, on a quarterly basis. The license agreement may be terminated by 7 to Stand if 1) SomaCeuticals does not begin clinical trials within one year of the agreement; 2) if SomaCeuticals terminates the continuation of the clinical trials; or 3) shall not commence marketing the product within reasonable time after obtaining FDA approval.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company paid <span id="xdx_90C_eus-gaap--PaymentsForRoyalties_do_c20221001__20230930__us-gaap--DeferredRevenueArrangementTypeAxis__us-gaap--RoyaltyArrangementMember_zK9RQM1DV2u4" title="Paid for royalties">no</span> royalties and accrued $<span id="xdx_904_eus-gaap--IncreaseDecreaseInRoyaltiesPayable_c20221001__20230930__us-gaap--DeferredRevenueArrangementTypeAxis__us-gaap--RoyaltyArrangementMember_z1B8rrXYVaM9" title="Royalties and late fess">43,851</span> of royalties and late fees during the year ended September 30, 2023. During the year ended September 30, 2023, the Company and 7 to Stand agreed to settle a total of $<span id="xdx_90D_eus-gaap--CommonStockValue_iI_c20230930__us-gaap--DeferredRevenueArrangementTypeAxis__us-gaap--RoyaltyArrangementMember_zHVcYY0MOxTj" title="Agreed to settle">50,102</span> by issuance of <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20230930__us-gaap--DeferredRevenueArrangementTypeAxis__us-gaap--RoyaltyArrangementMember_zvhL3VZ2yWrl" title="Shares issued">7,261,087</span> shares of common stock. The Company recognized a gain of $<span id="xdx_90E_eus-gaap--FormerGainContingencyRecognizedInCurrentPeriod_iI_c20230930__us-gaap--DeferredRevenueArrangementTypeAxis__us-gaap--RoyaltyArrangementMember_zenx4SJaZdp8" title="Recognized gain">10,166</span> based on the fair value of the shares issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company owed $<span id="xdx_908_eus-gaap--PaymentsForRoyalties_c20221001__20230930_zEFRQYIqypN" title="Paid for royalties">20,000</span> of royalties and late fees under this agreement as of September 30, 2023 and $<span id="xdx_904_eus-gaap--IncreaseDecreaseInRoyaltiesPayable_c20211001__20220930_zbMNxagnrRn1" title="Royalties and late fess">26,250</span> as of September 30, 2022.</p> 10610592 0.071 Common shares representing 5% of total number of outstanding common shares of the Company immediately following any change of control of the Company; the Company issued 29,130,167 shares of common stock as a result of the change of control discussed in Note 5. These shares were issued in July 2021. 29,130,167 Common shares immediately following the first round of funding under a private offer of equity or debt securities; These shares were issued in July 2021. 29,130,167 Common shares immediately following the commencement of clinical trials for Federal Drug Administration clearance of the product; and Common shares representing an adjustment to increase 7 to Stand’s total ownership to 19.99% of total number of outstanding common shares of the Company immediately following FDA clearance of the product for sale. The Company expects to issue 29,130,166 shares of common stock related to this provision if met. $40,000 of royalties to be paid to 7 to Stand annually, on a quarterly basis. The license agreement may be terminated by 7 to Stand if 1) SomaCeuticals does not begin clinical trials within one year of the agreement; 2) if SomaCeuticals terminates the continuation of the clinical trials; or 3) shall not commence marketing the product within reasonable time after obtaining FDA approval. 0 43851 50102 7261087 10166 20000 26250 <p id="xdx_809_eus-gaap--IncomeTaxDisclosureTextBlock_zVVUVPAu6Iia" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 10. <span id="xdx_82B_zkCTgwp9caF8">Income Taxes</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There is no current or deferred income tax expense or benefit for the period ended September 30, 2023 and 2021. The Company currently has net operating loss carryforwards aggregating approximately $<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_c20230930_zJZG7nUyzLJd" title="Operating loss carryforwards">5,217,000</span> which expire beginning in 2033. The deferred tax asset related to the net operating loss carryforwards has been fully reserved.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_89A_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z7ktPA7Os601" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The provision for income taxes is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes. The items causing this difference for the period from April 29, 2016 (date of inception) through September 30, 2023 and 2022 is the valuation allowance as follows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <span id="xdx_8BE_zxT9yqV6hiGg" style="display: none; visibility: hidden">Schedule of provision for income taxes</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" id="xdx_499_20221001__20230930_z6sE2nQuveSd" style="border-bottom: black 1pt solid; text-align: center"><b>September 30, 2023</b></td> <td> </td> <td colspan="2" id="xdx_498_20211001__20220930_z1mQvv167goi" style="border-bottom: black 1pt solid; text-align: center"><b>September 30, 2022</b></td> <td> </td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzhSZ_zJbBC68HqURe" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 61%">Net operating loss carryforward at statutory tax rate</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">1,096,000</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">962,000</td> <td style="width: 1%"> </td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzhSZ_z5FRj2F099ff" style="vertical-align: bottom; background-color: white"> <td style="text-indent: 6.5pt">Valuation allowance</td> <td> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(1,096,000</td> <td style="padding-bottom: 0.5pt">)</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(962,000</td> <td style="padding-bottom: 0.5pt">)</td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzhSZ_zdIpTZCmswg7" style="vertical-align: bottom; background-color: #CCEEFF"> <td>Deferred tax benefit, net</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1191">—</span></td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1192">—</span></td> <td> </td></tr> </table> <p id="xdx_8AF_z7tZkFeQfSoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has not recognized an income tax benefit for the period based on uncertainties concerning its ability to generate taxable income in future periods. The tax benefit for the current period presented is offset by a valuation allowance (100%) established against deferred tax assets arising from operating losses and other temporary differences, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The tax returns for fiscal year 2017 and forward are still open for review by the Internal Revenue Service.</p> 5217000 <p id="xdx_89A_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z7ktPA7Os601" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The provision for income taxes is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes. The items causing this difference for the period from April 29, 2016 (date of inception) through September 30, 2023 and 2022 is the valuation allowance as follows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <span id="xdx_8BE_zxT9yqV6hiGg" style="display: none; visibility: hidden">Schedule of provision for income taxes</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" id="xdx_499_20221001__20230930_z6sE2nQuveSd" style="border-bottom: black 1pt solid; text-align: center"><b>September 30, 2023</b></td> <td> </td> <td colspan="2" id="xdx_498_20211001__20220930_z1mQvv167goi" style="border-bottom: black 1pt solid; text-align: center"><b>September 30, 2022</b></td> <td> </td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzhSZ_zJbBC68HqURe" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 61%">Net operating loss carryforward at statutory tax rate</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">1,096,000</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">962,000</td> <td style="width: 1%"> </td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzhSZ_z5FRj2F099ff" style="vertical-align: bottom; background-color: white"> <td style="text-indent: 6.5pt">Valuation allowance</td> <td> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(1,096,000</td> <td style="padding-bottom: 0.5pt">)</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(962,000</td> <td style="padding-bottom: 0.5pt">)</td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzhSZ_zdIpTZCmswg7" style="vertical-align: bottom; background-color: #CCEEFF"> <td>Deferred tax benefit, net</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1191">—</span></td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1192">—</span></td> <td> </td></tr> </table> 1096000 962000 -1096000 -962000 <p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_z90Igjb3JhM5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 11. <span id="xdx_82B_zDjeewi3oyml">Subsequent Events</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 2, 2023, the Company entered into a consulting agreement with Advanced Innovate Partners (“AIP”) under which AIP will <span style="background-color: white">provide advice to GlobeStar and SMIHC on the global design, strategy and execution of clinical trials</span>. Pursuant to the agreement, the Company will pay the following <span id="xdx_904_eus-gaap--SubsequentEventDescription_c20231101__20231102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zs3ynIAOJzF8" title="Consulting agreement">(i) AIP $5,000 per month during Phase A period, if the Company receives regulatory approval to manufacture, sell and distribute products in India or the United States within 60 days of the agreement (ii) AIP $6,000 per month during Phase B period (iii) AIP a sales commission of between 10% and 15% related to any customers, distributors or sales agents introduced to the Company by AIP and (iv) a commission of 4% of any proceeds from equity investments to the Company introduced by AIP, or 2% of any loan proceeds from lenders introduced by AIP.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to September 30, 2023, the holder of the May 10, 2023 convertible note was issued <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20230930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z7k5jxkmygq" title="Convertible note shares issued">30,297,790</span> shares of common stock upon conversion of all $<span id="xdx_90F_eus-gaap--ConversionOfStockAmountConverted1_c20221001__20230930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zx6MPVCW7278" title="Conversion of all of principal">21,300</span> of principal and $<span id="xdx_90F_eus-gaap--InterestPayableCurrent_iI_c20230930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zZGtOafC3ZL6" title="Accrued interest">1,278</span> of accrued interest.</p> (i) AIP $5,000 per month during Phase A period, if the Company receives regulatory approval to manufacture, sell and distribute products in India or the United States within 60 days of the agreement (ii) AIP $6,000 per month during Phase B period (iii) AIP a sales commission of between 10% and 15% related to any customers, distributors or sales agents introduced to the Company by AIP and (iv) a commission of 4% of any proceeds from equity investments to the Company introduced by AIP, or 2% of any loan proceeds from lenders introduced by AIP. 30297790 21300 1278 EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 52 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 152 267 1 false 48 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://globestar.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://globestar.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://globestar.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://globestar.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT Sheet http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://globestar.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 00000007 - Disclosure - General Organization and Business Sheet http://globestar.com/role/GeneralOrganizationAndBusiness General Organization and Business Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://globestar.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Going Concern Sheet http://globestar.com/role/GoingConcern Going Concern Notes 9 false false R10.htm 00000010 - Disclosure - Related Party Transactions Sheet http://globestar.com/role/RelatedPartyTransactions Related Party Transactions Notes 10 false false R11.htm 00000011 - Disclosure - Convertible Notes Payable and Advances Notes http://globestar.com/role/ConvertibleNotesPayableAndAdvances Convertible Notes Payable and Advances Notes 11 false false R12.htm 00000012 - Disclosure - Stockholders??? deficit Sheet http://globestar.com/role/StockholdersDeficit Stockholders??? deficit Notes 12 false false R13.htm 00000013 - Disclosure - Series G Preferred Stock Sheet http://globestar.com/role/SeriesGPreferredStock Series G Preferred Stock Notes 13 false false R14.htm 00000014 - Disclosure - Commitments and Contingent Liabilities Sheet http://globestar.com/role/CommitmentsAndContingentLiabilities Commitments and Contingent Liabilities Notes 14 false false R15.htm 00000015 - Disclosure - License Agreement Sheet http://globestar.com/role/LicenseAgreement License Agreement Notes 15 false false R16.htm 00000016 - Disclosure - Income Taxes Sheet http://globestar.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 00000017 - Disclosure - Subsequent Events Sheet http://globestar.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 00000018 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://globestar.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://globestar.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - Convertible Notes Payable and Advances (Tables) Notes http://globestar.com/role/ConvertibleNotesPayableAndAdvancesTables Convertible Notes Payable and Advances (Tables) Tables http://globestar.com/role/ConvertibleNotesPayableAndAdvances 19 false false R20.htm 00000020 - Disclosure - Stockholders??? deficit (Tables) Sheet http://globestar.com/role/StockholdersDeficitTables Stockholders??? deficit (Tables) Tables http://globestar.com/role/StockholdersDeficit 20 false false R21.htm 00000021 - Disclosure - Income Taxes (Tables) Sheet http://globestar.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://globestar.com/role/IncomeTaxes 21 false false R22.htm 00000022 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://globestar.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://globestar.com/role/SummaryOfSignificantAccountingPoliciesPolicies 22 false false R23.htm 00000023 - Disclosure - Going Concern (Details Narrative) Sheet http://globestar.com/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) Details http://globestar.com/role/GoingConcern 23 false false R24.htm 00000024 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://globestar.com/role/RelatedPartyTransactions 24 false false R25.htm 00000025 - Disclosure - Convertible notes payable consisted of the following at September 30, 2023 and 2022: (Details) Notes http://globestar.com/role/ConvertibleNotesPayableConsistedOfFollowingAtSeptember302023And2022Details Convertible notes payable consisted of the following at September 30, 2023 and 2022: (Details) Details 25 false false R26.htm 00000026 - Disclosure - Convertible Notes Payable and Advances (Details Narrative) Notes http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative Convertible Notes Payable and Advances (Details Narrative) Details http://globestar.com/role/ConvertibleNotesPayableAndAdvancesTables 26 false false R27.htm 00000027 - Disclosure - The following table summarizes the stock warrant activity for the years ended September 30, 2023 and 2022: (Details) Sheet http://globestar.com/role/FollowingTableSummarizesStockWarrantActivityForYearsEndedSeptember302023And2022Details The following table summarizes the stock warrant activity for the years ended September 30, 2023 and 2022: (Details) Details 27 false false R28.htm 00000028 - Disclosure - The following table summarizes the stock option activity for the years ended September 30, 2023 and 2022: (Details) Sheet http://globestar.com/role/FollowingTableSummarizesStockOptionActivityForYearsEndedSeptember302023And2022Details The following table summarizes the stock option activity for the years ended September 30, 2023 and 2022: (Details) Details 28 false false R29.htm 00000029 - Disclosure - Stockholders??? deficit (Details Narrative) Sheet http://globestar.com/role/StockholdersDeficitDetailsNarrative Stockholders??? deficit (Details Narrative) Details http://globestar.com/role/StockholdersDeficitTables 29 false false R30.htm 00000030 - Disclosure - Series G Preferred Stock (Details Narrative) Sheet http://globestar.com/role/SeriesGPreferredStockDetailsNarrative Series G Preferred Stock (Details Narrative) Details http://globestar.com/role/SeriesGPreferredStock 30 false false R31.htm 00000031 - Disclosure - Commitments and Contingent Liabilities (Details Narrative) Sheet http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative Commitments and Contingent Liabilities (Details Narrative) Details http://globestar.com/role/CommitmentsAndContingentLiabilities 31 false false R32.htm 00000032 - Disclosure - License Agreement (Details Narrative) Sheet http://globestar.com/role/LicenseAgreementDetailsNarrative License Agreement (Details Narrative) Details http://globestar.com/role/LicenseAgreement 32 false false R33.htm 00000033 - Disclosure - Schedule of provision for income taxes (Details) Sheet http://globestar.com/role/ScheduleOfProvisionForIncomeTaxesDetails Schedule of provision for income taxes (Details) Details 33 false false R34.htm 00000034 - Disclosure - Income Taxes (Details Narrative) Sheet http://globestar.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://globestar.com/role/IncomeTaxesTables 34 false false R35.htm 00000035 - Disclosure - Subsequent Events (Details Narrative) Sheet http://globestar.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://globestar.com/role/SubsequentEvents 35 false false All Reports Book All Reports form_10-k.htm gstc-20230930.xsd gstc-20230930_cal.xml gstc-20230930_def.xml gstc-20230930_lab.xml gstc-20230930_pre.xml fruci_logo.jpg fruci_signature.jpg mkcpas_logo.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 57 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form_10-k.htm": { "nsprefix": "gstc", "nsuri": "http://globestar.com/20230930", "dts": { "inline": { "local": [ "form_10-k.htm" ] }, "schema": { "local": [ "gstc-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "gstc-20230930_cal.xml" ] }, "definitionLink": { "local": [ "gstc-20230930_def.xml" ] }, "labelLink": { "local": [ "gstc-20230930_lab.xml" ] }, "presentationLink": { "local": [ "gstc-20230930_pre.xml" ] } }, "keyStandard": 208, "keyCustom": 59, "axisStandard": 14, "axisCustom": 0, "memberStandard": 28, "memberCustom": 18, "hidden": { "total": 150, "http://fasb.org/us-gaap/2023": 95, "http://globestar.com/20230930": 49, "http://xbrl.sec.gov/dei/2023": 6 }, "contextCount": 152, "entityCount": 1, "segmentCount": 48, "elementCount": 408, "unitCount": 4, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 35, "http://fasb.org/us-gaap/2023": 538 }, "report": { "R1": { "role": "http://globestar.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R2": { "role": "http://globestar.com/role/ConsolidatedBalanceSheets", "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2022-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R3": { "role": "http://globestar.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2022-09-30", "name": "gstc:PreferredStockLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "unique": true } }, "R4": { "role": "http://globestar.com/role/ConsolidatedStatementsOfOperations", "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R5": { "role": "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit", "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2021-09-30_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2021-09-30_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R6": { "role": "http://globestar.com/role/ConsolidatedStatementsOfCashFlows", "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "unique": true } }, "R7": { "role": "http://globestar.com/role/GeneralOrganizationAndBusiness", "longName": "00000007 - Disclosure - General Organization and Business", "shortName": "General Organization and Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R8": { "role": "http://globestar.com/role/SummaryOfSignificantAccountingPolicies", "longName": "00000008 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R9": { "role": "http://globestar.com/role/GoingConcern", "longName": "00000009 - Disclosure - Going Concern", "shortName": "Going Concern", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R10": { "role": "http://globestar.com/role/RelatedPartyTransactions", "longName": "00000010 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R11": { "role": "http://globestar.com/role/ConvertibleNotesPayableAndAdvances", "longName": "00000011 - Disclosure - Convertible Notes Payable and Advances", "shortName": "Convertible Notes Payable and Advances", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R12": { "role": "http://globestar.com/role/StockholdersDeficit", "longName": "00000012 - Disclosure - Stockholders\u2019 deficit", "shortName": "Stockholders\u2019 deficit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R13": { "role": "http://globestar.com/role/SeriesGPreferredStock", "longName": "00000013 - Disclosure - Series G Preferred Stock", "shortName": "Series G Preferred Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "gstc:SeriesGPreferredStockDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "gstc:SeriesGPreferredStockDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R14": { "role": "http://globestar.com/role/CommitmentsAndContingentLiabilities", "longName": "00000014 - Disclosure - Commitments and Contingent Liabilities", "shortName": "Commitments and Contingent Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R15": { "role": "http://globestar.com/role/LicenseAgreement", "longName": "00000015 - Disclosure - License Agreement", "shortName": "License Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "gstc:LicenseAgreementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "gstc:LicenseAgreementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R16": { "role": "http://globestar.com/role/IncomeTaxes", "longName": "00000016 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R17": { "role": "http://globestar.com/role/SubsequentEvents", "longName": "00000017 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R18": { "role": "http://globestar.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "00000018 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "18", "firstAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R19": { "role": "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesTables", "longName": "00000019 - Disclosure - Convertible Notes Payable and Advances (Tables)", "shortName": "Convertible Notes Payable and Advances (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R20": { "role": "http://globestar.com/role/StockholdersDeficitTables", "longName": "00000020 - Disclosure - Stockholders\u2019 deficit (Tables)", "shortName": "Stockholders\u2019 deficit (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "gstc:ScheduleOfShareBasedCompensationStockWarrantsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "gstc:ScheduleOfShareBasedCompensationStockWarrantsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R21": { "role": "http://globestar.com/role/IncomeTaxesTables", "longName": "00000021 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R22": { "role": "http://globestar.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "00000022 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:MarketingAndAdvertisingExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:AdvertisingCostsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:MarketingAndAdvertisingExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:AdvertisingCostsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R23": { "role": "http://globestar.com/role/GoingConcernDetailsNarrative", "longName": "00000023 - Disclosure - Going Concern (Details Narrative)", "shortName": "Going Concern (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "gstc:WorkingCapital", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "unique": true } }, "R24": { "role": "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "00000024 - Disclosure - Related Party Transactions (Details Narrative)", "shortName": "Related Party Transactions (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:IncreaseDecreaseInDueToOtherRelatedPartiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "unique": true } }, "R25": { "role": "http://globestar.com/role/ConvertibleNotesPayableConsistedOfFollowingAtSeptember302023And2022Details", "longName": "00000025 - Disclosure - Convertible notes payable consisted of the following at September 30, 2023 and 2022: (Details)", "shortName": "Convertible notes payable consisted of the following at September 30, 2023 and 2022: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:ConvertibleDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:ConvertibleDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R26": { "role": "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative", "longName": "00000026 - Disclosure - Convertible Notes Payable and Advances (Details Narrative)", "shortName": "Convertible Notes Payable and Advances (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "From2022-02-012022-02-28", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-022023-07-03", "name": "us-gaap:ConversionOfStockDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "unique": true } }, "R27": { "role": "http://globestar.com/role/FollowingTableSummarizesStockWarrantActivityForYearsEndedSeptember302023And2022Details", "longName": "00000027 - Disclosure - The following table summarizes the stock warrant activity for the years ended September 30, 2023 and 2022: (Details)", "shortName": "The following table summarizes the stock warrant activity for the years ended September 30, 2023 and 2022: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "AsOf2022-09-30", "name": "gstc:ShareBasedCompensationArrangementWarrantOutstandingNumberOne", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "gstc:ScheduleOfShareBasedCompensationStockWarrantsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-09-30", "name": "gstc:ShareBasedCompensationArrangementWarrantOutstandingNumberOne", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "gstc:ScheduleOfShareBasedCompensationStockWarrantsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "unique": true } }, "R28": { "role": "http://globestar.com/role/FollowingTableSummarizesStockOptionActivityForYearsEndedSeptember302023And2022Details", "longName": "00000028 - Disclosure - The following table summarizes the stock option activity for the years ended September 30, 2023 and 2022: (Details)", "shortName": "The following table summarizes the stock option activity for the years ended September 30, 2023 and 2022: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "AsOf2022-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "unique": true } }, "R29": { "role": "http://globestar.com/role/StockholdersDeficitDetailsNarrative", "longName": "00000029 - Disclosure - Stockholders\u2019 deficit (Details Narrative)", "shortName": "Stockholders\u2019 deficit (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "AsOf2022-09-30", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-04-032023-04-06", "name": "us-gaap:GainLossOnFairValueHedgeIneffectivenessNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "unique": true } }, "R30": { "role": "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative", "longName": "00000030 - Disclosure - Series G Preferred Stock (Details Narrative)", "shortName": "Series G Preferred Stock (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "gstc:NetCashProceeds", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "gstc:SeriesGPreferredStockDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "gstc:NetCashProceeds", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "gstc:SeriesGPreferredStockDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R31": { "role": "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "longName": "00000031 - Disclosure - Commitments and Contingent Liabilities (Details Narrative)", "shortName": "Commitments and Contingent Liabilities (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "From2022-02-012022-02-28", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-02-012022-02-28", "name": "us-gaap:OtherCommitmentsDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "unique": true } }, "R32": { "role": "http://globestar.com/role/LicenseAgreementDetailsNarrative", "longName": "00000032 - Disclosure - License Agreement (Details Narrative)", "shortName": "License Agreement (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "From2022-02-012022-02-28", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2020-08-222020-08-23", "name": "gstc:DescriptionOfMilestones", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "gstc:LicenseAgreementDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "unique": true } }, "R33": { "role": "http://globestar.com/role/ScheduleOfProvisionForIncomeTaxesDetails", "longName": "00000033 - Disclosure - Schedule of provision for income taxes (Details)", "shortName": "Schedule of provision for income taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-10-01to2023-09-30", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R34": { "role": "http://globestar.com/role/IncomeTaxesDetailsNarrative", "longName": "00000034 - Disclosure - Income Taxes (Details Narrative)", "shortName": "Income Taxes (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true, "unique": true } }, "R35": { "role": "http://globestar.com/role/SubsequentEventsDetailsNarrative", "longName": "00000035 - Disclosure - Subsequent Events (Details Narrative)", "shortName": "Subsequent Events (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-10-012023-09-30_us-gaap_ConvertibleNotesPayableMember", "name": "us-gaap:ConversionOfStockAmountConverted1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "form_10-k.htm", "unique": true } } }, "tag": { "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense", "crdr": "credit", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrecognized expenses related to options", "documentation": "Value of stock issued as a result of the exercise of stock options, after deduction of related income tax (expense) benefit." } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://globestar.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r6", "r10" ] }, "us-gaap_ConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayable", "crdr": "credit", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative", "http://globestar.com/role/ConvertibleNotesPayableConsistedOfFollowingAtSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Total convertible notes payable", "verboseLabel": "Principal amount", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r11", "r115", "r656" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r95", "r96", "r97" ] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r102", "r260", "r261", "r271", "r272", "r273", "r277", "r278", "r279", "r280", "r281", "r559", "r560", "r561", "r562", "r563" ] }, "us-gaap_ConvertibleNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayableCurrent", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current portion of convertible notes payable", "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r17", "r157", "r227", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r348", "r349", "r350", "r361", "r478", "r555", "r579", "r632", "r646", "r647" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOW FROM OPERATING ACTIVITIES:" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r593" ] }, "gstc_CashProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "CashProceeds", "crdr": "debit", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash proceeds", "documentation": "The element represents cash proceeds." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r591", "r593", "r594", "r596" ] }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible preferred stock shares", "documentation": "Number of shares issued for each share of convertible preferred stock that is converted." } } }, "auth_ref": [ "r12", "r49", "r78", "r106", "r298" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r597" ] }, "gstc_DescriptionIndefiniteLivedLicenseAgreements": { "xbrltype": "stringItemType", "nsuri": "http://globestar.com/20230930", "localname": "DescriptionIndefiniteLivedLicenseAgreements", "presentation": [ "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Royalty on any sales under the agreement", "documentation": "The element represents description indefinite lived license agreements." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r593" ] }, "us-gaap_PreferredStockConversionBasis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockConversionBasis", "presentation": [ "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, conversion basis", "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted." } } }, "auth_ref": [ "r49", "r78" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r582" ] }, "gstc_ShareBasedCompensationArrangementWarrantOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://globestar.com/20230930", "localname": "ShareBasedCompensationArrangementWarrantOutstandingWeightedAverageExercisePrice", "presentation": [ "http://globestar.com/role/FollowingTableSummarizesStockWarrantActivityForYearsEndedSeptember302023And2022Details", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "periodStartLabel": "Warrants outstanding, beginning (in per shares)", "periodEndLabel": "Warrants outstanding, ending (in per shares)", "label": "Amended the exercise price", "documentation": "The element represents share based compensation arrangement warrant outstanding weighted average exercise price." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r580" ] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PatentsMember", "presentation": [ "http://globestar.com/role/LicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r111" ] }, "gstc_ShareBasedCompensationArrangementWarrantExercisedWeightedAverageTwoExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://globestar.com/20230930", "localname": "ShareBasedCompensationArrangementWarrantExercisedWeightedAverageTwoExercisePrice", "presentation": [ "http://globestar.com/role/FollowingTableSummarizesStockWarrantActivityForYearsEndedSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Granted (in per shares)", "documentation": "The element represents share based compensation arrangement warrant exercised weighted average two exercise price." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid during the period for:" } } }, "auth_ref": [] }, "gstc_PreferredStockSharesDesignated": { "xbrltype": "sharesItemType", "nsuri": "http://globestar.com/20230930", "localname": "PreferredStockSharesDesignated", "presentation": [ "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock shares designated", "verboseLabel": "Preferred stock, shares designated", "documentation": "The element represents preferred stock shares designated." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r84", "r116", "r435", "r567", "r617", "r627", "r643" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrivatePlacementMember", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://globestar.com/role/StockholdersDeficitTables" ], "lang": { "en-us": { "role": { "label": "The following table summarizes the stock option activity for the years ended September 30, 2023 and 2022:", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r8", "r9", "r55" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "auth_ref": [] }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeBenefitsAndShareBasedCompensation", "crdr": "debit", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock based compensation related to repricing", "documentation": "Amount of expense for employee benefit and equity-based compensation." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": [ "http://globestar.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": [ "r42", "r549" ] }, "gstc_ShareBasedCompensationArrangementWarrantGrantedNumberone": { "xbrltype": "sharesItemType", "nsuri": "http://globestar.com/20230930", "localname": "ShareBasedCompensationArrangementWarrantGrantedNumberone", "presentation": [ "http://globestar.com/role/FollowingTableSummarizesStockWarrantActivityForYearsEndedSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Granted", "documentation": "The element represents share based compensation arrangement warrant granted numberone." } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r284", "r301", "r357", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r437", "r558", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r623", "r624", "r625", "r626" ] }, "gstc_ShareBasedCompensationArrangementWarrantOutstandingNumberOne": { "xbrltype": "sharesItemType", "nsuri": "http://globestar.com/20230930", "localname": "ShareBasedCompensationArrangementWarrantOutstandingNumberOne", "presentation": [ "http://globestar.com/role/FollowingTableSummarizesStockWarrantActivityForYearsEndedSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "periodStartLabel": "Warrants outstanding, beginning", "periodEndLabel": "Warrants outstanding, ending", "documentation": "The element represents share based compensation arrangement warrant outstanding number one.", "label": "Share Based Compensation Arrangement Warrant Outstanding Number One" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Grant stock price, per share", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value of warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r0", "r5" ] }, "gstc_StockPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://globestar.com/20230930", "localname": "StockPayableMember", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Payable [Member]", "documentation": "The element represents stock payable member." } } }, "auth_ref": [] }, "gstc_July2023SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://globestar.com/20230930", "localname": "July2023SecuritiesPurchaseAgreementMember", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "July 2023 Securities Purchase Agreement [Member]", "documentation": "The element represents july 2023 securities purchase agreement member." } } }, "auth_ref": [] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from convertible notes payable", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r28" ] }, "gstc_ConvertibleDebtOneMember": { "xbrltype": "domainItemType", "nsuri": "http://globestar.com/20230930", "localname": "ConvertibleDebtOneMember", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Debt One [Member]", "documentation": "The element represents convertible debt one member." } } }, "auth_ref": [] }, "gstc_May2023SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://globestar.com/20230930", "localname": "May2023SecuritiesPurchaseAgreementMember", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "May 2023 Securities Purchase Agreement [Member]", "documentation": "The element represents may 2023 securities purchase agreement member." } } }, "auth_ref": [] }, "gstc_ConvertibleNoteDateMay102023Member": { "xbrltype": "domainItemType", "nsuri": "http://globestar.com/20230930", "localname": "ConvertibleNoteDateMay102023Member", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableConsistedOfFollowingAtSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Convertible Note Date May 10 2023 [Member]", "documentation": "The element represents convertible note date may 102 023 member." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r594" ] }, "gstc_MrKatzaroffMember": { "xbrltype": "domainItemType", "nsuri": "http://globestar.com/20230930", "localname": "MrKatzaroffMember", "presentation": [ "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Mr Katzaroff [Member]", "documentation": "The element represents mr katzaroff member." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r594" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r582" ] }, "gstc_ConvertibleNoteDateJuly32023Member": { "xbrltype": "domainItemType", "nsuri": "http://globestar.com/20230930", "localname": "ConvertibleNoteDateJuly32023Member", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableConsistedOfFollowingAtSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Convertible Note Date July 3, 2023 [Member]", "documentation": "The element represents convertible note date july 3 2023 member." } } }, "auth_ref": [] }, "gstc_RobertChicoskiMember": { "xbrltype": "domainItemType", "nsuri": "http://globestar.com/20230930", "localname": "RobertChicoskiMember", "presentation": [ "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Robert Chicoski [Member]", "documentation": "The element represents robert chicoski member." } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets", "http://globestar.com/role/ConsolidatedBalanceSheetsParenthetical", "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit", "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r160", "r161", "r162", "r177", "r413", "r445", "r468", "r471", "r473", "r474", "r475", "r476", "r477", "r480", "r483", "r484", "r485", "r486", "r487", "r489", "r490", "r491", "r492", "r494", "r495", "r496", "r497", "r498", "r500", "r503", "r504", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r525", "r572" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r593" ] }, "gstc_InterestRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "InterestRecognized", "crdr": "credit", "presentation": [ "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest recognized", "documentation": "The element represents interest recognized." } } }, "auth_ref": [] }, "gstc_ConvertibleNoteDateApril132017Member": { "xbrltype": "domainItemType", "nsuri": "http://globestar.com/20230930", "localname": "ConvertibleNoteDateApril132017Member", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableConsistedOfFollowingAtSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Convertible Note Date April 13 2017 [Member]", "documentation": "The element represents convertible note date member." } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of share sold", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative", "http://globestar.com/role/LicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r346" ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableAndAdvances" ], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable and Advances", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r101", "r155", "r259", "r265", "r266", "r267", "r268", "r269", "r270", "r275", "r282", "r283", "r285" ] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative", "http://globestar.com/role/ConvertibleNotesPayableConsistedOfFollowingAtSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Schedule of Short-Term Debt [Table]", "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtLineItems", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative", "http://globestar.com/role/ConvertibleNotesPayableConsistedOfFollowingAtSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://globestar.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r379", "r381" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://globestar.com/role/LicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r346" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "gstc_ConversionOfStockDescriptionOther": { "xbrltype": "stringItemType", "nsuri": "http://globestar.com/20230930", "localname": "ConversionOfStockDescriptionOther", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Other description", "documentation": "The element represents conversion of stock description other." } } }, "auth_ref": [] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, value", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r78", "r432", "r567" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheetsParenthetical", "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, issued", "verboseLabel": "Preferred stock, shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r78", "r288" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://globestar.com/role/LicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r240", "r241", "r242", "r243", "r414", "r415" ] }, "us-gaap_AccruedLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesMember", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities [Member]", "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered." } } }, "auth_ref": [ "r18" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://globestar.com/role/LicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r346" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://globestar.com/role/LicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r40", "r41" ] }, "gstc_DescriptionOfMilestones": { "xbrltype": "stringItemType", "nsuri": "http://globestar.com/20230930", "localname": "DescriptionOfMilestones", "presentation": [ "http://globestar.com/role/LicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Description of milestone", "documentation": "The element represents description of milestones." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheetsParenthetical", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "verboseLabel": "Preferred stock authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r78", "r480" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheetsParenthetical", "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r78", "r480", "r499", "r664", "r665" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://globestar.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r368", "r380" ] }, "us-gaap_PreferredStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockVotingRights", "presentation": [ "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Description of voting rights", "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": [ "r49", "r78" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Advances payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r72", "r655" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://globestar.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest expense to a note payable", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r66", "r118", "r147", "r183", "r369", "r510", "r577", "r661" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Noncash investing and financing transactions:" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued liabilities", "label": "Accounts Payable and Accrued Liabilities", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations." } } }, "auth_ref": [ "r71" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of discount on convertible note payable", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r281", "r370", "r562", "r563", "r614" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "OTHER INCOME (EXPENSE)" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheetsParenthetical", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r78", "r288" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r45", "r46", "r47", "r49", "r50", "r51", "r53", "r105", "r107", "r108", "r136", "r137", "r138", "r178", "r288", "r289", "r290", "r292", "r295", "r301", "r303", "r447", "r448", "r449", "r450", "r564", "r601", "r615" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r136", "r137", "r138", "r178", "r288", "r289", "r290", "r292", "r295", "r301", "r303", "r447", "r448", "r449", "r450", "r564", "r601", "r615" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan", "crdr": "credit", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://globestar.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r98", "r154" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative", "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of shares", "verboseLabel": "Conversion of stock shares converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r34", "r35", "r36" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total other expenses", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r93" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Benefit Plan", "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan." } } }, "auth_ref": [] }, "us-gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockDividendRatePercentage", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock dividend rate", "documentation": "The percentage rate used to calculate dividend payments on preferred stock." } } }, "auth_ref": [ "r289", "r534", "r536", "r537", "r541" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountNoncurrent", "crdr": "debit", "presentation": [ "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unamortized discount", "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r64", "r67" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "documentation": "Information by form of arrangement related to research and development." } } }, "auth_ref": [ "r327", "r639" ] }, "us-gaap_ConversionOfStockAmountConverted1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockAmountConverted1", "crdr": "debit", "presentation": [ "http://globestar.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of all of principal", "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r34", "r35", "r36" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": [ "r327", "r639" ] }, "gstc_DescriptionOfMilestones2": { "xbrltype": "stringItemType", "nsuri": "http://globestar.com/20230930", "localname": "DescriptionOfMilestones2", "presentation": [ "http://globestar.com/role/LicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Description of milestone two", "documentation": "The element represents description of milestones2." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "periodStartLabel": "Shares, Outstanding, Beginning Balance", "periodEndLabel": "Shares, Outstanding, Ending Balance", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationBargainPurchaseGainRecognizedDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationBargainPurchaseGainRecognizedDescription", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Description of purchase agreement", "documentation": "In a business combination in which the amount of net identifiable assets acquired and liabilities assumed exceeds the aggregate consideration transferred or to be transferred (as defined), this element represents a description of the reasons why the transaction resulted in a gain." } } }, "auth_ref": [ "r57", "r58", "r59", "r60", "r61", "r62" ] }, "us-gaap_ConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebt", "crdr": "credit", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableConsistedOfFollowingAtSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Total current convertible notes payable, net of discount", "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company." } } }, "auth_ref": [ "r11", "r115", "r656" ] }, "us-gaap_PreferredStockDividendsShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockDividendsShares", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock dividends", "documentation": "Number of shares of preferred stock issued as dividends during the period. Excludes stock splits." } } }, "auth_ref": [ "r7" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative", "http://globestar.com/role/ConvertibleNotesPayableConsistedOfFollowingAtSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest", "label": "Interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r20", "r261" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r19", "r133", "r157", "r227", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r348", "r349", "r350", "r361", "r567", "r632", "r646", "r647" ] }, "srt_BoardOfDirectorsChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "BoardOfDirectorsChairmanMember", "presentation": [ "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Board of Directors Chairman [Member]" } } }, "auth_ref": [ "r622" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Recognized of discount", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r66", "r271", "r286", "r560", "r561" ] }, "us-gaap_LicenseAgreementTermsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LicenseAgreementTermsMember", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "License Agreement Terms [Member]", "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current Liabilities" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r18" ] }, "us-gaap_InterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestReceivable", "crdr": "debit", "presentation": [ "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued interest", "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable." } } }, "auth_ref": [ "r613", "r666" ] }, "srt_ChiefFinancialOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefFinancialOfficerMember", "presentation": [ "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]" } } }, "auth_ref": [ "r622" ] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "DirectorMember", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "auth_ref": [ "r622", "r659" ] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://globestar.com/role/GoingConcern" ], "lang": { "en-us": { "role": { "label": "Going Concern", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r75" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_AccruedSalariesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedSalariesCurrent", "crdr": "credit", "presentation": [ "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Compensation", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r18", "r554" ] }, "us-gaap_ProceedsFromRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRelatedPartyDebt", "crdr": "debit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from related party advances", "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates." } } }, "auth_ref": [ "r28" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "auth_ref": [ "r622" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableConsistedOfFollowingAtSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r22", "r159", "r260", "r261", "r262", "r263", "r264", "r266", "r271", "r272", "r273", "r274", "r276", "r277", "r278", "r279", "r280", "r281", "r371", "r559", "r560", "r561", "r562", "r563", "r616" ] }, "gstc_NetCashProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "NetCashProceeds", "crdr": "credit", "presentation": [ "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net cash proceeds", "documentation": "The element represents net cash proceeds." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r4" ] }, "us-gaap_LossOnFairValueHedgeIneffectiveness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossOnFairValueHedgeIneffectiveness", "crdr": "debit", "presentation": [ "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Recognized loss", "documentation": "Amount of recognized loss from the hedging ineffectiveness of a fair value hedge." } } }, "auth_ref": [ "r112" ] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative", "http://globestar.com/role/ConvertibleNotesPayableConsistedOfFollowingAtSeptember302023And2022Details", "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Unamortized discount", "label": "Debt discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r64", "r67", "r635" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://globestar.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r31", "r134", "r552" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://globestar.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r32" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://globestar.com/role/GeneralOrganizationAndBusiness" ], "lang": { "en-us": { "role": { "label": "General Organization and Business", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r121", "r128" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r307", "r310", "r319", "r320", "r321", "r388", "r412", "r439", "r469", "r470", "r533", "r535", "r538", "r539", "r540", "r550", "r551", "r557", "r564", "r565", "r568", "r571", "r628", "r634", "r649", "r650", "r651", "r652", "r653" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://globestar.com/role/FollowingTableSummarizesStockOptionActivityForYearsEndedSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "negatedLabel": "Expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r316" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://globestar.com/role/FollowingTableSummarizesStockOptionActivityForYearsEndedSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r315" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://globestar.com/role/FollowingTableSummarizesStockWarrantActivityForYearsEndedSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Expired", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r638" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableConsistedOfFollowingAtSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r11", "r76", "r77", "r114", "r115", "r159", "r260", "r261", "r262", "r263", "r264", "r266", "r271", "r272", "r273", "r274", "r276", "r277", "r278", "r279", "r280", "r281", "r371", "r559", "r560", "r561", "r562", "r563", "r616" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r310", "r412", "r439", "r469", "r470", "r533", "r535", "r538", "r539", "r540", "r550", "r551", "r557", "r564", "r565", "r568", "r634", "r648", "r649", "r650", "r651", "r652", "r653" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "auth_ref": [ "r246", "r247", "r248", "r249", "r307", "r310", "r319", "r320", "r321", "r388", "r412", "r439", "r469", "r470", "r533", "r535", "r538", "r539", "r540", "r550", "r551", "r557", "r564", "r565", "r568", "r571", "r628", "r634", "r649", "r650", "r651", "r652", "r653" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value", "verboseLabel": "Aggregate intrinsic value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r54" ] }, "srt_OfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OfficerMember", "presentation": [ "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Officer [Member]" } } }, "auth_ref": [ "r196", "r659" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://globestar.com/role/FollowingTableSummarizesStockOptionActivityForYearsEndedSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "periodStartLabel": "Option outstanding, beginning", "periodEndLabel": "Option outstanding, ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r311", "r312" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://globestar.com/role/FollowingTableSummarizesStockOptionActivityForYearsEndedSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "periodStartLabel": "Option outstanding, beginning (in per shares)", "periodEndLabel": "Option outstanding, ending (in per shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r311", "r312" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r310", "r412", "r439", "r469", "r470", "r533", "r535", "r538", "r539", "r540", "r550", "r551", "r557", "r564", "r565", "r568", "r634", "r648", "r649", "r650", "r651", "r652", "r653" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://globestar.com/role/ConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows", "http://globestar.com/role/ConsolidatedStatementsOfOperations", "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit", "http://globestar.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "negatedLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r85", "r97", "r117", "r131", "r141", "r142", "r146", "r157", "r163", "r165", "r166", "r167", "r168", "r170", "r171", "r174", "r180", "r186", "r190", "r192", "r227", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r360", "r361", "r436", "r501", "r523", "r524", "r556", "r577", "r632" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r320" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://globestar.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash equivalents", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r609", "r657" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 DEFICIT" } } }, "auth_ref": [] }, "gstc_OptiongGrantsValue": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "OptiongGrantsValue", "crdr": "debit", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value of option grants", "documentation": "The element represents optiong grants value." } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit (loss)", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r87", "r157", "r180", "r186", "r190", "r192", "r227", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r361", "r556", "r632" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://globestar.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r139", "r238", "r239", "r553" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets", "http://globestar.com/role/ConsolidatedBalanceSheetsParenthetical", "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit", "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r160", "r161", "r162", "r177", "r413", "r445", "r468", "r471", "r473", "r474", "r475", "r476", "r477", "r480", "r483", "r484", "r485", "r486", "r487", "r489", "r490", "r491", "r492", "r494", "r495", "r496", "r497", "r498", "r500", "r503", "r504", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r525", "r572" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r599" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r590" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r598" ] }, "us-gaap_OtherCommitmentsDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsDescription", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Description of commitment", "documentation": "Description of the nature and terms of commitment." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expected remaining life", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r109" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expected term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r318" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r149", "r151", "r152" ] }, "us-gaap_AccountsPayableAndOtherAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndOtherAccruedLiabilities", "crdr": "credit", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued liabilities", "label": "Accounts Payable and Other Accrued Liabilities", "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other." } } }, "auth_ref": [ "r472" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r582" ] }, "us-gaap_SeriesEPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesEPreferredStockMember", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets", "http://globestar.com/role/ConsolidatedBalanceSheetsParenthetical", "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series E Preferred Stock [Member]", "documentation": "Series E preferred stock." } } }, "auth_ref": [ "r611", "r612", "r637" ] }, "us-gaap_SeriesCPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesCPreferredStockMember", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets", "http://globestar.com/role/ConsolidatedBalanceSheetsParenthetical", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series C Preferred Stock [Member]", "documentation": "Series C preferred stock." } } }, "auth_ref": [ "r611", "r612", "r637" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise price, per shares", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r304" ] }, "us-gaap_SeriesDPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesDPreferredStockMember", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets", "http://globestar.com/role/ConsolidatedBalanceSheetsParenthetical", "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series D Preferred Stock [Member]", "documentation": "Series D preferred stock." } } }, "auth_ref": [ "r611", "r612", "r637" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r582" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SettlementLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SettlementLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Settlement of liabilities", "documentation": "Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers." } } }, "auth_ref": [] }, "us-gaap_SeriesGPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesGPreferredStockMember", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheetsParenthetical", "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series G Preferred Stock [Member]", "documentation": "Series G preferred stock." } } }, "auth_ref": [ "r611", "r612", "r637" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://globestar.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recently Issued Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesBPreferredStockMember", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets", "http://globestar.com/role/ConsolidatedBalanceSheetsParenthetical", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } }, "auth_ref": [ "r611", "r612", "r637" ] }, "us-gaap_SeriesFPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesFPreferredStockMember", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets", "http://globestar.com/role/ConsolidatedBalanceSheetsParenthetical", "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series F Preferred Stock [Member]", "documentation": "Series F preferred stock." } } }, "auth_ref": [ "r611", "r612", "r637" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r582" ] }, "us-gaap_OtherNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNotesPayableCurrent", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Note payable", "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r18" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets", "http://globestar.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r81", "r108", "r434", "r443", "r444", "r451", "r481", "r567" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r582" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r600" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets", "http://globestar.com/role/ConsolidatedBalanceSheetsParenthetical", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": [ "r611", "r612", "r637" ] }, "gstc_ExercisePrice1": { "xbrltype": "perShareItemType", "nsuri": "http://globestar.com/20230930", "localname": "ExercisePrice1", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise price", "documentation": "The element represents exercise price 1." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r284", "r301", "r357", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r437", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r623", "r624", "r625", "r626" ] }, "us-gaap_CommonStockSharesAuthorizedUnlimited": { "xbrltype": "authorizedUnlimitedItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorizedUnlimited", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is \"Unlimited\"." } } }, "auth_ref": [ "r25" ] }, "us-gaap_RoyaltyArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RoyaltyArrangementMember", "presentation": [ "http://globestar.com/role/LicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Royalty Arrangement [Member]", "documentation": "Category of deferred revenue by arrangement wherein certain rights are granted to exploit one or more products, under which royalties received are taken into income as revenue recognition criteria are met." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r593" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://globestar.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating loss carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r56" ] }, "us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDueToOtherRelatedPartiesCurrent", "crdr": "debit", "presentation": [ "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Related party advances", "label": "Increase (Decrease) in Due to Other Related Parties, Current", "documentation": "Amount of increase (decrease) in related party payables classified as other, due within one year or operating cycle, if longer." } } }, "auth_ref": [ "r4" ] }, "us-gaap_RoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RoyaltyExpense", "crdr": "debit", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Royalty expense", "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property." } } }, "auth_ref": [ "r89" ] }, "gstc_LossOnConversionOfPreferredStockLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "LossOnConversionOfPreferredStockLiability", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "http://globestar.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows", "http://globestar.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Loss on conversion of preferred stock liability", "negatedLabel": "Loss on conversion of preferred stock liability", "documentation": "The element represents loss on conversion of preferred stock liability." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Volatility rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r319" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "gstc_EarningsPerSharesBasicAndDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://globestar.com/20230930", "localname": "EarningsPerSharesBasicAndDiluted", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per share available to common shareholders", "documentation": "The element represents earnings per shares basic and diluted." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r322", "r323", "r324", "r456", "r618", "r619", "r620", "r641", "r664" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Risk free rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r321" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r317" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://globestar.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r113", "r135", "r157", "r180", "r187", "r191", "r227", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r347", "r349", "r361", "r429", "r493", "r567", "r579", "r632", "r633", "r646" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfOperations", "http://globestar.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "REVENUE", "verboseLabel": "Revenue", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r148", "r157", "r181", "r182", "r185", "r188", "r189", "r193", "r194", "r195", "r227", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r361", "r428", "r632" ] }, "us-gaap_FormerGainContingencyRecognizedInCurrentPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FormerGainContingencyRecognizedInCurrentPeriod", "crdr": "credit", "presentation": [ "http://globestar.com/role/LicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Recognized gain", "label": "Former Gain Contingency, Recognized in Current Period", "documentation": "Amount of gain recognized in the period that had been disclosed in prior periods as a contingent gain." } } }, "auth_ref": [ "r631" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r4" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "LOSS FROM OPERATIONS", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r180", "r186", "r190", "r192", "r556" ] }, "gstc_CommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://globestar.com/20230930", "localname": "CommonStockWarrantsMember", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock Warrants [Member]", "documentation": "The element represents common stock warrants member." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "gstc_AdvanceMember": { "xbrltype": "domainItemType", "nsuri": "http://globestar.com/20230930", "localname": "AdvanceMember", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Advance [Member]", "documentation": "The element represents advance member." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r24", "r73", "r430", "r479" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit", "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r7", "r27", "r130", "r144", "r145", "r146", "r160", "r161", "r162", "r164", "r169", "r171", "r177", "r228", "r229", "r305", "r322", "r323", "r324", "r339", "r340", "r351", "r352", "r353", "r354", "r355", "r356", "r359", "r362", "r363", "r364", "r365", "r366", "r367", "r372", "r440", "r441", "r442", "r456", "r525" ] }, "gstc_ExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://globestar.com/20230930", "localname": "ExercisePrice", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise price to purchase common stock", "documentation": "The element represents exercise price." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r130", "r160", "r161", "r162", "r164", "r169", "r171", "r228", "r229", "r322", "r323", "r324", "r339", "r340", "r351", "r353", "r354", "r356", "r359", "r440", "r442", "r456", "r664" ] }, "gstc_SpivakManagementIncMember": { "xbrltype": "domainItemType", "nsuri": "http://globestar.com/20230930", "localname": "SpivakManagementIncMember", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Spivak Management Inc [Member]", "documentation": "The element represents spivak management inc member." } } }, "auth_ref": [] }, "gstc_MrPenderghastMember": { "xbrltype": "domainItemType", "nsuri": "http://globestar.com/20230930", "localname": "MrPenderghastMember", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Mr Penderghast [Member]" } } }, "auth_ref": [] }, "gstc_AdditionalShareToBeIssued": { "xbrltype": "sharesItemType", "nsuri": "http://globestar.com/20230930", "localname": "AdditionalShareToBeIssued", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Additional share to be issued", "documentation": "The element represents additional share to be issued." } } }, "auth_ref": [] }, "gstc_MrFarleyMember": { "xbrltype": "domainItemType", "nsuri": "http://globestar.com/20230930", "localname": "MrFarleyMember", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Mr Farley [Member]", "documentation": "The element represents mr farley member." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit", "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r7", "r130", "r144", "r145", "r146", "r160", "r161", "r162", "r164", "r169", "r171", "r177", "r228", "r229", "r305", "r322", "r323", "r324", "r339", "r340", "r351", "r352", "r353", "r354", "r355", "r356", "r359", "r362", "r363", "r364", "r365", "r366", "r367", "r372", "r440", "r441", "r442", "r456", "r525" ] }, "gstc_ConsultantAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://globestar.com/20230930", "localname": "ConsultantAgreementMember", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consultant Agreement [Member]", "documentation": "The element represents consultant agreemen member." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares converted", "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r7", "r49", "r78", "r79", "r108" ] }, "gstc_MrSpivakMember": { "xbrltype": "domainItemType", "nsuri": "http://globestar.com/20230930", "localname": "MrSpivakMember", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Mr Spivak [Member]", "documentation": "The element represents Mr Spivak member." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r583" ] }, "us-gaap_IncreaseDecreaseInRoyaltiesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInRoyaltiesPayable", "crdr": "debit", "presentation": [ "http://globestar.com/role/LicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Royalties and late fess", "documentation": "The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction." } } }, "auth_ref": [ "r4" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "crdr": "credit", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Principal amount", "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r7", "r27", "r108" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r586" ] }, "gstc_LicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://globestar.com/20230930", "localname": "LicenseAgreementMember", "presentation": [ "http://globestar.com/role/LicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "License Agreement [Member]", "documentation": "The element represents license agreement member." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative", "http://globestar.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r14" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://globestar.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Advertising and Marketing Costs", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r122" ] }, "gstc_FabrizioDeSilvestriMember": { "xbrltype": "domainItemType", "nsuri": "http://globestar.com/20230930", "localname": "FabrizioDeSilvestriMember", "presentation": [ "http://globestar.com/role/LicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fabrizio De Silvestri [Member]", "documentation": "The element represents fabrizio de silvestri member." } } }, "auth_ref": [] }, "us-gaap_PreferredStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockLiquidationPreference", "presentation": [ "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock liquidation preference", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share." } } }, "auth_ref": [ "r49", "r50", "r78", "r615", "r636" ] }, "gstc_ShareBasedCompensationArrangementWarrantExpirationWeightedAverageTwoExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://globestar.com/20230930", "localname": "ShareBasedCompensationArrangementWarrantExpirationWeightedAverageTwoExercisePrice", "presentation": [ "http://globestar.com/role/FollowingTableSummarizesStockWarrantActivityForYearsEndedSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Expired (in per shares)", "documentation": "The element represents share based compensation arrangement warrant expiration weighted average two exercise price." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r582" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://globestar.com/role/FollowingTableSummarizesStockOptionActivityForYearsEndedSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted (in per shares)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r313" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r587" ] }, "gstc_RelatedPartyAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "RelatedPartyAdvances", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Related party advances", "documentation": "The element represents related party advances." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://globestar.com/role/FollowingTableSummarizesStockOptionActivityForYearsEndedSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Exercised (in per shares)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r314" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://globestar.com/role/FollowingTableSummarizesStockOptionActivityForYearsEndedSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "verboseLabel": "Expired (in per shares)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r316" ] }, "us-gaap_ConversionOfStockDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockDescription", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of stock description", "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r34", "r35", "r36" ] }, "gstc_CashReceiveOnSubscription": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "CashReceiveOnSubscription", "crdr": "debit", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash received", "documentation": "The element represents cash receive on subscription." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "crdr": "debit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows", "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued liabilities to related party", "verboseLabel": "Compensation", "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r4" ] }, "gstc_PreferredStockLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "PreferredStockLiability", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets", "http://globestar.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Series G Preferred Stock Liability, net of discount of $0 and $12,581, respectively", "verboseLabel": "Preferred stock liability", "documentation": "The element represents preferred stock liability." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://globestar.com/role/FollowingTableSummarizesStockOptionActivityForYearsEndedSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Forfeited (in per shares)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r315" ] }, "gstc_LossOnSettlementOfLabilitiesRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "LossOnSettlementOfLabilitiesRelatedParty", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Gain (loss) on settlement of liabilities, related party", "documentation": "The element represents loss on settlement of labilities related party." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative", "http://globestar.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r15" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r588" ] }, "gstc_StockPayableShares": { "xbrltype": "sharesItemType", "nsuri": "http://globestar.com/20230930", "localname": "StockPayableShares", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Stock payable, shares", "documentation": "The element represents stock payable shares." } } }, "auth_ref": [] }, "gstc_StockPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "StockPayable", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stock payable, consisting of 0 and 1,515,152 shares to be issued at September 30, 2023 and 2022, respectively", "documentation": "The element represents stock payable." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableConsistedOfFollowingAtSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Conversion price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r103", "r262" ] }, "gstc_WeightedAverageSharesOutstandingBasicAndDiluted": { "xbrltype": "sharesItemType", "nsuri": "http://globestar.com/20230930", "localname": "WeightedAverageSharesOutstandingBasicAndDiluted", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding - basic and diluted", "documentation": "The element represents weighted average shares outstanding basic and diluted." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit", "http://globestar.com/role/LicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Shares issue", "terseLabel": "Rights to issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r7", "r78", "r79", "r108", "r447", "r525", "r543" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://globestar.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Costs", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r325" ] }, "us-gaap_SignificantPurchaseCommitmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantPurchaseCommitmentDescription", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Purchase Commitment, Description", "documentation": "Excluding long-term commitments, description of arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers, which may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing (such as penalties) of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions." } } }, "auth_ref": [ "r24", "r73" ] }, "gstc_SettlementOfAccountsPayableWithRelatedPartyShares": { "xbrltype": "sharesItemType", "nsuri": "http://globestar.com/20230930", "localname": "SettlementOfAccountsPayableWithRelatedPartyShares", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Settlement of Accounts Payable with Related Party Shares", "documentation": "The element represents settlement of accounts payable with related party shares." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://globestar.com/role/ConsolidatedBalanceSheetsParenthetical", "http://globestar.com/role/LicenseAgreementDetailsNarrative", "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative", "http://globestar.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "verboseLabel": "Issuance of common stock", "terseLabel": "Common stock issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r79" ] }, "gstc_DescriptionOfMilestones4": { "xbrltype": "stringItemType", "nsuri": "http://globestar.com/20230930", "localname": "DescriptionOfMilestones4", "presentation": [ "http://globestar.com/role/LicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Description of milestone four", "documentation": "The element represents description of milestones4." } } }, "auth_ref": [] }, "gstc_StockIssuedDuringPeriodValueCommonStockIssuedForSettlementOfLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "StockIssuedDuringPeriodValueCommonStockIssuedForSettlementOfLiability", "crdr": "credit", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Common stock issued for settlement liability", "documentation": "The element represents stock issued during period value common stock issued for settlement of liability." } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://globestar.com/role/ConsolidatedBalanceSheets", "http://globestar.com/role/LicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.001 par value, unlimited shares authorized; 996,119,530 and 722,326,669 shares issued and outstanding at September 30, 2023 and 2022, respectively", "verboseLabel": "Common stock, value", "terseLabel": "Agreed to settle", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r79", "r433", "r567" ] }, "gstc_StockBasedCompensationRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "StockBasedCompensationRelatedParties", "crdr": "credit", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation, related parties", "documentation": "The element represents stock based compensation related parties." } } }, "auth_ref": [] }, "gstc_ConversionOfSeriesGPreferredStockToCommon": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "ConversionOfSeriesGPreferredStockToCommon", "crdr": "credit", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Conversion of Series G Preferred Stock to common", "documentation": "The element represents conversion of series g preferred stock to common." } } }, "auth_ref": [] }, "gstc_ConversionOfSeriesGPreferredStockToCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://globestar.com/20230930", "localname": "ConversionOfSeriesGPreferredStockToCommonShares", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Conversion of Series G Preferred Stock to Common Shares", "documentation": "The element represents conversion of series g preferred stock to common shares." } } }, "auth_ref": [] }, "gstc_ConversionOfSeriesDPreferredStockToCommon": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "ConversionOfSeriesDPreferredStockToCommon", "crdr": "credit", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Conversion of Series D Preferred Stock to common", "documentation": "The element represents conversion of series d preferred stock to common." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheetsParenthetical", "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r7", "r79", "r480", "r499", "r664", "r665" ] }, "gstc_ConversionOfSeriesDPreferredStockToCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://globestar.com/20230930", "localname": "ConversionOfSeriesDPreferredStockToCommonShares", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Conversion of Series D Preferred Stock to Common Shares", "documentation": "The element represents conversion of series d preferred stock to common shares." } } }, "auth_ref": [] }, "gstc_CommonStockIssuedForTheConversionOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "CommonStockIssuedForTheConversionOfDebt", "crdr": "debit", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Common stock issued for the conversion of debt", "documentation": "The element represents common stock issued for the conversion of debt." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "presentation": [ "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Amortization of debt discount", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r5", "r64", "r94", "r281" ] }, "gstc_CommonStockIssuedForTheConversionOfDebtShares": { "xbrltype": "sharesItemType", "nsuri": "http://globestar.com/20230930", "localname": "CommonStockIssuedForTheConversionOfDebtShares", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Common Stock Issued for The Conversion of Debt Shares", "documentation": "The element represents common stock issued for the conversion of debt shares." } } }, "auth_ref": [] }, "gstc_CommonStockIssuedForSettlementOfLiabilityRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "CommonStockIssuedForSettlementOfLiabilityRelatedParty", "crdr": "debit", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Common stock issued for settlement of liability, related party", "documentation": "The element represents common stock issued for settlement of liability related party." } } }, "auth_ref": [] }, "gstc_CommonStockIssuedForSettlementOfLiabilityRelatedPartyInShares": { "xbrltype": "sharesItemType", "nsuri": "http://globestar.com/20230930", "localname": "CommonStockIssuedForSettlementOfLiabilityRelatedPartyInShares", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Common Stock Issued for Settlement of Liability Related Party in Shares", "documentation": "The element represents common stock issued for settlement of liability related party in shares." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesSubscribedButUnissued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesSubscribedButUnissued", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares subscribe", "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds." } } }, "auth_ref": [ "r79" ] }, "gstc_StockCompensationRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "StockCompensationRelatedParties", "crdr": "debit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Stock compensation, related parties", "documentation": "The element represents stock compensation related parties." } } }, "auth_ref": [] }, "gstc_ConversionOfSeriesGPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "ConversionOfSeriesGPreferredStock", "crdr": "credit", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion of Series G preferred stock", "documentation": "The element represents conversion of series g preferred stock." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://globestar.com/role/FollowingTableSummarizesStockOptionActivityForYearsEndedSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r7", "r78", "r79", "r108", "r314" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "verboseLabel": "Stock issued during period, shares, conversion of convertible securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r7", "r26", "r49", "r108", "r276" ] }, "gstc_ProceedsFromSaleOfSharesettledSeriesGPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "ProceedsFromSaleOfSharesettledSeriesGPreferredStock", "crdr": "debit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale of share-settled Series G preferred stock", "documentation": "The element represents proceeds from sale of sharesettled series g preferred stock." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://globestar.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "gstc_ConversionOfSeriesDPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "ConversionOfSeriesDPreferredStock", "crdr": "credit", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion of Series D preferred stock", "documentation": "The element represents conversion of series d preferred stock." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "crdr": "credit", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Obligation benefits paid", "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services." } } }, "auth_ref": [ "r306", "r309" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r80", "r567", "r660" ] }, "gstc_ConversionOfSeriesFPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "ConversionOfSeriesFPreferredStock", "crdr": "credit", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion of Series F preferred stock", "documentation": "The element represents conversion of series f preferred stock." } } }, "auth_ref": [] }, "gstc_CommonStockIssuedForStockPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "CommonStockIssuedForStockPayable", "crdr": "debit", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock issued for stock payable", "documentation": "The element represents common stock issued for stock payable.", "label": "Common Stock Issued for Stock Payable" } } }, "auth_ref": [] }, "gstc_CommonStockIssuedForSettlementOfLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "CommonStockIssuedForSettlementOfLiabilities", "crdr": "debit", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Common stock issued for settlement of liabilities", "documentation": "The element represents common stock issued for settlement of liabilities." } } }, "auth_ref": [] }, "gstc_DescriptionOfMilestones1": { "xbrltype": "stringItemType", "nsuri": "http://globestar.com/20230930", "localname": "DescriptionOfMilestones1", "presentation": [ "http://globestar.com/role/LicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Description of milestone one", "documentation": "The element represents description of milestones1." } } }, "auth_ref": [] }, "us-gaap_OtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherExpenses", "crdr": "debit", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expenses paid", "documentation": "Amount of expense classified as other." } } }, "auth_ref": [ "r91" ] }, "gstc_CommonStockIssuedForConversionOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "CommonStockIssuedForConversionOfDebt", "crdr": "debit", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock issued for the conversion of debt", "documentation": "The element represents common stock issued for conversion of debt.", "label": "Common Stock Issued for Conversion of Debt" } } }, "auth_ref": [] }, "gstc_NotePayableIssuedForSettlementOfAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "NotePayableIssuedForSettlementOfAccountsPayable", "crdr": "debit", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Note payable issued for settlement of accounts payable", "documentation": "The element represents note payable issued for settlement of accounts payable." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Taxes", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income." } } }, "auth_ref": [ "r30", "r33" ] }, "gstc_DisclosureSeriesGPreferredStockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://globestar.com/20230930", "localname": "DisclosureSeriesGPreferredStockAbstract", "lang": { "en-us": { "role": { "label": "Series G Preferred Stock" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise term", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r566" ] }, "gstc_SeriesGPreferredStockDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://globestar.com/20230930", "localname": "SeriesGPreferredStockDisclosureTextBlock", "presentation": [ "http://globestar.com/role/SeriesGPreferredStock" ], "lang": { "en-us": { "role": { "verboseLabel": "Series G Preferred Stock", "documentation": "The element represents series g preferred stock disclosure text block.", "label": "Series G Preferred Stock Disclosure [Text Block]" } } }, "auth_ref": [] }, "gstc_DisclosureLicenseAgreementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://globestar.com/20230930", "localname": "DisclosureLicenseAgreementAbstract", "lang": { "en-us": { "role": { "label": "License Agreement" } } }, "auth_ref": [] }, "gstc_LicenseAgreementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://globestar.com/20230930", "localname": "LicenseAgreementDisclosureTextBlock", "presentation": [ "http://globestar.com/role/LicenseAgreement" ], "lang": { "en-us": { "role": { "verboseLabel": "License Agreement", "documentation": "The element represents license agreement disclosure text block.", "label": "License Agreement Disclosure[Text Block]" } } }, "auth_ref": [] }, "gstc_ScheduleOfShareBasedCompensationStockWarrantsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://globestar.com/20230930", "localname": "ScheduleOfShareBasedCompensationStockWarrantsActivityTableTextBlock", "presentation": [ "http://globestar.com/role/StockholdersDeficitTables" ], "lang": { "en-us": { "role": { "label": "The following table summarizes the stock warrant activity for the years ended September 30, 2023 and 2022:", "documentation": "The element represents schedule of share based compensation stock warrants activity table text block." } } }, "auth_ref": [] }, "gstc_WorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "WorkingCapital", "crdr": "credit", "presentation": [ "http://globestar.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Working capital deficit", "documentation": "The element represents working capital." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "gstc_PayableToConsultantTerm": { "xbrltype": "durationItemType", "nsuri": "http://globestar.com/20230930", "localname": "PayableToConsultantTerm", "presentation": [ "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payable to consultant term", "documentation": "The element represents payable to consultant term." } } }, "auth_ref": [] }, "gstc_DescriptionOfOptions": { "xbrltype": "stringItemType", "nsuri": "http://globestar.com/20230930", "localname": "DescriptionOfOptions", "presentation": [ "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Description of options", "documentation": "The element represents description of options." } } }, "auth_ref": [] }, "gstc_RoyaltyOfNetSalesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://globestar.com/20230930", "localname": "RoyaltyOfNetSalesPercentage", "presentation": [ "http://globestar.com/role/LicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Royalty of net sales", "documentation": "The element represents royalty of net sales percentage." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://globestar.com/role/LicenseAgreementDetailsNarrative", "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r308", "r376", "r377", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r473", "r474", "r475", "r476", "r477", "r498", "r500", "r532", "r645" ] }, "us-gaap_CompensatingBalanceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensatingBalanceAmount", "crdr": "debit", "presentation": [ "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Settelment amount", "documentation": "The amount of a specific compensating balance arrangement that is maintained under an agreement for a bank loan or future credit availability." } } }, "auth_ref": [ "r134" ] }, "gstc_DescriptionOfAdditionalOptions": { "xbrltype": "stringItemType", "nsuri": "http://globestar.com/20230930", "localname": "DescriptionOfAdditionalOptions", "presentation": [ "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Description of additional options", "documentation": "The element represents description of additional options." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r150" ] }, "us-gaap_DebtInstrumentIssuanceDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentIssuanceDate1", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableConsistedOfFollowingAtSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Dated", "documentation": "Date the debt instrument was issued, in YYYY-MM-DD format." } } }, "auth_ref": [ "r13", "r634" ] }, "gstc_DescriptionOfMilestones3": { "xbrltype": "stringItemType", "nsuri": "http://globestar.com/20230930", "localname": "DescriptionOfMilestones3", "presentation": [ "http://globestar.com/role/LicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Description of milestone three", "documentation": "The element represents description of milestones3." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://globestar.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r373", "r374", "r375", "r377", "r378", "r453", "r454", "r455", "r507", "r508", "r509", "r529", "r531" ] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock issued for stock payable", "verboseLabel": "Subscription payables settle", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://globestar.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of provision for income taxes", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r110" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r68", "r69", "r505", "r506", "r509" ] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares issued to settle subscription payables", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r505", "r506", "r509" ] }, "gstc_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities1": { "xbrltype": "sharesItemType", "nsuri": "http://globestar.com/20230930", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities1", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock issued during period, shares, conversion of convertible securities", "documentation": "The element represents stock issued during period shares conversion of convertible securities1." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://globestar.com/role/FollowingTableSummarizesStockOptionActivityForYearsEndedSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r313" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://globestar.com/role/LicenseAgreementDetailsNarrative", "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r308", "r376", "r377", "r473", "r474", "r475", "r476", "r477", "r498", "r500", "r532" ] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": [ "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Liabilities related to stock", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r23" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative", "http://globestar.com/role/LicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r346" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r79" ] }, "us-gaap_GainLossOnFairValueHedgeIneffectivenessNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnFairValueHedgeIneffectivenessNet", "crdr": "credit", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value of shares issued", "documentation": "Amount of gain (loss)recognized in the income statement from the hedging ineffectiveness of a fair value hedge." } } }, "auth_ref": [ "r112" ] }, "us-gaap_OtherGeneralExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherGeneralExpense", "crdr": "debit", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expenses related to warrants", "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses." } } }, "auth_ref": [ "r92" ] }, "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnFairValueHedgesRecognizedInEarnings", "crdr": "credit", "presentation": [ "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Recognized loss", "label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings", "documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period." } } }, "auth_ref": [ "r63" ] }, "us-gaap_DeferredRevenueArrangementTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueArrangementTypeAxis", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://globestar.com/role/LicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred Revenue Arrangement Type [Axis]", "documentation": "Information by type of deferred revenue arrangement." } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets", "http://globestar.com/role/ConsolidatedBalanceSheetsParenthetical", "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit", "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r129", "r136", "r137", "r138", "r157", "r172", "r173", "r175", "r176", "r178", "r179", "r227", "r250", "r252", "r253", "r254", "r257", "r258", "r288", "r289", "r292", "r295", "r303", "r361", "r447", "r448", "r449", "r450", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r468", "r480", "r502", "r525", "r542", "r543", "r544", "r545", "r546", "r601", "r615", "r621" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets", "http://globestar.com/role/ConsolidatedBalanceSheetsParenthetical", "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit", "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r129", "r136", "r137", "r138", "r157", "r172", "r173", "r175", "r176", "r178", "r179", "r227", "r250", "r252", "r253", "r254", "r257", "r258", "r288", "r289", "r292", "r295", "r303", "r361", "r447", "r448", "r449", "r450", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r468", "r480", "r502", "r525", "r542", "r543", "r544", "r545", "r546", "r601", "r615", "r621" ] }, "gstc_FairValueExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://globestar.com/20230930", "localname": "FairValueExpenses", "crdr": "debit", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expenses related to the fair value", "documentation": "The element represents fair value expenses." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued liabilities", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r14", "r567" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Additional expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r86" ] }, "us-gaap_ConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtTableTextBlock", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesTables" ], "lang": { "en-us": { "role": { "label": "Convertible notes payable consisted of the following at September 30, 2023 and 2022:", "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable to related party", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r16" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherDeferredCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherDeferredCostsGross", "crdr": "debit", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred finance costs", "documentation": "Gross amount of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs or deferred acquisition costs of insurance companies." } } }, "auth_ref": [ "r610" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueArrangementTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueArrangementTypeDomain", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://globestar.com/role/LicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfRelatedPartyDebt", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of related party advances", "label": "Repayments of Related Party Debt", "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates." } } }, "auth_ref": [ "r29" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock issued for stock payable", "label": "Value of share issue", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r7", "r78", "r79", "r108", "r456", "r525", "r543", "r578" ] }, "us-gaap_PaymentsForFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForFees", "crdr": "credit", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fee accrued in accounts payable", "documentation": "Amount of cash outflow for fees classified as other." } } }, "auth_ref": [ "r3" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "NET INCREASE (DECREASE) IN CASH", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r95" ] }, "us-gaap_PreferredStockRedemptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockRedemptionPricePerShare", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock redemption price per share", "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer." } } }, "auth_ref": [ "r48", "r49", "r52" ] }, "us-gaap_GainLossRelatedToLitigationSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossRelatedToLitigationSettlement", "crdr": "credit", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gain (loss) related to settlement of liabilities", "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process." } } }, "auth_ref": [ "r630" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash at beginning of period", "periodEndLabel": "Cash at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r31", "r95", "r153" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueOther", "crdr": "credit", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Common stock subscribed for cash proceeds", "documentation": "Value of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_GainOnFairValueHedgeIneffectiveness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainOnFairValueHedgeIneffectiveness", "crdr": "credit", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Recognized gain", "documentation": "Amount of gain recognized in the income statement from the hedging ineffectiveness of a fair value hedge." } } }, "auth_ref": [ "r112" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Common stock issued for conversion of convertible note payable and accrued interest", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r7", "r27", "r108" ] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Other", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "(Gain) loss on settlement of liabilities, related party", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r5", "r43", "r44" ] }, "us-gaap_StockIssuedDuringPeriodValueStockDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockDividend", "crdr": "credit", "presentation": [ "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dividend value", "documentation": "Value of stock issued to shareholders as a dividend during the period." } } }, "auth_ref": [ "r7", "r27", "r108" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r569", "r570", "r573", "r574", "r575", "r576" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative expenses", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r90", "r504" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://globestar.com/role/StockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 deficit", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r104", "r156", "r287", "r289", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r299", "r300", "r302", "r305", "r358", "r528", "r530", "r547" ] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://globestar.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r158", "r328", "r333", "r334", "r337", "r341", "r343", "r344", "r345", "r452" ] }, "us-gaap_SubscriptionArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubscriptionArrangementMember", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subscription Arrangement [Member]", "documentation": "Category of deferred revenue by arrangement wherein a subscribers pay in advance for media (TV, newspaper, magazine, internet), which will generally be recognized as revenue as the media is delivered." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturityDate", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative", "http://globestar.com/role/ConvertibleNotesPayableConsistedOfFollowingAtSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Maturity date", "documentation": "Maturity date of long-term debt, in YYYY-MM-DD format." } } }, "auth_ref": [ "r642" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r622", "r644" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleTermsOfConversionFeature", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableAndAdvancesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Beneficial conversion discount on convertible note payable", "documentation": "Description of conversion terms for debt instrument." } } }, "auth_ref": [ "r21", "r49", "r105", "r107" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilities" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingent Liabilities", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r100", "r244", "r245", "r548", "r629" ] }, "us-gaap_OperatingCostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingCostsAndExpenses", "crdr": "debit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Costs and Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://globestar.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r368", "r380" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://globestar.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r143", "r329", "r330", "r334", "r335", "r336", "r338", "r446" ] }, "us-gaap_SubsequentEventDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventDescription", "presentation": [ "http://globestar.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consulting agreement", "documentation": "Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued." } } }, "auth_ref": [ "r70" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Stock compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://globestar.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r368", "r380" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://globestar.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r368", "r380" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://globestar.com/role/ScheduleOfProvisionForIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://globestar.com/role/ScheduleOfProvisionForIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Valuation allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r640" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://globestar.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r37", "r38", "r39", "r123", "r124", "r125", "r126" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://globestar.com/role/ConvertibleNotesPayableConsistedOfFollowingAtSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r65", "r67", "r260", "r371", "r560", "r561" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit", "http://globestar.com/role/SeriesGPreferredStockDetailsNarrative", "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r569", "r570", "r571", "r573", "r574", "r575", "r576", "r618", "r619", "r641", "r658", "r664" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets", "http://globestar.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued interest payable", "verboseLabel": "Accrued interest", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r18" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://globestar.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets", "http://globestar.com/role/ConsolidatedStatementsOfStockholdersDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL STOCKHOLDERS\u2019 DEFICIT", "periodStartLabel": "Beginning balance, value", "periodEndLabel": "Ending balance, value", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r79", "r82", "r83", "r99", "r482", "r499", "r526", "r527", "r567", "r579", "r617", "r627", "r643", "r664" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://globestar.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r74", "r326", "r654" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r581" ] }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInterestPayableNet", "crdr": "debit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued interest payable", "label": "Increase (Decrease) in Interest Payable, Net", "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity." } } }, "auth_ref": [ "r4" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://globestar.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r368", "r380" ] }, "us-gaap_ConvertibleNotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayableMember", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative", "http://globestar.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable [Member]", "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r76", "r114" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://globestar.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of goods sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r88", "r413" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "us-gaap_NotesPayableOtherPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableOtherPayablesMember", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Notes Payable, Other Payables [Member]", "documentation": "A written promise to pay a note to a third party." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://globestar.com/role/ScheduleOfProvisionForIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://globestar.com/role/ScheduleOfProvisionForIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred tax benefit, net", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r119", "r127", "r170", "r171", "r184", "r331", "r342", "r438" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r591", "r593", "r594" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r591", "r593", "r594" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://globestar.com/role/ScheduleOfProvisionForIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://globestar.com/role/ScheduleOfProvisionForIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Net operating loss carryforward at statutory tax rate", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r332" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r594" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r584" ] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfessionalFees", "crdr": "debit", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://globestar.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Annual fees", "verboseLabel": "Consultant fees", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": [ "r577", "r662", "r663" ] }, "us-gaap_MarketingAndAdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketingAndAdvertisingExpense", "crdr": "debit", "presentation": [ "http://globestar.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Advertising and marketing costs", "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising." } } }, "auth_ref": [ "r90" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://globestar.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r585" ] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "presentation": [ "http://globestar.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r120", "r431", "r467", "r488", "r567", "r579", "r609" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r591", "r593", "r594" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://globestar.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r132", "r140", "r157", "r227", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r347", "r349", "r361", "r567", "r632", "r633", "r646" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r591", "r593", "r594" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r589" ] }, "us-gaap_PaymentsForRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRoyalties", "crdr": "credit", "presentation": [ "http://globestar.com/role/LicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Paid for royalties", "documentation": "The amount of cash paid for royalties during the current period." } } }, "auth_ref": [ "r3" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://globestar.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r592" ] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayable", "crdr": "credit", "presentation": [ "http://globestar.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Notes payable", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r11", "r115", "r656" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://globestar.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r595" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-11" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-3" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-4" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "30", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-5" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "30", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-6" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "855", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(1),(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-40/tableOfContent" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4,6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "25", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-4" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(10)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r555": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r557": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r559": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r560": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r561": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r563": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r580": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r601": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483049/450-30-50-1" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" } } } ZIP 58 0001161697-24-000049-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001161697-24-000049-xbrl.zip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